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Using Saccharomyces cerevisiae for the biosynthesis of tetracycline antibiotics 
Ehud Herbst 
Developing treatments for antibiotic resistant bacterial infections is among the most urgent public 
health challenges worldwide. Tetracyclines are one of the most important classes of antibiotics, 
but like other antibiotics classes, have fallen prey to antibiotic resistance. Key small changes in 
the tetracycline structure can lead to major and distinct pharmaceutically essential improvements. 
Thus, the development of new synthetic capabilities has repeatedly been the enabling tool for 
powerful new tetracyclines that combatted tetracycline-resistance. Traditionally, tetracycline 
antibiotics were accessed through bacterial natural products or semisynthetic analogs derived from 
these products or their intermediates. More recently, total synthesis provided an additional route 
as well. Importantly however, key promising antibiotic candidates remained inaccessible through 
existing synthetic approaches.  
Heterologous biosynthesis is tackling the production of medicinally important and structurally 
intriguing natural products and their unnatural analogs in tractable hosts such as Saccharomyces 
cerevisiae. Recently, the heterologous biosynthesis of several tetracyclines was achieved in 
Streptomyces lividans through the expression of their respective biosynthetic pathways. In 
addition, the heterologous biosynthesis of fungal anhydrotetracyclines was shown in S. cerevisiae. 
This dissertation describes the use of Saccharomyces cerevisiae towards the biosynthesis of target 
tetracyclines that have promising prospects as antibiotics based on the established structure-
activity relationship of tetracyclines but have been previously synthetically inaccessible.  
Chapter 1 provides an introduction to the pursuit of tetracycline antibiotics using S. cerevisiae. 
Following an overview of tetracycline drugs, the chapter describes the methods for making 
 
 
tetracyclines and their limitations in accessing the tetracycline analogs targeted in this study. The 
desirability of making these target analogs as well as key desired properties are then exemplified 
by natural products, totally synthetic and semisynthetic derivatives. The target tetracycline analogs 
pursued in this study are then outlined and the considerations in choosing their desired properties 
are discussed, as well as the reasons for employing S. cerevisiae in their synthesis.  
Chapter 2 describes the use of Saccharomyces cerevisiae for the final steps of tetracycline 
biosynthesis, setting the stage for total biosynthesis of tetracyclines in Saccharomyces cerevisiae. 
Chapter 3 describes the work towards biosynthesis of the target tetracycline analogs using 
Saccharomyces cerevisiae, utilizing successful expression optimization and gene biomining 
approaches. Chapter 4 describes the work towards the target tetracycline analogs from fungal 
anhydrotetracyclines in Saccharomyces cerevisiae. 
The challenge of enzyme evolution towards unnatural substrates and the complex environment of 
cells require metabolic engineering efforts to be performed in libraries, as it is currently impossible 
to predetermine which modifications will prove beneficial. Traditional methods in DNA 
mutagenesis and increasingly, advances in DNA synthesis, DNA assembly and genome 
engineering are enabling high throughput strain construction. Thus, there is a need for a general, 
high-throughput, versatile and readily implemented assay for the detection of target molecule 
biosynthesis. The development of such an assay is described in Chapter 5. The assay is 
demonstrated to detect tetracycline derivatives, and differentiate a producer and a nonproducer 
strain of the fungal anhydrotetracycline TAN-1612. The yeast three hybrid assay for metabolic 
engineering of tetracycline derivatives described in this chapter could be used in the next steps 
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1.1 Chapter outline 
This chapter provides an introduction to the pursuit of tetracycline antibiotics using S. cerevisiae. 
First, the significance of the production of new antibiotic analogs from a human health perspective 
is mentioned (Section 1.2). Then, the general historical context for developing tetracycline 
antibiotics is given (Section 1.3.1), the antibiotic promise in making tetracycline analogs is 
discussed (Section 1.3.2) and a structural overview of FDA-approved tetracyclines follows 
(Section 1.3.3).  
Three modes of synthesis of tetracycline antibiotic are then introduced in the historical order in 
which they appeared, biosynthesis and semisynthesis using the original microbial hosts (Section 
1.4.1), total synthesis (Section 1.4.2) and heterologous biosynthesis and semisynthesis (Section 
1.4.3). The desirability of making 6-position analogs of tetracyclines as well as key desired 
properties of such analogs is then exemplified by natural products (Section 1.5.1), totally synthetic 
(Section 1.5.2) and semisynthetic derivatives  (Section 1.5.3). 
The target tetracycline analogs pursued in this study are then outlined and the considerations in 
choosing their desired properties are then discussed (Sections 1.6.1, 1.6.2 and 1.6.3)  as well as the 
reasons for employing S. cerevisiae in their synthesis (Section 1.6.4). Finally, an overview of the 
research plan and its execution throughout this dissertation is given (Section 1.7). 
1.2 An antibiotic crisis 
Developing treatments for antibiotic resistant bacterial infections is among the most urgent public 
health challenges world-wide.(1) The US Center for Disease Control reports over 2 million 
illnesses and 20,000 deaths annually in the United States as a result of antibiotic resistance.(1) 
Novel antibiotic drug candidates have traditionally been accessed through natural product 
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screening, total synthesis, semisynthesis and combinatorial chemistry. However, the number of 
new antibiotics approved by the FDA has dropped significantly from previous decades, from 29 
approvals in the 1980s to 9 in the 2000s.(2, 3) To reverse this trend, transformative new 
technologies for discovery of new antibiotics are needed.  
1.3 Tetracycline antibiotics 
1.3.1 General historical context for tetracycline antibiotics and tetracycline-
resistance 
Tetracyclines are one of the most important classes of antibiotics,(4) but like other classes of 
antibiotics, have fallen prey to resistance.(5) From their discovery in the 1940’s, tetracyclines were 
used as broad spectrum antibiotics, as well as for other types of disease, such as periodontitis.(6) 
The tetracyclines inhibit bacterial protein synthesis by binding reversibly to the 30S ribosomal 
subunit and sterically hindering aminoacyl-tRNA binding to the ribosomal A-site.(7, 8) However, 
bacteria have evolved a growing number of resistance mechanisms – including efflux pumps,(9) 
ribosomal protection proteins,(10) rRNA mutations,(11) and enzymatic degradation.(12)   
1.3.2 Tetracycline analogs – small structural changes can lead to major 
pharmaceutical improvements 
Small changes in the tetracycline structure can lead to major and distinct pharmaceutically 
essential improvements. Examples include tetracycline analogs differing from tetracycline in only 
up to three positions and showing improved pharmacokinetic properties, binding affinity to the 
ribosome, activity against resistant strains and non-antimicrobial properties.(13-16)  
Thus, for example, a difference in the position of one hydroxy group between tetracycline and 
doxycycline improves the half-life, tissue penetration and matrix metalloproteinase (MMP) 
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inhibition properties of the latter (Figure 1-1 and Table 1-1).(13) Due to such advantages, 
doxycycline is not only one of the most commonly clinically indicated tetracycline antibiotics, it 
is the only clinically available MMP inhibitor as of 2010 and is indicated for the treatment of 
periodontitis.(14) 
Minocycline differs from tetracycline in only three functional groups, a hydroxy, a methyl and an 
N,N-dimethylamino (Figure 1-1 and Table 1-1). Impressively, these differences are enough to 
improve minocycline relative to tetracycline in its pharmacokinetic profile, radical oxygen species 
scavenging and other anti-inflammatory properties.(13, 14) While tetracycline is unable to cross 
the blood-brain barrier (BBB), minocycline is known for its neuroprotective properties that have 
been demonstrated pre-clinically and clinically in the treatment of various neurological disease. 
Examples include ischemia, traumatic brain injury and neuropathic pain, Parkinson's disease, 
Huntington's disease, amyotrophic lateral sclerosis, Alzheimer's disease, multiple sclerosis and 
spinal cord injury.(15)  
Lastly, tigecycline, being identical to minocycline except for the 9-t-butyl-glycylamido group has 
a better binding affinity to the A-site of the ribosome and an improved antimicrobial activity 
against tetracycline-resistant strains (Figure 1-1 and Table 1-1).(16) On the other hand, these 
changes also led to tigecycline being orally unavailable and furthermore, tigecycline use is 
associated with an increased risk of death.(17)  
1.3.3 A structural overview of the FDA-approved tetracyclines   
As of 2018, all nine FDA approved tetracycline antibiotics were either bacterial natural products 
or semisynthetic analogs derived from bacterial natural products or their intermediates, and all 
nine are produced commercially partly or wholly by fermentation (Figure 1-1).(6, 18-20) Three of 
these nine tetracycline antibiotics, chlortetracycline, meclocycline and metacycline, were 
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discontinued.(20) In 2018, three additional tetracycline antibiotics have received their FDA 
approval, omadacycline, sarecycline and eravacycline.(20-22) Importantly, FDA approved 
tetracycline derivatives are identical in all positions but for the 5α-, 6α-, 6β-, 7- and 9-positions 
(Table 1-1).  
  
Figure 1-1 Structural comparison of FDA-approved tetracyclines 
The common name, a full name outlining the structural relationship between the different 
derivatives and the year of FDA approval, are mentioned below the structures.(6, 20, 23) 
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Table 1-1 FDA approved tetracycline derivatives and their differentiating functional groups  
Namea 5α 6α 6β 7 9 
Chlortetracycline  Me OH Cl  
Oxytetracycline OH Me OH   
Tetracycline  Me OH   
Demeclocycline   OH Cl  
Doxycycline OH Me    
Minocycline    dimethylamino  
Meclocycline OH CH2 CH2 Cl  
Metacycline OH CH2 CH2   
Tigecycline    dimethylamino tBu-glycylamido 
Sarecycline    (methoxy(methyl)amino) 
methyl 
 
Omadacycline    dimethylamino neopentylaminomethyl 
Eravacycline    F pyrrolidinoacetamido 
aFDA approved tetracycline derivatives are identical in all positions but the 5α-, 6α-, 6β-, 7- and 
9-positions. Empty cells indicate implicit Hs.  
 
The identity of the FDA approved tetracyclines at all positions but for 5α, 6α, 7, 8 and 9 could be 
explained as stemming from two major reasons. One is the antibacterial ineffectiveness of 
tetracycline analogs generated so far in positions 10, 11, 11a, 12, 12a, 1, 2, 3 and 4. The other is 
limited semisynthetic and total synthetic access to modifications in positions such as 4a and 6α 
that could potentially yield successful tetracycline antibiotics but are awaiting efficient synthetic 
methods to access them. Both of these topics will be expanded on below.  
Given that positions 10, 12a, 1, 2 and 3, as well as the β-diketone of 11,11a and 12 of tetracyclines 
(Figure 1-1) are considered to interact with the ribosome and thus to be directly responsible for 
tetracyclines antibiotic activity,(8, 24) it is not surprising that modifications in these positions do 
not yield effective antibiotics. The 2-position is somewhat of an exception as modification at this 
position can yield tetracycline antibiotic prodrugs that hydrolyze to the unmodified 2-carboxamido 
functional group (Section 1.4.1). Modifications at the 4-position have also not yielded 
antibiotically active tetracyclines even though this position is not considered to be important for 
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ribosome binding. The prevalent hypothesis to explain the requirement for the 4α-dimethylamino 
group in tetracycline antibiotics is the importance of maintaining an equilibrium between a 
zwitterionic and a nonionic (lipophilic) structures (Figure 1-2, Section 1.4.1).(25) This equilibrium 
is considered crucial for tetracycline antibiotic activity as the zwitterionic form is the form of 
tetracycline that binds to the ribosome,(8) and the nonionic form is the form that can cross the 
cytoplasmic membrane.(26) It is therefore clear that the promising positions for modifications that 
could yield tetracycline antibiotics are likely to be limited to positions 4a, 5, 5a, 6, 7, 8 and 9. 
 
Figure 1-2 Comparison of the tetracycline lipophilic and zwitterionic forms 
Adapted from (26). 
 
In order to explain which modifications in which positions are of promise to obtain tetracycline 
analogs with desired antibiotic activity but have not yet been accessed, the following two 
subsections of the introduction are given. The first (Section 1.4) introduces three different fronts 
of tetracycline synthesis to access tetracycline antibiotic analogs, biosynthesis and semisynthesis 
using the original microbial hosts (Section 1.4.1), total synthesis (Section 1.4.2) and heterologous 
biosynthesis and semisynthesis (Section 1.4.3). Specifically, Section 1.4 discusses which 
modifications were so far inaccessible by all existing methods. The following section introduces 
desirable tetracyclines that are inaccessible by biosynthesis and semisynthesis using the original 
microbical hosts and by total synthesis and could be conceived to made by heterologous 
biosynthesis (Section 1.5). Finally, the last two sections of the introduction describe the plan to 
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access these target antibiotics using S. cerevisiae (Section 1.6) and the overview of the 
experimental progress and future plans towards these analogs (Section 1.7).  
1.4 Making tetracycline antibiotics 
In this section an overview of the three main methods for the production of tetracycline antibiotics 
is given, biosynthesis and semisynthesis using the original microbial hosts (Section 1.4.1), total 
synthesis (Section 1.4.2) and heterologous biosynthesis and semisynthesis (Section 1.4.3). This 
overview emphasizes two main points. For one, it is shown here that synthetic advancements in 
the tetracycline field have time and again led to the development of FDA approved tetracyclines. 
The second point emphasized in this overview is the inaccessibility of key tetracycline antibiotic 
analogs through both of the established methods of tetracycline analog production, biosynthesis 
and semisynthesis using the original microbial hosts (Section 1.4.1) and total synthesis (Section 
1.4.2).  
Some example for the first main point include the FDA approval of minocycline on 1971 following 
the mutgenesis studies that enabled the fermentation of 6-demethyltetracyclines (e.g. 
demeclocycline) and the followup synthetic studies that enabled aromatic substitutions in the 7-
position. This synthetic achievement was in turn followed up with studies on aromatic substitions 
of minocycline in the 9-position that gave birth to the tigecycline that received its FDA approval 
on 2005 (Section 1.4.1). Similarly, a breakthrough in the younger field of tetracycline total 
synthesis, enabling unprecedented modifications in the tetracycline D-ring such as 7-
fluorotetracyclines, gave birth to eravacycline that was FDA approved on 2018 (Section 1.4.2).  
Some examples for the second main point include promising tetracycline analogs at the 6- and 4a-
positions that are further discussed in Section 1.5. It remains to be seen whether unique 
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transformations enabled by the much younger field of heterologous biosynthesis and semisynthesis 
of tetracyclines would yield FDA approved antibiotics (Section 1.4.3).  
1.4.1 Biosynthesis and semisynthesis of tetracyclines using the original 
microbial hosts 
Tetracycline biosynthesis and semisynthesis using the original microbial hosts products can yield 
modifications in positions 1, 2, 3, 4, 5, 5a, 6, 7, 9, 11, 11a, 12 and 12a.(25) The original microbial 
hosts referred to here include Streptomyces aureofaciens and Streptomyces rimosus, the original 
producers of chlortetracycline and oxytetracycline, as well as the S. aureofaciens mutants that 
produce tetracycline and demeclocycline.(27) Despite the limitations on the positions that can be 
modified and more importantly despite the limitations on the functional group that could be 
introduced in these positions, this strategy yielded all FDA-approved tetracyclines that are not 
natural products prior to 2018.(19)  
Considering that positions 12a, 1, 2 and 3 and the β-diketone of 11,11a and 12 are known to be 
important for the interaction of tetracyclines with the ribosome,(8, 24, 25) it is not surprising that 
modifications in these positions have never led to a new tetracycline antibiotic drug. I will therefore 
provide a short overview for biosynthetic and semisynthetic modifications using the original host 
that led to tetracyclines modified in positions 4, 5, 5a, 6, 7, and 9. For a broader review of the 
semisynthesis of tetracyclines using the original microbial hosts the reader is directed to the 
excellent book chapter by Rogalski.(25) For more recent reviews in the field, covering tigecycline 
and related derivatives as well, the reader is referred to references (6, 22, 28-31). 
Modifications at the 4-position have so far not presented tetracycline analogs with improved 
antibiotic activity and most commonly have worsened antibiotic outcomes in comparison to the 
unmodified counterparts. For example, 4-epitetracycline, 4-dedimethylaminotetracycline and 4-
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hydroxy-4-dedimethylaminotetracycline all present much higher MIC values relative to 
tetracycline.(25) Increasing bulk on the 4-position in 6-demethyltetracycline derivatives leads to 
reduced antibiotic activity as well. 6-demethyltetracycline derivatives containing 
methylethylamino, methylpropylamino, diethylamino and methyl(2-hydroxyethyl)-amino at the 
4α-position instead of the 4α-dimethylamino group of 6-demethyltetracycline show 75%, 50%, 
25% and 12%, respectively, of the antibiotic activity of tetracycline against Staphylococcus aureus 
while 6-demethyltetracycline maintains 96% of the activity.(32)  
The study the effect of reducing bulk on the 4-amino group was attempted as well by synthesizing 
4-monoalkylamines, but only the synthesis of 4β-methylamines has succeeded. Considering that 
4-epitetracycline has much reduced antibiotic activity it is not surprising that these derivatives 
were much less effective antibiotics than tetracycline as well. The one monoalkylamino 
successfully generated, 6-demethyl-4-dedimethylamino-4-methylaminotetracycline has shown 
only 7% of the antibiotic activity of tetracycline.(32)  
While 6-methylene tetracycline has effective antibiotic activity (e.g., MIC value of 0.2 against 
tetracycline-sensitive S. aureus), its 4-trimethylammonium derivative 6-methylenetetracycline 
methiodide does not (e.g., MIC value of 12 against tetracycline-sensitive S. aureus).(23) While 
some of the difference could stem from the partial epimerization at the 4-position for the 
methiodide, the partial epimerization alone cannot explain the difference. The lack of the proton 
on the 4-dimethylammonium required to form the characteristic H-bond of the zwitterionic form 
(Figure 1-2) is hypothesized to explain why 4-quaternary ammonium derivatives cannot form the 
zwitterionic tetracycline form,(33) and could be a reason for their higher MIC values. 4-
epitetracyclines would be incapable of forming the zwitterionic form (Figure 1-2) as well and 
similar problems could arise with increasing bulk on the 4-amino group.  
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The 4a proton was unmodified by biosynthesis and semisynthesis of tetracycline derivatives using 
the original microbial hosts, as is to be expected given that C-H activation of the tertiary 4a-proton 
is challenging in a highly functionalized molecule such as tetracycline and its natural and 
semisynthetic analogs.(25, 34) A 4a(12a)-anhydrotetracycline was made and found to have less 
than 1% the activity of tetracycline.(25) 
Modifications at the 5-position enabled by biosynthesis and semisynthesis using the original 
microbial hosts were focused on modifications of oxytetracycline and doxycycline (Figure 1-1), 
such as esterification, and oxidation. In general, these modifications have either yielded 
tetracycline derivatives with similar or worse antibiotic activity.(25) Modifications at the 5a-
position were mostly limited to dehydration, isomerization and 5a-methyl installation but have not 
produced improvements on biological activity.  
Modifications at the 6-position have yielded many of the currently FDA-approved tetracyclines 
(Figure 1-1, Table 1-1). Some of the 6-position analogs made had the following functional groups 
in the α and β positions, respectively:  Me,OH; Me,H; H,Me; Me,-; H,OH; H,H; CH2,-; RSCH2,H; 
OH,-; OH, HOCH2; PhCH2,H; RSOCH2,H; CH3COCH2,H; HOCH2CH2CH2,H; PhCH2CH2,H; 
F,H; H,F; F,-; F,Me; H, OAc; with R indicating and alkyl, phenyl or a derivatized alkyl or phenyl 
and a hyphen indicating an SP2 carbon at the 6-position.(25) Thus, it is clear that alkyl 
derivatizations of the 6α-position were explored, as well as some heteroatoms such as fluorine. 
However, the scope was still limited and has not included 6-epi-6-demethytetracyclines, a point 
that will be revisited in section 1.6. This is to be expected considering that natural tetracyclines 
such as tetracycline, oxytetracycline and chlortetracycline give ready access to a 6β-
hydroxytetracyclines. Notably, 6-demethyltetracyclines such as demeclocycline (Figure 1-1) were 
accessed by strain mutagenesis.(25) 
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Experimental success with aromatic substitutions enabled initially the semisynthetic derivatization 
of the 7-position generating minocycline that later received FDA approval (Figure 1-1).(6) 9-
position substation followed and thus the road was paved for the newer generation of semisynthetic 
tetracyclines, tigecycline, sarecycline and omadacycline (Figure 1-1).(21, 22, 25, 28, 35, 36) 
However, the scope of possible substitutions in the D-ring has been significantly expanded with 
the Myers convergent approach to tetracycline total synthesis, covered in Section 1.4.2.  
Modifications at the 2-position have generated tetracycline antibiotics that were approved outside 
the United States. Rolitetracycline, lymecycline (N-lysinomethyltetracycline) and clomocycline 
are such examples. However, the modifications in general made for tetracycline prodrugs with 
improved water solubility that hydrolyze to tetracyclines unmodified in the 2-position, which is 
their active form.(25) 
1.4.2 Total synthesis of tetracycline antibiotics 
Early efforts at the total synthesis of tetracyclines include the first total synthesis of a biologically 
active tetracycline, 6-demethyl-6-deoxytetracycline by the Woodward laboratory in the 1960s, 
albeit as a racemic mixture.(37) Later synthetic efforts of interest to antibiotically active analog 
generation included generating heteroatoms at the 6-position in derivatives such as 6-
thiatetracycline.(25) However, the latter was found to be acting as an antibiotic by an alternative 
mechanism that does not involve the ribosome and was labeled, along with anhydrotetracycline, 
anhydrochlortetracycline, chelocardin and 4-epianhydrochlortetracycline, as an atypical 
tetracycline. Importantly, adverse side effects precluded the latter group from being perused as 
antibiotic agents.(38) 
While other total syntheses of tetracyclines appeared over the years, (39, 40) the Myers’ group 
convergent enantioselective total synthesis of tetracyclines,(41) was the first one to produce a 
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totally synthetic FDA approved tetracycline.(20, 42) This convergent approach to tetracycline total 
synthesis permitted tetracycline analog modifications previously impossible, particularly in the 7-
, 8- and 9-positions. These modifications enabled the synthesis of TP-271, a clinical candidate and 
the FDA approved eravacycline, both 7-dedimethylamino-7-fluoro-9-amidominocyclines (Figure 
1-1).(18, 43, 44) Additional tetracycline analogs that became accessible by later developments in 
this total synthesis approach are 5-oxo analogs with an oxygen instead of the C5 carbon and 5a-
quaternary carbon analogs.(45, 46) Importantly, the Myers convergent synthesis of tetracyclines 
does involve a fermentation process in its first step, the enantioselective dihydroxylation of 
benzoic acid.(41, 47) However, this synthesis is clearly distinct from the semisynthetic efforts 
towards tetracyclines that modify fully formed tetracycline fermentation products (Section 1.4.1).    
On the other hand, the synthetic strategy for forming the AB-ring precursor and then coupling it 
with the D-ring precursor across the C-ring limits modifications to the AB-ring junction and C-
ring.(41) Specifically, the Michael-Claisen cyclization that forms the ABCD tetracycline core from 
the AB- and D-ring precursors demands a D-ring precursor that can undergo anionization at the 
carbon precursor to the C6 carbon and then serve as a nucleophile for 1,4-addition reaction to an 
α,β-unsaturated carbonyl (Figure 1-3-a). This demand limits the functional diversity that can be 
convergently generated at the 6α-position (Figure 1-1). 6α-substituents that were thus published in 
the Myers group include alkyl, aryl, heteroaryl, and proton substituents.(41, 42) Thus, some 6-
deoxytetracyclines such as doxycycline and some 6-deoxy-6-demethyl tetracyclines such as 
eravacycline can be convergently synthesized using this total synthesis strategy.(41, 42, 44) 
However, other simple tetracyclines, such as tetracycline itself, require an alternative cyclization 
strategy and further oxygenation following the cyclization, and thus while the overall yield for 
doxycycline was 8.3%, the overall yield for tetracycline was 1.1%.(41, 48)  
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Substitutions at the 4a-positions also appear limited by the convergent approach to tetracycline 
total synthesis, as epoxide formation and opening on this position are critical to the formation of 
the AB-ring intermediate (Figure 1-3-b).(41)  Finally, it is also unclear at this point whether this 
method of tetracycline total synthesis can compete economically with fermentation, or with 
semisynthesis from a fermentation intermediate, for commercial process chemistry of a wide range 
of tetracyclines indicated for a wide range of infectious diseases.  
 
Figure 1-3 Key steps in the Myers convergent total synthesis of tetracyclines 
The key step to form the (a) ABCD precursor and (b) AB-ring precursor in the total synthesis of 
doxycycline. Adapted from (41) 
 
1.4.3 Heterologous biosynthesis and semisynthesis of tetracyclines 
Heterologous biosynthesis of natural products and their analogs is a rapidly developing field and 
is importing important biosynthetic pathways into tractable hosts, such as Escherichia coli and 
Saccharomyces cerevisiae. This field relies heavily on recent breakthrough in the fields of DNA 
synthesis, DNA sequencing, methods in genetic manipulation of model organisms and information 
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regarding natural product pathways in a variety of organisms.(49) Heterologous biosynthesis is 
tackling the production of medicinally important and structurally complex natural products such 
as taxol,(50) erythromycin,(51) and lovastatin.(52) Notably, heterologous biosynthesis offers a 
greener or more economically feasible approach to the production of known compounds.(53, 54) 
While much of the effort in heterologous biosynthesis is still focused on the production of natural 
products themselves, an ultimate goal is to obtain their unnatural derivatives as well.(55)  
Heterologous biosynthesis in the tetracycline field was spearheaded by the Tang laboratory who 
produced in Streptomyces lividans K4 by herelogous expression oxytetracycline (Figure 1-1), 
dactylocyclinone (Figure 1-4) and SF2575 through the expression of their respective biosynthetic 
pathways.(56) Analog production of the antitumor agent SF2575 was also shown in this study by 
the elimination of biosynthetic enzymes from the SF2575 pathway. As is the common case for the 
heterologous production of other glycosylated natural products,(57) the aglycone, 
dactylocyclinone and not the glycosylated natural products dactylocyclines has been 
produced.(56)  
The power of genetic modifications to the biosynthetic pathway in yielding tetracycline derivatives 
was historically used in the original hosts. For example, in the production of tetracycline and 
demeclocycline by mutants of Streptomyces aureofaciens that naturally produces 
chlortetracycline.(58) Demeclocycline is an intermediate in the semisynthesis of the important 
drug minocycline and a tetracycline drug on its own right (Figure 1-1).(59) While impressive for 
having taken place before full deciphering of the tetracycline biosynthetic pathway and prior to 
the development of efficient tools for genomic engineering, these two analogs were obtained by 
elimination of function rather than by introduction of function, which is more challenging. The 
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genetic revolution that intervened and the use of genetically tractable heterologous organisms such 
as S. cerevisiae are a potential avenue towards such challenging transformations.(49) 
Importantly the Tang group has also heterologously expressed in S. cerevisiae the biosynthetic 
pathway of the fungal anhydrotetracycline derivative, TAN-1612.(60) Fungal 
anhydrotetracyclines such as TAN-1612 and viridicatumtoxin serve as excellent scaffolds for 
generating tetracycline analogs in S. cerevisiae (Section 1.6.4 and Chapter 4). While not pursued 
thus far in tetracyclines, heterologous semisynthesis combining the power of heterologous 
biosynthesis with the often complimentary advantages of synthetic chemistry is exciting. Such 
combination has led to the production of artemisinin from artemisinic acid fermented in yeast,(61) 
and could prove especially beneficial for generating tetracycline analogs (Section 1.6.4). 
In conclusion, for each of the fronts of tetracycline synthesis, biosynthesis and semisynthesis using 
the original microbial hosts, total synthesis and heterologous biosynthesis and semisynthesis, the 
emergence of new capabilities is the enabling tool for powerful new antibiotics. Thus, the 
development of semisynthetic capabilities in the 6-, 7- and 9-positions enabled the synthesis of 
novel more powerful tetracycline antibiotics such as doxycycline, minocycline and tigecycline 
(Section 1.4.1). The expansion of the range of possible modifications at the 7- and 9-positions by 
total synthesis enabled the synthesis of 7-fluoro-9-amidotetracycline antibiotics such as 
eravacycline (Section 1.4.2). Importantly however, key tetracycline analogs such as 6-demethyl-
6-epitetracyclines and 4a-hydroxytetracyclines, as well as their derivatives remained inaccessible 
through the existing synthetic approaches  (Sections 1.4.1 and 1.4.2) It is now to be tested whether 
the new efforts enabling the heterologous expression of tetracycline biosynthetic pathways will 
give rise to new tetracycline antibiotic drugs (Section 1.4.3). Section 1.5 describes exciting 
potential structures for such tetracyclines. 
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1.5 Tetracycline analogs in the 6-position 
The 6-position of tetracycline has been particularly useful for generating tetracycline analogs. 
Indeed, no less than five different functional group combinations in the 6-position exist for FDA-
approved tetracyclines (Figure 1-1 and Table 1-1). As noted by Rogalski in 1985, “Modifications 
at the C6 atom have produced by far the greatest success in evolving highly active 
tetracyclines.”(25) Three different classes of 6-position tetracycline analogs will be outlined here 
as inspiration for future tetracycline antibiotics analogs in the 6-position, the natural product 
dactylocyclines (Section 1.5.1) the totally synthetic 6α-aryltetracyclines (Section 1.5.2) and the 
semisynthetic 6α-methylenemercaptantetracyclines (Section 1.5.3). 
1.5.1 Dactylocyclines – natural product 6-epiglycotetracyclines 
Dactylocyclines are tetracycline antibiotics isolated in the early 1990’s from Dactylosporangium 
sp. (ATCC 53693) in a screen by Bristol-Myers Squibb for antibiotics active against tetracycline-
resistant strains.(62) Dactylocyclines are 4a-hydroxy-6-epi-6-glyco-7-chloro-8-
methoxytetracyclines (Figure 1-4). While the 7-chloro substitution is known for existing 
tetracycline antibiotics on the market, the 4a, 6, and 8 substitutions are unique (Figure 1-1). 
Dactylocyclines were found to be antibiotically active, although not of an exceptional potency, 
with MIC values of 3.1-6.3 μg/mL against gram-positive tetracycline-resistant strains of 
Straphylococcus aureus, Staphylococcus epidermis and Streptococcus faecalis. However, 
dactylocyclines exhibited high MIC values (>100 μg/mL) against gram-negative tetracycline-
resistant strains.(63) Importantly, the antibiotic activity of dactylocyclines against tetracycline-
resistant strains is dependent on the glycoside group, with dactylocyclinone, the aglycone of 
dactylocycline, not presenting similar antibiotic properties.(63) 
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Despite their promising antibacterial activity outlook, two main disadvantages prevented 
dactylocyclines’ further development as antibiotics. For one, dactylocyclines are extremely acid 
labile. Specifically, the glycoside installed on the tertiary hydroxyl group of the 6-epitetracycline 
aglycone dactylocyclinone is acid labile in mildly acidic conditions.(56, 62) Secondly, the fields 
of synthetic biology and metabolic engineering were not yet ripe to generate dactylocycline 
analogs at the early 1990’s when dactylocyclines were discovered. Twenty years later, with higher 
maturity of these fields, the pathway towards the dactylocycline aglycone, dactylocyclinone, was 
successfully heterologously expressed by the Tang group.(56) Thus, today there is an outlook for 
generating dacylocycline analogs that build on the advantages of the natural dactylocyclines and 
overcome their disadvantages (Section 1.6).  
 
Figure 1-4 Structures of the dactylocycline family of natural products 
Adapted from (62). 
 
1.5.2 6-demethyl-6-deoxy-6α-aryltetracyclines – totally synthetic tetracyclines 
6-demethyl-6-deoxy-6α-aryltetracyclines and 6-demethyl-6-deoxy-6α-heteroaryltetracyclines 
have been accessed through the Myers convergent total synthesis of tetracyclines and described in 
2008.(42) Among the 6α-aryls synthesized are included, phenyl, 4-toluyl and 3,5-eifluorophenyl. 
While these derivatives showed good MIC values of <1 μg/mL against gram-positive tetracycline-
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resistant strains, they showed values of ≥8 μg/mL against gram-negative tetracycline-resistant 
strains.(42)  However, despite promising MIC values, when one of these derivatives, 6-demethyl-
6-deoxy-6α-phenyltetracycline was tested in vivo in mice infected with tetracycline-sensitive 
gram-positive S. aureus, it was found to be much less effective than tetracycline, requiring a 
concentration  at least 10 times higher to achieve the same rescuing ability.(42) A possible reason 
for the ineffectiveness of 6α-aryltetracyclines against gram-negative tetracycline-resistant bacteria 
in vitro and against tetracycline-sensitive infections in vivo could be their high expected 
lipophilicity, a topic explored in Section 1.5.3. 
1.5.3 6-demethyl-6-deoxy-6α-methylenemercaptantetracyclines – 
semisynthetic tetracyclines 
6-demethyl-6-deoxy-6α-methylenemercaptantetracyclines are an example for the potential 
importance of the polarity of 6α-substituents on the antibacterial activity of 6α-substituted 6-
demethyltetracycline analogs. 6-demethyl-6-deoxy-6α-methylenemercaptantetracyclines were 
synthesized from the semisynthetic 6-methylenetetracycline  and 6-methyleneoxytetracycline 
(metacycline, Figure 1-1).(23)  
Mercaptan derivatives of 6-methylenetetracycline with lipophilic substituents such as Ph and Bn 
showed a much reduced activity relative to tetracycline against the gram-negative Klebsiella 
pneumoniae (Figure 1-5-a). However, in the case of the phenyl and benzyl derivatives of 6-
methyleneoxytetracycline the reduction in activity was lower, presumably due to the mediating 
hydrophilicity of the 5α-hydroxy (Figure 1-5-b). Similarly, in the case of the more polar benzyl 
and phenyl sulfoxide derivatives of 6-methylenetetracycline the reduction in activity relative to 
tetracycline was lower as well (Figure 1-5-c). The smaller and more polar acetyl derivatives 
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showed better activity in both mercaptan derivatives of 6-methylenetetracycline and 6-
methyleneoxytetracycline (Figure 1-5-a and Figure 1-5-b).(23) 
 
Figure 1-5 6-demethyl-6-deoxy-6α-methylenemercaptantetracyclines and their antibiotic 
activities 
(a) 6-demethyl-6-deoxy-6α-methylenemercaptantetracyclines derived from 6-
methylenetetracycline, (b) 6-demethyl-6-deoxy-6α-methylenemercaptanoxytetracyclines derived 
from 6-methyleneoxytetracycline (metacycline) and (c)  6-demethyl-6-deoxy-6α-
methylenemercaptantetracycline oxides derived from 6-methylenetetracycline. The numeric value 
stated for each of the derivative is its normalized turbidimetric bioassay value (relative to 
tetracycline) against the gram-negative Klebsiella pneumoniae.(23, 64) 
 
Based on these results it was hypothesized that bulky and lipophilic substituents on the 6-position 
reduce antibacterial activity, especially against gram-negative organisms. Importantly, however, 
MIC values for the derivatives of Figure 1-5 did not follow the above mentioned trend and were 
generally high, with the acetyl derivatives of 6-methyleneoxytetracycline performing better than 
the others.(23) It is of interest to see whether this strategy of improving gram-negative efficacy by 
reducing lipophilicity of the 6α-substituent, namely the glycoside, could be effective in the case of 
6-demethyl-6-epiglycotetracyclines (Section 1.6). 
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1.6 Design of the biosynthesis of 6-demethyl-6-
epiglycotetracyclines using S. cerevisiae 
Given the promise in tetracycline analogs in the 6-position to make effective antibiotics (Section 
1.5) and given the limitations in existing synthetic methods to access key analogs in this position 
(Section 1.4), I decided to focus my efforts on 6-position analogs. Specifically, inspired by the 
natural products dactylocyclines (Section 1.5.1) I focused my efforts towards making acid stable 
broad spectrum antibiotic derivatives of dactylocyclines effective against tetracycline-resistant 
strains. The sections below outline the specific structural elements of the target tetracycline 
analogs. Namely, making 6-demethyl derivatives for acid stability (Section 1.6.1), aiming for 
broad spectrum activity using glycoside libraries (Section 1.6.2) and ensuring antibiotic efficacy 
using 6-demethyl-6-epitetracyclines as opposed to 6-demethyltetracyclines (Section 1.6.3). 
Finally, I describe why S. cerevisiae was chosen as the heterologous host for making these target 
tetracycline analogs (Section 1.6.4). 
1.6.1 Targeting 6-demethyl derivatives of 6-epiglycotetracyclines for acid 
stability  
To improve on the extreme acid lability of dactylocyclines, I propose making 6-demethyl-6-
epiglycotetracyclines, instead of 6-epiglycotetracyclines such as dactylocyclines. Dactylocyclines 
show promising antibacterial activity against tetracycline-resistant strains. However, 
dactylocyclines’ extreme acid lability prevents their development as antibiotics (Section 1.5.1). In 
weak acidic conditions dactylocyclines are known to convert to their aglycone, dactylocyclinone 
and thereby lose their antibiotic activity against tetracycline-resistant strains.(62, 63)  
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The extreme acid lability of dactylocyclines is likely originating in the tertiary 6α-hydroxy to 
which the glycoside is bound in dactylocyclines (Figure 1-4). As Figure 1-6 shows, the acidic 
hydrolysis bond splitting mechanism of the glycosidic bond is hypothesized to shift based on the 
aglycone ability to form a stable carbonium ion. Thus, in aglycones that cannot form stable 
carbonium ion, the oxonium ion would form on the glycoside and in aglycones that can form a 
stable carbonium ion the carbonium ion would form on the aglycone. Examples for aglycones that 
can form a stable carbonium ion are aglycones that are bound to the glycoside through a tertiary 
or benzylic hydroxyl.(65) 
As expected according to this hypothesis, the acid hydrolysis reaction rate is increased in the case 
of a tert-butyl aglycone that can form a stable tertiary carbocation relative to the case of a methyl 
aglycone (Table 1-2). However, the adamantyl carbocation is not similarly stabilized and 
nevertheless when adamantyl is the aglycone the reaction rate is higher than in the case of other 
substituents such as Me, Et and Pr. This incongruence led to the hypothesis that F-strain produced 
by bulky aglycones enhances the hydrolysis rate as well.(65) Thus, in the case of the aglycone 
dactylocyclinone, where the aglycone is both bulky tertiary and benzylic, it is indeed expected to 
undergo facile hydrolysis in low acid concentrations. 
 
Figure 1-6 Two possible C-O bond cleavage pathways in glycoside hydrolysis  
Adapted from (65). 
23 
 
Table 1-2 Rates of hydrolysis of β-D-glycopyranosides in 0.5 M aqueous sulfuric acid 
Aglycone Methyl Ethyl isopropyl tButyl  Benzyl Adamantyl 
Hydrolysis ratea 1 1.1 1.9 555.8 1.1 48.6 
ahydroylsis rate is normalized to a methyl aglycone. The rate was calculated at 60 oC at 0.5 M 
aqueous sulfuric acid or extrapolated or interpolated from data at different temperatures.(66, 67) 
 
To produce 6-epiglycotetracycline analogs inspired by dactylocyclines but with a much increased 
acid stability, I therefore propose to produce 6-demethyl-6-epiglycotetracyclines rather than 6-
epiglycotetracyclines. An example for such tetracycline derivatives would be 6-
demethyldactylocyclines. However, additional modifications are likely to be required to lead to 
improved activity of 6-demethyl-6-epiglycotetracyclines against tetracycline-resistant gram-
positive and especially gram-negative strains. Such modifications are the subject of Section 1.6.2. 
1.6.2 Targeting glycoside libraries on 6-demethyl-6-epiglycotetracyclines for 
broad spectrum activity  
For improving broad spectrum antibiotic activity against tetracycline-resistant strains I propose 
installing a library of glycoside moieties on the 6-demethyl-6-epitetracycline aglycone. The 
extremely limited tools in synthetic biology around the time of discovery of dactylocyclines 
restricted exploring unnatural derivatives in this manner. However, throughout the intervening 
years much progress has been achieved in producing diversified glycosylated natural products by 
employing glycoside libraries for natural product aglycones.(68-70) Progress in this field is 
fostered by the natural glycoside promiscuity of many glycosyltransferase.(68)  
It was recently shown that installing sterically accessible amines on antibiotics that are only 
effective against gram-positive strains can assist in transforming them into broad spectrum 
antibiotics.(71) Thus, installing a library of glycosamines on 6-demethyl-6-epitetracyclines could 
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be a promising avenue to test whether tetracyclines active against gram-positive strains alone could 
be transformed into broad-spectrum tetracyclines in this manner as well. Many glycosamines with 
a primary amine have been previously reported in the literature and could be employed in this 
glycodiversification effort.(69) 
More specifically for tetracyclines, it was shown that reducing lipophilicity of 6α-substituents or 
overall lipophilicity of 6-demethyl-6-deoxy-6α-methylmarcaptantetracyclines can increase their 
gram-negative activity (Section 1.5.3). Importantly, dactylocyclines were noted for being 
unusually more lipophilic than commercially available tetracyclines.(62) Their lipophilicity could 
theoretically be stemming from any of the differentiating elements between dactylocyclines and 
commercially available tetracyclines (Figure 1-1). These include a 4a-hydroxy, a 6-epi 
configuration, a 7-chloro and an 8-methoxy (Section 1.5.1, Figure 1-4). Given that the 4a-hydroxy 
and the 8-methoxy are unlikely to make dactylocyclines more lipophilic and given the presence of 
the 7-chloro in commercially available tetracyclines (Table 1-1) it is likely the uniqueness in the 
6-position that makes dactylocyclines more lipophilic. The 6-epi configuration of dactylocyclines 
is unlikely to contribute to their unusually high lipophilicity relative to commercially available 
tetracyclines because 6α-methyltetracyclines are generally known to be more lipophilic than 6β-
methyltetracyclines (Section 1.6.3). Thus, the 6-glycoside is the likely main contributor to 
dactylocyclines lipophilicity, especially considering that the glycoside of dactylocyclines is rather 
lipophilic with a 2,6-dideoxy and a 4-methoxy, leaving it with only one or zero hydroxyls (Figure 
1-4). It would therefore be of interest to test whether 6-demethyl-6-epiglycotetracyclines with a 




1.6.3 Targeting the 6-epi forms of 6-demethylglycotetracyclines for antibiotic 
efficacy 
C6 monosubstituted tetracyclines are generally more antibiotically active when substituted at the 
α-position than when substituted at the β-position (Figure 1-1).(25) For example, doxycycline (6-
deoxyoxytetracycline) had lower MIC values than 6-epidoxycycline (6-epi-6-
deoxyoxytetracycline) in 7 / 7 gram-positive and gram-negative strains tested in one set of 
experiments and its in vivo protective dose was lower as well.(23) Similar results, although less 
pronounced, were reported for 6-deoxytetracycline versus 6-epi-6-deoxytetracycline,(23) and 6α-
fluoro-6-demethyl-6-deoxytetracycline was also shown to be  more effective than its 6-epimer, 6β-
fluoro-6-demethyl-6-deoxytetracycline.  
A possible explanation to the advantage 6α-tetracycline analogs have over their 6β counterparts is 
that 6α-analogs more efficiently maintain the important balance between the zwitterionic and the 
lipophilic forms of tetracyclines (Section 1.3.3 and Section 1.4.1). This explanation is supported 
by the following known trend in lipophilicity, with lipophilicity levels ranking oxytetraycline < 6-
epi-6-deoxyoxytetracycline < 6-deoxyoxytetracycline, and with 6-epi-6-deoxyoxytetracycline 
showing only a modest increase in lipophilicity relative to oxytetracycline. While the increase in 
lipophilcity between oxytetracycline and its two 6-deoxy derivatives is expected based on a loss 
of a hydrophilic hydroxy group, the increase in lipophilicity between the two deoxyoxytetracycline 
epimers is less immediately reasoned. The commonly proposed reasoning is that a 6β-functional 
group leads to steric clashes with the 4α-dimethylamino and thus destabilizes the lipophilic 
conformation of the tetracycline, making the tetracycline derivative less lipophilic as a whole. In 
contrast, an 6α-substiuent does not disrupt the important balance between the lipophilic and 
zwitterionic forms of tetracycline derivatives.(72) 
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While these difference in lipophilicity and antibiotic activity are noted for 6α- and 6β-methyl 
groups, they are all the more relevant when a much bulkier glycoside is installed on the 6-hydroxyl. 
It is thus perhaps not surprising that dactylocyclines, the only known 6-glycotetrayclines natural 
products, are 6-epitetracyclines while other tetracycline natural products such as oxytetracycline 
and chlortetracyclines are not. Thus, 6-demethyl-6-epiglycotetracyclines are proposed in this study 
and not 6-demethyl-6-glycotetracyclines. This point is of special importance given the higher 
accessibility of 6β-hydroxytetracyclines over their 6α-hydroxytetracycline counterparts in all 
methods of tetracycline preparation (Section 1.4.1 and Section 1.4.2 and Chapter 3). 
1.6.4 S. cerevisiae as the heterologous host of choice for 6-demethyl-6-
epiglycotetracycline biosynthesis 
Given that 6-demethyl-6-epiglycotetracyclines were marked here as highly desirable tetracycline 
targets to synthesize and test as antibiotics (Sections 1.6.1, 1.6.2 and 1.6.3), the question arises 
what would be the appropriate synthetic tool. Section 1.4.1 mentions the limitations in accessing 
6-demethyl-6-epiglycotetracyclines by semisynthesis from the mainstream tetracycline 
fermentation products, such as tetracycline, oxytetracycline, chlortetracycline and demeclocycline, 
that are all 6β-hydroxy. Similarly, Section 1.4.2 mentions the difficulty in accessing 6-demethyl-
6-epitetracyclines by total synthesis due to the inherent limitations in the synthetic approach that 
requires constructing the C-ring from AB- and D-ring precursors. Recent advances in metabolic 
engineering and synthetic biology render it especially exciting to test heterologous biosynthesis 
for generating 6-demethyl-6-epitetracyclines, the precursors to the desired 6-demethyl-6-
epiglycotetracyclines. Importantly, the following glycodiversification step can take place either in 
vivo or by isolating 6-demethyl-6-epitetracyclines and appending activated glycosides on them 




Figure 1-7 Retrosynthetic analysis of 6-demethyl-6-epiglycotetracyclines 
 
Saccharomyces cerevisiae is uniquely positioned to the synthesis of 6-demethyl-6-
epiglycotetracyclines. First, as a highly genetically tractable model organism that is easy to culture 
and quick to reproduce, S. cerevisiae has been demonstrated a useful heterologous host for the 
production of a variety of natural products of importance to human health.(61, 73-75) The 
advantages, sometimes unexpected, of performing chemistry in S. cerevisiae are also exemplified 
in this study  (e.g., Section 2.4.2).  
Nevertheless, 6-demethyl-6-epiglycotetracyclines or 6-demethyl-6-epitetracyclines could also 
theoretically be accessed from the native host Dactylosporangium sp. (ATCC 53693) or from an 
alternative heterologous host, such as S. lividans K4 previously used for dactylocyclinone 
biosynthesis.(56, 63) However, the native host Dactylosporangium sp. (ATCC 53693) is reported 
to grow at an exceedingly slow rate and to be completely inaccessible for genetic 
modifications.(56) It is yet to be determined whether an alternative heterologous host such as S. 
lividans K4 has better or worse outcomes than S. cerevisiae for this biosynthesis goal. 
Importantly, the Tang laboratory has reported the heterologous biosynthesis of the fungal 
anhydrotetracycline TAN-1612 in S. cerevisiae (Section 1.4.3) and TAN-1612 is well positioned 
to serve as a scaffold for the production of 6-demethyl-6-epiglycotetracyclines in S. cerevisiae. 
TAN-1612 holds important structural similarities to anhydrodactylocyclinone, such as the 4a-
hydroxy and the 8-methoxy functional groups, that can render it a good starting point for further 
derivatization. These substitutions are not observed in the anhydrotetracycline precursors of the 
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commonly fermented tetracyclines, such as chloranhydrotetracycline and anhydrotetracycline. 
Also favorably to the target molecules outlined (Figure 1-7), TAN-1612 lacks a 6-methyl group 
(Figure 1-8). 
 
Figure 1-8 Structural Comparison between anhydrotetracycline, chloranhydrotetracycline, 
TAN-1612 and anhydrotdactylocyclinone 
In grey are marked potentially desirable functional groups TAN-1612 has relative to the 
commercially available anhydrotetracycline as a scaffold for 6-demethyl-6-epiglycotetracycline 
biosynthesis. The stereochemistry of TAN-1612 at positions 4a and 12a was not yet confirmed by 
X-ray crystallography. Empty cells indicate implicit Hs.  
 
However, TAN-1612 is also lacking structural features that are important for antibiotic activity in 
tetracyclines in the A-ring such as the 4α-dimethylamino and the 2-carboxamido (Figure 1-8). The 
furnishing of a 2-carboxamido derivative of TAN-1612 or a related molecule in S. cerevisiae  could 
be envisioned by heterologously expressing the relevant genes from the oxytetracycline 
biosynthetic pathway of S. rimosus. An alternative pathway to harvest the relevant genes is the 
biosynthetic pathway towards the fungal polyketide viridicatumtoxin, which is homologous to that 
of TAN-1612. This effort would likely require evolving the TAN-1612 biosynthetic enzymes to 
the unnatural substrate.(76, 77)  
The Yeast three hybrid (Y3H) system for metabolic engineering of tetracycline analogs could be 
crucial to assay mutants of the TAN-1612 pathway enzymes for relaxed substrate specificity 
towards the new 2-carboxamido intermediates (Section 1.7.4 and Chapter 5). Likewise, 
hydroxylation and oxidation of the 4-position of TAN-1612 can be envisioned by OxyE and OxyL 
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from the oxytetracycline pathway (78) evolved for TAN-1612 specificity by employing the Y3H 
as well. These steps could be followed by reductive amination to furnish the 4α-dimethylamino or 
a related functional group on TAN-1612 or a related derivative. Finally, fermentation of 6-
demethyl-6-epiglycotetracyclines or 6-demethyl-6-epitetracyclines in S. cerevisiae could readily 
open up possibilities in the longer term for commercial production of new tetracycline 
therapeutics. 
 
1.7 Research progress and future goals in the biosynthesis of 
6-demethyl-6-epiglycotetracyclines using S. cerevisiae 
1.7.1 Chapter 2 – Using Saccharomyces cerevisiae for the final steps of 
tetracycline biosynthesis 
This chapter describes the use of Saccharomyces cerevisiae for the final steps of tetracycline 
biosynthesis, setting the stage for total biosynthesis of tetracycline in S. cerevisiae. Specifically, 
data presented in this chapter supports the conversion of anydrotetracycline to tetracycline or an 
epimer in S. cerevisiae by heterologous expression of the 6β-hydroxylase enzyme form the 
oxytetracycline pathway, OxyS. This result is surprising as it was expected that the expression of 
a reductase enzyme that uses a cofactor not native to yeast would be required as well. It was also 
expected that OxyS would lead to an oxytetracycline intermediate and not to tetracycline by 
performing two hydroxylation steps as reported previously and not one as shown in this study. The 
ability to perform the required steps for tetracycline biosynthesis from anhydrotetracycline 
supports the ongoing efforts to produce 6-demethyl-6-epitetracyclines from anhydrotetracyclines 
(Figure 1-7, Chapter 3 and Chapter 4).  
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1.7.2 Chapter 3 – Towards the biosynthesis of 6-demethyl-6-epitetracyclines 
using S. cerevisiae 
This chapter describes the work towards 6-demethyl-6-epitetracyclines biosynthesis in S. 
cerevisiae. 6α-hydroxylation of a 6-demethylanhydrotetracycline by an enzyme such as DacO1 is 
required for the synthesis of 6-demethyl-6-epitetracyclines as opposed to 6β-hydroxylation by 
enzymes such as OxyS leading to 6-demethyltetracyclines. However, previous attempts using 
multiple heterologous hosts to heterologously express DacO1 without the rest of the 
dactylocyclinone pathway have not yielded stably expressed protein. The chapter describes the 
successful development of a stably expressing form of DacO1 in S. cerevisiae by employing 
rational design approaches for optimizing DacO1 expression. This chapter also describes the 
successful hydroxylation of anhydrotetracycline by another 6α-hydroxylase candidate, PgaE. The 
next step towards 6-demethyl-6-epitetracyclines is to test the stably expressed DacO1 and PgaE in 
larger scale for 6α-hydroxylation of anhydrotetracycline and/or anhydrodactylocyclinone and/or 
6-demethylanhydrodactylocyclinone. 
1.7.3 Chapter 4 – Towards the biosynthesis of 6-demethyl-6-epitracyclines 
from TAN-1612 in Saccharomyces cerevisiae 
This chapter describes the work towards 6-demethyl-6-epitracycline derivatives of the fungal 
anhydrotetracycline TAN-1612 in Saccharomyces cerevisiae. TAN-1612 is indicated as a unique 
anhydrotetracycline scaffold for the production of 6-demethyl-6-epitetracyclines (Section 1.6.4), 
the precursors to the target molecules 6-demethyl-6-epiglycotetracyclines (Figure 1-7). The 
progress and future steps towards the directed evolution and biomining of a TAN-1612 6α-
hydroxylase are outlined and the isolation and characterization of a new major product in a strain 
coexpressing PgaE and the TAN-1612 pathway is described. 
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1.7.4 Chapter 5 – a yeast three hybrid system for the metabolic engineering of 
tetracycline derivatives 
The transformation of anhydrotetracyline to tetracycline could be readily detected by a UV/Vis 
based assay due to the blue-shift in the excitation and emission of the molecule (Chapters 2-4). 
However, most transformations of tetracyclines and other molecules that do not involve such a 
major UV/Vis shift, such as the proposed glycosylation and A-ring modifications (Section 1.6.4) 
require the development of a general assay for their detection. This chapter describes the 
development of a yeast three hybrid (Y3H) assay as such a general, high-throughput, versatile and 
readily implemented approach for the detection of target molecule biosynthesis. The Y3H assay is 
presented here as a tool for the reactions in the next steps towards the heterologous biosynthesis 
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2 Using Saccharomyces cerevisiae for the final steps of 










*The contents of this chapter will be published in: 
E. Herbst, V. W. Cornish, et al “Using Saccharomyces cerevisiae for the final steps of tetracycline 
biosynthesis”, in preparation.  
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2.1 Chapter outline  
This chapter describes the use of Saccharomyces cerevisiae for the final steps of tetracycline 
biosynthesis, setting the stage for total biosynthesis of tetracycline in S. cerevisiae. Key results 
described in this chapter are that OxyS performs in S. cerevisiae just one hydroxylation step as 
opposed to two performed in vitro, thus enabling the biosynthesis of tetracycline instead of 
oxytetracycline (Section 2.4.1 and 2.5.1). In addition, this chapter describes the reduction of the 
hydroxylation product of OxyS in yeast cell lysate, without the need for heterologous expression 
of a dedicated reduction enzyme, such as OxyR (Section 2.4.2). This result is important as OxyR 
uses a cofactor not native to yeast. Thus, circumventing the need to express OxyR also circumvents 
the need to heterologously express the biosynthetic pathway of the cofactor or to extragenously 
supply it or its equivalent (Sections 2.4.2 and 2.5.2). Finally, this chapter describes mass 
spectrometry and UV/Vis results supporting the production of 5a(11a)-dehydrotetracycline using 
S. cerevsiae even though its further hydroxylation and/or degradation hampered previous analysis 
when produced by OxyS in vitro and in vivo (Sections 2.4.2 and 2.5.2).   
2.2 Introduction 
S. cerevisiae has proven itself a useful heterologous host for the production of a variety of natural 
products of importance to human health. A key example is the production of artemisinic acid, a 
key intermediate in the production of artemisinin,(1) with more recent examples being the 
production of hydrocodone, Δ9-tetrahydrocannabinolic acid (THCA) and penicillin.(2-4) One of 
the promises in natural product biosynthesis using S. cerevisiae is the access to unnatural analogs 
of natural products.(3) Tetracyclines are one of the most important classes of antibiotics and 
tetracycline analogs are needed to combat the resistance to current tetracycline antibiotics on the 
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market given the current and impending antibiotic crisis (Chapter 1). Thus, from an applied science 
perspective, research on heterologous biosynthesis of tetracyclines is important for its potential to 
lead to new and effective tetracycline antibiotics. From a pure science perspective, heterologous 
biosynthesis of is often highly instructive for the study of the biosynthetic steps that take place in 
the natural hosts, as is exemplified throughout this chapter.  
Granted, Heterologous biosynthesis of oxytetracycline was already shown in Streptomyces 
lividans K4‐11. This is a more readily achievable feat given the existence in that host of a 
biosynthetic pathway to cofactor F420, a required cofactor in the biosynthesis of tetracyclines that 
is not native to S. cerevisiae, and the capacity of bacterial heterologous hosts to express whole 
gene clusters from other bacteria.(5) However, its eukaryotic family lineage is also a key advantage 
for S. cerevisiae as a heterologous host to bacterial natural products such as tetracycline. 
Expression in S. cerevisiae allows orthogonal and complementary chemistry to be performed, 
giving access to analogs that are otherwise inaccessible in heterologous expression in bacterial 
hosts.(6) Examples for the rich, useful, and sometimes unexpected chemical possibilities of S. 
cerevisiae in the heterologous biosynthesis of bacterial natural products such as tetracycline are 
demonstrated in this chapter (2.4.2 and 2.5.2).  
2.3 Materials and methods 
See Chapter 5 for general methods.  
2.3.1 General protocol for hydroxylation/reduction assay in cell lysate 
Fresh patches of strains harboring the plasmid for the hydroxylation and/or reduction enzyme and 
control strains were inoculated in 5 mL selective media (U- or HU-) in 15 mL culture tubes 
(Corning 352059) and placed in shaker overnight to OD600 2-3. Overnight cultures were used to 
inoculate 100 mL selective media (U- or HU-) cultures in 500 mL conical flasks with a starting OD 
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of 0.01-0.05. Cells were grown to final OD of 0.6-0.8 before pelleting in 2 50 mL tubes (Corning 
352098) at 4 °C, 4,000 rpm for 20 min. Each pellet was redissolved in 0.5 mL H2O and the 
suspension was distributed into two presterilized 1.5 mL Eppendorf tubes and pelleted at 14,000 
rpm for 10 min at 4 °C. Pellets were stored at -20 °C prior to further use. 
Pellets were weighed and thawn on ice. A 99:1 mixture of Y-PER yeast protein extraction reagent 
(ThermoFisher Scientific 78991) and HALT protease inhibitor cocktail (ThermoFisher Scientific 
PI87786) was added in a ratio of 3 μL mixture per mg pellet and placed on orbital shaker for 20 
min at r.t., followed by 10 min centrifugation at 14,000 rpm at 4 °C and the cell lysate was 
transferred to a new 1.5 mL Eppendorf tube, kept on ice and used within 1 h.  
The cell lysate (80 μL) was added as the last component to a 4 mL vial (Chemglass CG-4900-01) 
containing 280 μL of 143 mM Tris (pH 7.45), 7.7 mM anhydrotetracycline HCl (AdipoGen CDX-
A0197-M500), 4.3 mM NADPH tetrasodium hydrate (Sigma-Aldrich N7505), 26.4 mM 
mercaptoehtanol and 14.285 mM glucose-6-phosphate (in experiments labeled +G6P, 0 mM 
glucose-6-phophsate in all other experiments) and 40 μL glucose (278 mM) for final 
concentrations of 100 mM Tris, 5.4 mM anhydrotetracycline HCl, 3 mM NADPH, 18.5 mM 
mercaptoethanol, 0 or 10 mM G6P as indicated and 27.8 mM glucose. A septum was placed on 
top of the vial through which a needle was inserted to allow air exchange and the reaction was left 
at r.t. overnight. After night, 1 mL of MeOH was added, the contents were mixed and the reaction 
was filtered through a PTFE 0.2 μm filter (Acrodisc 4423) prior to analysis by mass and UV/VIS 
spectrometry.  
2.3.2 Protocol for hydroxylation/reduction assay in whole cells 
Fresh patches of strains harboring the plasmid for the hydroxylation and/or reduction enzyme and 
control strains were inoculated in 5 mL selective media (U- or HU-) in 15 mL culture tubes 
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(Corning 352059) and placed in shaker overnight to OD600 2-3. Overnight cultures were used to 
inoculate 100 mL selective media (U- or HU-) cultures in 500 mL conical flasks with a starting OD 
of 0.08. Cells were grown to an OD of 1.3 before placing at 15 °C for an additional 10 h until a 
final OD of 1.65. Cells were then pelleted in 2 50 mL tubes (Corning 352098) at 10 °C, 3,500 rpm 
for 5 min. Each pellet was redissolved in 0.5 mL H2O and the suspension was distributed into a 
presterilized 1.5 mL Eppendorf tube and pelleted at 11,000 rpm for 3 min at 10 °C. Pellets were 
placed on ice and used within 1 h.  
Pellets from 50 mL culture were redissolved in H2O (1,025 μL) and added as the last component 
to 15 mL culture tubes (Corning 352059) containing 1,100 μL of 8 mg/mL anhydrotetracycline 
HCl, 125 μL glucose solution in H2O (40%) and 250 μL 1 M Tris buffer pH 7.45 and were placed 
in shaker at 350 rpm at 21 °C for 27 h. Cultures were then pelleted and the supernatant was diluted 
10X into H2O before being used for UV/VIS spectral measurements. 
2.4 Results 
2.4.1 6β-hydroxylation of anhydrotetracycline in S. cerevisiae 
The first step required to convert anhydrotetracyclines to tetracyclines is the 6-hydroxylation of 
the anhydrotetracyclines. This step was studied in the oxytetracycline biosynthetic pathway and it 
was shown that anhydrotetracycline 6-hydroxylation is catalyzed by OxyS. A similar step is 
hypothesized to be catalyzed on 7-chloroanhydrotetracycline by the homologous enzyme Cts8 of 
the chlortetracycline pathway.(7) As tetracycline is biosynthesized in 7-chlorotetracycline 
producers with reduced chlorination ability,(8) anhydrotetracycline hydroxylation is likely to be 
the first in the final sequence of steps in tetracycline biosynthesis.  
To test the capacity of Saccharomyces cerevisiae to hydroxylate an anhydrotetracycline, the model 
hydroxylating enzyme OxyS was used together with its native substrate, anhydrotetracycline 
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(Scheme 2-1). This enzyme-substrate pair was chosen as OxyS was shown to functionally express 
in Escherichia coli by the Tang laboratory and anhydrotetracycline is commercially available.(7) 
The expression plasmid pSP-G1 was chosen in order to facilitate the coexpression of a reductase 
enzyme, to append antibody tags to both hydroxylase and reductase and to constitutively express 
both enzymes.(9) OxyS was cloned into pSP-G1 under the transcriptional control of the strong 
constitutive promoter TEF1 with a FLAG antibody tag at its C-terminus. The resulting plasmid 
(AL-1-101) was transformed into FY251 and BJ5464-NpgA to generate strains EH-3-98-6 and 
EH-3-248-1, respectively. 
Scheme 2-1 Two-step enzymatic conversion of anhydrotetracycline to tetracycline 
 
The OxyS-catalyzed reaction to convert anhydrotetracycline to 5a(11a)-dehydrotetracycline in S. 
cerevisiae is supported by mass spectrometry. When a cell lysate expressing OxyS is added to 
anhydrotetracycline the molecular ion corresponding to 5a(11a)-dehydrotetracycline ([M+H]+) has 
much higher ion counts compared to the molecular ion corresponding to anhydrotetracycline 
([M+H]+). However, the opposite is the case when a cell lysate not expressing OxyS is added to 




Figure 2-1 Mass spectrometry analysis of anhydrotetracycline hydroxylation in cell lysate 
expressing OxyS 
Cell lysate of OxyS expressing strain EH-3-248-1 (+OxyS) or a no-hydroxylase control EH-3-
248-8 (-OxyS) was placed overnight in Tris buffer (100 mM, pH 7.45) containing 
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anhydrotetracycline (5.4 mM), glucose (27.8 mM), NADPH (3 mM) and mercaptoethanol (18.5 
mM). After night, MeOH was added, the contents were mixed and the reaction was filtered prior 
to MS analysis. 
 
Following this encouraging result with a cell lysate, the ability of OxyS to hydroxylate 
anhydrotetracycline was tested in whole cells as well. As for the cell lysate, the molecular ion 
corresponding to 5a(11a)-dehydrotetracycline had much higher ion counts in the +OxyS sample 
relative to the -OxyS sample (data not shown). Given that anhydrotetracycline absorbs and 
fluoresces in the visible range, it was logical to test whether the reaction could be monitored using 
a simple UV/Vis assay using a spectrophotometer. Indeed, reducing the -OxyS spectrum from the 
+OxyS spectrum shows a reduction in the 440 nm absorption and 570 nm emission peaks 
corresponding to anhydrotetracycline and a formation of 380 nm absorption and 500 nm emission 
peaks (Figure 2-2).  
The blue shift in absorption and emission is supportive for the formation of 5a(11a)-
dehydrotetracycline from anhydrotetracycline as anhydrotetracycline’s conjugation in the CD-
rings is expected to be significantly reduced by 6-hydroxylation (Scheme 2-1). Indeed, the 
corresponding red shift in the absorption spectrum for the opposite transformation, where 
chlortetracycline is converted to anhydrochlortetracycline was previously reported (λmax = 373 




Figure 2-2 UV/Vis spectroscopy analysis of the reaction of anhydrotetracycline in whole cells 
expressing OxyS  
The spectra shown are Δ spectra, that is, the absorption/emission values for the OxyS expressing 






2.4.2 5a(11a)-dehydrotetracycline reduction in S. cerevisiae 
The second step in the synthesis of tetracycline from anhydrotetracycline is to reduce the 5a(11a) 
α,β-unsaturated double bond (Scheme 2-1). The reduction at the 5a(11a) bond is known to be key 
to tetracyclines’ antibiotic activity, with 7-chlorotetracycline being over 20X more potent than 7-
chloro-5a(11a)-dehydrotetracycline against Staphylococcus aureus.(11) In order to execute the 
reduction step OxyR, the reductase of 5a(11a)-dehydrooxytetracycline,(7) was placed under the 
control of a PGK1 promoter in the pSP-G1-OxyS plasmid AL-1-101 to generate AL-1-119-A-C7. 
To function properly, OxyR requires cofactor F420, a cofactor that is not native to S. cerevisiae. 
Cofactor Fo is an intermediate in cofactor F420 biosynthesis and is known to successfully replace 
cofactor F420 in several F420 dependent enzymes with similar Km and Kcat values.(12-15) Given that 
Fo synthases, employing known yeast metabolites to biosynthesize Fo were previously 
characterized, an attempt was made to heterologousy produce Fo in S. cerevisiae. Fo synthase from 
Thermobifida fusca and Chlamydomonas reinhardtii, was placed under the control of promoter 
pADH1 to generate plasmids AL-1-183-C and AL-1-183-D, respectively.(16, 17) However, 
following transformations of the plasmids to S. cerevisiae no Fo biosynthesis was confirmed by 
MS (data not shown). 
In order to test whether OxyR could be functional in S. cerevisiae with Fo as a cofactor, synthetic 
Fo,(18) a generous gift from Frank Foss, was exogenously added to a yeast strain expressing OxyS, 
OxyR and an Fo reductase. Fo reductase was placed under the control of pGPD (pTDH3) on PRS413 to 
generate AL-215-D-C1, AL-255-C1 and AL-235-C5, encoding F420 reductase from Mycobacterium 
tuberculosis, Archeoglobus fulgidus and Streptomyces griseus, respectively.(19-22) The reaction 
mixture in Tris buffer (pH 7.45) also contained anhydrotetracycline, glucose, NADPH, and in the 
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case of Fo reductase from M. tuberculosis, glucose-6-phosphate for Fo reduction. It was found that 
the levels of the molecular ion peak corresponding to tetracycline, the reduction product of 
5a(11a)-dehydrotetracycline, are increased when glucose-6-phosphate is added (Figure 2-3). 
Contrary to the expectation that glucose-6-phosphate serves as a substrate for the Fo reductase, it 
was found that neither Fo, the Fo reductase or OxyR increased the levels of the molecular ion peak 





Figure 2-3 Mass spectrometry of anhydrotetracycline hydroxylation and reduction in cell 
lysate expressing OxyS in the presence of G6P 
Cell lysate of OxyS expressing strain EH-3-248-1 was placed overnight in Tris buffer (100 mM, 
pH 7.45) containing anhydrotetracycline (5.4 mM), glucose (27.8 mM), NADPH (3 mM), 10 mM 





To test whether a native reductase to S. cerevisiae is reducing 5a(11a)-dehydrotetracycline, the 
native old yellow enzyme (OYE) reductases, OYE2 and OYE3 from S. cerevisiae were expressed 
under the strong promoter pPGK1, along with their fungal homolog OYE1 from Saccharomyces 
carlsbergensis.(23-26) OYE proteins are known to reduce the olefinic bond in α,β-unsaturated 
carbonyls, such as the reduction of 2-cyclohexenone to cyclohexanone and are known to have a 
flexible substrate specificity.(23) However, coexpression of the OYE proteins together with OxyS 
did not enhance the reduction compared to the expression of OxyS alone (data not shown). 
2.5 Discussion 
2.5.1 6β-hydroxylation of anhydrotetracycline in S. cerevisiae 
When OxyS and OxyR were used in vitro, oxytetracycline (5-hydroxytetracycline) and not 
tetracycline was formed as the major product, indicating that OxyS is catalyzing both 
hydroxylation steps at C5 and C6  prior to OxyR reduction of the 5a(11a) double bond (Scheme 
2-1).(7) Interestingly however, when expressed in S. cerevisiae, both in cell lysate and whole cells, 
OxyS is catalyzing just one hydroxylation step (Figure 2-1 and data not shown). It could be that 
the absence of the 5-hydroxyl is the reason for the lack of contribution of OxyR to reduction as 
OxyR’s native substrate is the doubly hydroxylated 5a(11a)-dehydrooxytetracycline and not the 
singly hydroxylated 5a(11a)-dehydrotetracycline. Given that DacO4 and CtcR are known to 
hydroxylate 5a(11a)-dehydrotetracycline,(7) an attempt of the hydroxylase-reductase pairs OxyS-
DacO4 and OxyS-CtcR is warranted in S. cerevisiae where OxyS performs only a single 
hydroxylation step.  
Furthermore, previously in the absence of OxyR the reaction product of OxyS rapidly degraded 
both in vitro and in vivo in ΔoxyR Streptomyces lividans.(7) However, in the S. cerevisiae 
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expression system both in whole cells and in cell lysate the hydroxylation product of OxyS was 
analyzable (Figure 2-1, Figure 2-2). This could be explained by the additional degradation 
pathways possible due to the presence of the 5-hydroxy. For example, anhydrooxytetracycline (5-
hydroxyanhydrotetracycline) is known to undergo B-ring scission degradation that is not possible 
in anhydrotetracycline.(27)  
The ability to observe the hydroxylated product of anhydrotetracycline could also be because in 
this study prior to mass spectrometry analysis MeOH added and the samples were filtered, while 
in the in vitro study of OxyS acidic organic extraction using 1% AcOH in EtOAc was employed.(7) 
Anhydrooxytetracycline is known to undergo B-ring scission specifically in the presence of dilute 
acid.(27).  
Importantly, it could be that some double hydroxylation product is formed in the reactions of the 
+OxyS S. cerevisiae strain with anhydrotetracycline (Figures 2-1, 2-2 and 2-3) but degraded prior 
to analysis. However, even if that is the case, it is still notable that a significant proportion of a 
singly hydroxylated product is formed as well (Figure 2-1), in contrast to the previously reported 
OxyS double hydroxylation in vitro and in S. lividans.(7) 
The literature reported ability to isolate and analyze 7-chloro-5a(11a)-dehydrotetracycline could 
provide further support for the potential role of the second hydroxylation step in destabilizing the 
5a(11a)-dehydro product. 7-chloro-5a(11a)-dehydrotetracycline, lacking the 5α-hydroxy present 
in 5a(11a)-dehydrooxytetracycline, is produced by mutant strain S-1308 of Streptomyces lividans 
and can be isolated and analyzed.(11) The corresponding S. lividans wild type strain normally 
produces 7-chlorotetracycline, which, like tetracycline is also lacking the additional 5-hydroxy 
group. However, the 7-chloro group could also be responsible for the stability of 7-chloro-5a(11a)-
dehydrotetracycline, previously reported to be the only stable 5a(11a)-dehydrotetetracycline of the 
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ones that have been prepared.(28) Purification of the hydroxylation product of anhydrotetracycline 
and NMR characterization will enable verifying whether 5a(11a)-dehydrotetracycline is indeed 
produced.  
2.5.2 5a(11a)-dehydrotetracycline reduction in S. cerevisiae 
Recently, the biosynthetic pathway of cofactor F420 was fully characterized and F420 was 
successfully heterologously produced in E. coli by recombinant expression of four genes.(29) The 
substrates for the F420 pathway, lactate, tyrosine, and 5-amino-6-ribitylamino-2,4[1H,3H]-
pyrimidinedione, are native to yeast.(30, 31) Thus, a future attempt to natively produce F420 in 
yeast to allow functional expression of cofactor F420-dependent enzymes such as OxyR is now 
more feasible. Alternatively, cofactor F420 or its precursors might become more readily available 
to be exogenously supplied to S. cerevisiae through heterologous production in another organism 
such as E. coli. Importantly however, a reduction that takes place in S. cerevisiae in the absence 
of OxyR and F420 (Figure 2-3) potentially circumvents the need to heterologously express F420 in 
S. cerevisiae, a formidable challenge on its own right. 
Another alternative route to tetracycline from 5a(11a)-dehydrotetracycline is chemical reduction. 
However, the process is not necessarily stereoselective and can yield an additional stereoisomer to 
tetracycline, 5a-epitetracycline, of significantly lesser antibiotic activity (e.g. against S. aureus) 
than tetracycline.(11) Stereoselectivity was achieved however in the chemical reduction of the 
5a(11a)-bond of 7-chloro-5a(11a)-dehydrotetracycline and of the 6-peroxidated derivative of 
5a(11a)-dehydrotetracycline.(32-34) Larger scale culturing, isolation and NMR analysis of the 
reduction product of OxyS hydroxylation (Figure 2-3) will be needed to confirm whether the 
reduction takes place in the 5a(11a)-bond and if it does, whether it is stereoselective.  
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While the conversion percent for the hydroxylation of anhydrotetracycline by OxyS is high (Figure 
2-1), the conversion percent of the reduction reaction is much lower (Figure 2-3), assuming equal 
ionization capacity of anhydrotetracycline, its hydroxylated intermediate and its hydroxylated and 
reduced product (Scheme 2-1). Thus, optimization of the reduction reaction is likely to be needed. 
An obvious method for optimization of the reduction reaction would be to identify the native 
reductase enzyme in S. cerevisiae and overexpress it. In order to identify the endogenous reductase 
enzyme in S. cerevisiae a screen could be done using a plasmid collection of yeast genes and a 
screening method such as described in the next chapter.(35) An alternative assay would be an 
overlay of the yeast on bacteria given the much higher antibiotic activity of tetracycline over 
5a(11a)-dehydrotetracycline.(11) Instead of a library of yeast genes, a library of yeast deletion 
mutants could be screened, using similar assays, to identify yeast mutants that cannot reduce the 
hydroxylation products of OxyS.(36, 37)  
Importantly however, for these assays to function, the reduction of OxyS’s hydroxylation product 
needs to happen in whole cells and not only in cell lysates and whether and in which conditions 
this is the case is still unanswered. Thus, a cell lysate assay employing a more specific library of 
yeast reductases or ene-reductases or even ene-reductases of α,β-unsat carbonyls is preferable.(38-
40) An alternative method will be to screen additional OYE proteins for the reduction step and 
potentially perform directed evolution for improved substrate recognition and stereoselectivity in 
similar methods to those described in the next chapters.(41-50) Finally, OxyR homologs with F420 
or an intermediate in its biosynthesis are a potential alternative as well (Section 2.5.1). 
2.6 Conclusion 
The data presented in this chapter supports that the use of OxyS as the sole heterologously 
expressed enzyme in S. cerevisiae allows both a single hydroxylation and reduction steps of 
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anhydrotetracycline to take place using S. cerevisiae in the presence of G6P (Figure 2-3). This 
result is unexpected for two reasons. One, OxyS is known to perform two hydroxylation steps on 
anhydrotetracycline in vitro and in vivo. Two, it was expected that the coexpression of the 
dedicated reductase enzyme and the supply / heterologous biosynthesis of its nonnative cofactor 
would be required for the reduction step. Work on isolation and NMR analysis of the hydroxylation 
and hydroxylation + reduction products of anhydrotetracycline and 6-
demethylanhydrotetracycline to complement the results presented in this chapter is ongoing.  
The work presented in this chapter paves the road for total biosynthesis of tetracyclines using S. 
cerevisiae by expressing the additional bacterial biosynthetic enzymes from the oxytetracycline or 
the chlortetracycline pathways.(51-54) In addition, the work presented in this chapter paves the 
road for producing key tetracycline analogs from bacterial and fungal anhydrotetracyclines such 




Table 2-1 Strains used in this study 
 Genotype  Source/Reference 
FY251 MATa leu2-Δ1 trpΔ63 ura3-52 his3-Δ200 ATCC 96098 
BJ5464-
NpgA 
MATα ura3-52 his3-Δ200 leu2-Δ1 
trp1 pep4::HIS3 δ:: pADH2-npgA-tADH2 prb1Δ1.6R can1 
GAL 
a / (55) 
EH-3-80-3 FY251 pSP-G1 This Study 
EH-3-98-6 FY-251 AL-1-101-C10 This Study 
EH-3-142-A AL-1-141-A-C6 This Study 
EH-3-142-B AL-1-151-A-C4 This Study 
EH-3-142-C AL-1-151-B-C2 This Study 
ΕΗ-5-153-8 FY-251 AL-1-119-A-C7 This Study 
EH-3-204-5 FY-251 AL-1-119-A-C7, AL-215-D-C1 This Study 
EH-3-204-6 FY-251 AL-1-119-A-C7, AL-255-C1 This Study 
EH-3-204-7 FY-251 AL-1-119-A-C7, AL-235-C5 This Study 
EH-3-204-8 FY-251 AL-1-119-A-C7, pRS413-pGAL1 This Study 
EH-3-204-9 FY-251 AL-1-101-C10, pRS413-pGAL1 This Study 
EH-3-248-1 BJ5464-NpgA AL-1-101-C10 This Study 
EH-3-248-8 BJ5464-NpgA pSP-G1 This Study 
a Y. Tang, University of California, Los Angeles, Department of Chemical and Biomolecular 
Engineering & Department of Chemistry and Biochemistry, Department of Bioengineering 
 
Table 2-2 Plasmids used in this study 
 Description  Source/Reference 
pSP-G1 pTEF1-FLAG-tADH1, pPGK1-MYC-tCYC1, 2 μ, Ura Addgene 64736 
pRS413-
pGAL1 
Shuttle vector (empty), His marker, CEN ATCC 87326 
AL-1-101-
C10 
pTEF1-oxyS-tADH1 in pSP-G1 This Study 
AL-1-119-A-
C7 
pTEF1-oxyS-tADH1, pPGK1-oxyR-tCYC1 in pSP-G1 This Study 
AL-1-141-A-
C6 
pTEF1-oxyS-tADH1, pPGK1-OYE1-tCYC1 in pSP-G1 This Study 
AL-1-151-A-
C4 
pTEF1-oxyS-tADH1, pPGK1-OYE2-tCYC1 in pSP-G1 This Study 
AL-1-151-B-
C2 
pTEF1-oxyS-tADH1, pPGK1-OYE3-tCYC1 in pSP-G1 This Study 
AL-1-183-C-
C8 





Fo synthase Chlamydomonas reinhardtii This Study 
AL-1-215-D-
C1 
FGD1 from Mycobacterium tuberculosis This Study 
AL-1-255-C1 F420-dependent NADP+ oxidoreductase from 
Archeoglobus fulgidus  
This Study 




Table 2-3 Sequences used in this study 
The sequence for the hydroxylase OxyS from Streptomyces rimosus (GenBank AAZ78342.1) is 
shown capitalized within the context of the pSP-G1 backbone containing pTEF1, the FLAG tag 
and tADH1 (partial, decapitalized).  
The sequence for the reductase OxyR from Streptomyces rimosus (GenBank: DQ143963.2) is 
shown capitalized within the context of the pSP-G1 backbone containing pPGK1, the myc tag and 
tCYC1 (partial, decapitalized). 
Sequences for the three F420 reductases from M. tuberculosis, A. fulgidus and S. griseus are shown 
along with the pGPD (pTDH3) promoter capitalized within the context of the pRS413 backbone 
containing the tCYC1 terminator (partial, decapitalized). The NCBI/Genbank reference sequences 
used for the Fo reductases from M. tuberculosis, A. fulgidus and S. griseus are CP023708.1,  
NC_000917.1 and NC_010572.1 (6172267..6172977). Prior to codon optimization, leucine codon 
in M. tuberculosis F420 reductases in subsequence LTGAACAACACCCGGTTT was changed to 
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3 Towards the biosynthesis of 6-demethyl-6-










*The contents of this chapter will be published in: 
E. Herbst, V. W. Cornish, et al “Biosynthesis of 6-demethyl-6-epitetracyclines using 
Saccharomyces cerevisiae”, in preparation.  
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3.1 Chapter outline 
This chapter describes the work towards 6-demethyl-6-epitetracyclines biosynthesis using S. 
cerevisiae. 6α-hydroxylation by an enzyme such as DacO1 is required for the synthesis of 6-
demethyl-6-epitetracyclines as opposed to 6β-hydroxylation by enzymes such as OxyS leading to 
6-demethyltetracycline (Scheme 3-1 and Scheme 3-2). However, previous attempts in multiple 
heterologous hosts to heterologously express DacO1 without the rest of the dactylocyclinone 
pathway have not yielded stably expressed protein. Thus, the chapter first describes rational design 
approaches for optimizing DacO1 expression in S. cerevisiae (Section 3.4.1). The rationale behind 
the choices for bacterial hydroxylases screened for 6α-hydroxylase activity on anhydrotetracycline 
is explained (Section 3.4.2). Screening for 6-hydroxylase activity towards the biosynthesis of 6-
demethyl-6-epitetracyclines required the development of a multititer plate assay for 
anhydrotetracycline biosynthesis (Section 3.4.3). This assay was put to the use in screening for 
error-prone mutants of DacO1 in an attempt to identify 6α-hydroxylases of anhydrotetracycline 
(Section 3.4.4). Finally, the results of testing the rational design DacO1 expression optimization 
library as well as the other bacterial candidates for 6α-hydroxylation in S. cerevisiae are described 
(Section 3.4.5). Key results in this chapter are the the development of a stably expressing form of 
DacO1 in S. cerevisiae (Figure 3-8), the identification of PgaE as an anhydrotetracycline 
hydroxylase (Figure 3-9 and Figure 3-10), and the discovery that a larger proportion of PgaE 
hydroxylated intermediates undergo reduction in the presence of glucose-6-phosphate than is the 
case in OxyS (Figure 3-11). Finally, the next required steps towards 6-demethyl-6-epitetracyclines 





As mentioned in Chapter 1, the synthesis of 6-demethyl-6-epiglycotetracyclines for testing is 
highly desirable due to their highly promising outlook as antibiotics. The first two steps in the 
synthesis of 6-demethyl-6-epiglycotetracyclines are the synthesis of 6-demethyl-6-epitetracyclines 
from anhydrotetracyclines. This chapter shows the progress towards developing an S. cerevisiae 
platform for 6-demethyl-6-epitetracyclines biosynthesis using bacterial hydroxylase enzymes as a 
starting point for directed evolution and rational design as well as anhydrotetracycline as a model 
substrate. DacO1, a bacterial flavin-dependent monooxygenase homologous to OxyS was 
hypothesized to perform a 6α-hydroxylation on its native substrate that leads to 6-
epiglycotetracyclines in its native host, Dactylosporangium sp. SC 14051 (ATCC 53693).(1, 2) 
Thus, DacO1, along with other bacterial hydroxylases, is used here as a template to evolve a 6α-
hydroxylase in S. cerevisiae towards the biosynthesis of 6-demethyl-6-epiglycotetracyclines. 
3.3 Materials and methods 
See Chapter 5 for general methods. See Chapter 2 for general protocol for hydroxylation/reduction 
assay in cell lysate. 
3.3.1 General protocol for high throughput assay of hydroxylation/reduction 
in whole cells in microtiter plates 
Fresh colonies of strains harboring a plasmid encoding a hydroxylase and/or reductase and control 
strains (EH-3-98-6 encoding OxyS as positive control and EH-3-80-3 with no hydroxylase as 
negative control) were inoculated in 200 μL selective media (U- or HU-) in 96-well  plates (Corning 
353072) and placed in shaker overnight. Overnight cultures were used to inoculate 1 mL selective 
media (U- or HU-) cultures in deep well plates (Corning P-2ML-SQ-C-S) with an average starting 
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OD of 0.01. The plate was covered with two layers of SealMate film (Excel Scientific, SM-KIT-
BS) and placed in shaker overnight. Cells were then pelleted at 4 °C at 4,000 rpm. Each pellet was 
redissolved in 0.3 mL containing a 150 μL solution of 5 mg / mL anhydrotetracycline HCl, 30 μL 
1 M Tris buffer pH 7.45, 15 μL 40% glucose solution in H2O and 105 μL H2O for final 
concentrations of 2.5 mg/mL anhydrotetracycline HCl, 100 mM Tris pH 7.45 and 2% glucose. The 
plates were then covered with two layers of SealMate film (Excel Scientific, SM-KIT-BS) and 
placed in shaker overnight at 800 rpm. 2 μL of Overnight suspensions were diluted into 198 μL of 
H2O in Corning 3603 plates before UV/VIS spectroscopic measurements. UV/VIS spectroscopic 
measurements taken were as follows: (i) absorption spectrum 350 nm – 500 nm, (ii) emission 
spectrum 450 nm – 550 nm (λexcitation = 400 nm), (iii) excitation spectrum 305 nm – 455 nm (λemission 
= 500 nm). Spectral steps in the spectra were 25 nm. 
3.3.2 General protocol for western blots 
Fresh patches or colonies of strains harboring the plasmid for the hydroxylation and/or reduction 
enzyme and control strains were inoculated in 3 mL selective media (U-) in 15 mL culture tubes 
(Corning 352059) and placed in shaker overnight. Overnight cultures were used to reinoculate 3 
mL selective media (U-) in 15 mL culture tubes (Corning 352059) and placed in shaker overnight 
with a starting OD of 0.01-0.05 (all western Blots shown in this study except for western blots 
shown in Figure 3-1 which were pelleted and lysed immediately). Cells were grown to final OD 
of 0.6-0.8 before pelleting in 2 separate microcentrifuge tubes (1 mL culture each) at 4 °C at 14,000 
rpm, removing the supernatant and freezing at -20 °C prior to further use.  
100 μL of a 99:1 mixture of Y-PER yeast protein extraction reagent (ThermoFisher Scientific 
78991) and HALT protease inhibitor cocktail (ThermoFisher Scientific PI87786) were added to 
each microcentrifuge tube. The tubes were placed on orbital shaker for 20 min at r.t., followed by 
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10 min centrifugation at 14,000 rpm at 4 °C and the cell lysate was transferred to a new 1.5 mL 
microcentrifuge tube and kept on ice. Following 5 min at 95 °C with SDS loading buffer,(3) an 
SDS-page was run with a Kaleidoscope Prestained Standard (Bio-Rad 161-0324, Figure 3-1) or a 
Precision Plus Protein Kaleidoscope (Bio-Rad 161-0375, all other western blots shown),(4) the 
gels were transferred to PVDF blots (Thermo Fisher Scientific IB24001) and western blots were 
performed according to manufacturer guidelines (Thermo Fisher R951-25 and Sigma-Aldrich 
A8592 for myc-and FLAG-tag, respectively) with BSA used instead of milk and analyzed with 
Thremo Scientific 34000 substrate kit for horseradish peroxidase. 
3.4 Results 
3.4.1 Optimizing DacO1 expression in S. cerevisiae – rational design 
Following the successful hydroxylation of anhydrotetracycline in S. cerevisiae by OxyS described 
in Chapter 2, the 6α-hydroxylation of anhydrotetracycline in S. cerevisiae by DacO1 was 
attempted. DacO1 is 66% homologous to OxyS and is assumed to perform the 6α-hydroxylation 
on its native substrate, anhydrodactylocyclinone, as opposed to the 6β-hydroxylation that OxyS 
performs on anhydrotetracycline (Scheme 3-1).(1)  
DacO1 heterologous expression, along with the rest of the Dactylocyclinone pathway was 
previously attempted in Streptomyces lividans K4‐114 and has led to the successful biosynthesis 
of dactylocyclinone. Assuming correct assignment for the role of DacO1 in the dactylocycline 
pathway, given its homology to OxyS, this result supports that DacO1 was successfully 
heterologously expressed in S. lividans.(2) However, previous attempts to obtain soluble forms of 
heterologously expressed DacO1 from Streptomyces and E. coli, when heterologously expressed 
without the rest of its pathway, were not successful.(1)  
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My initial attempts to hydroxylate anhydrotetracycline with DacO1 yielded either little or no 
hydroxylation when assayed by mass spectrometry (data not shown) but little hydroxylation was 
supported by UV/Vis spectroscopy (Figure 3-4). Therefore, the expression levels of DacO1 were 
examined by western blotting with FLAG-tag to determine whether a problem in expression leads 
to the low/no hydroxylation levels with DacO1. Another likely explanation for low/no 
hydroxylation is difference between anhydrotetracycline, the model substrate I used, and 
anhydrodactylocyclinone, the native substrate of DacO1 (Scheme 3-1). Indeed, DacO1 expression 
levels were found to be significantly lower than its counterpart OxyS (Figure 3-1-a). 
 
Figure 3-1 Western Blot of DacO1 and OxyS 
Cultures of DacO1, DacO4 and OxyS, OxyR encoding strains EH-3-153-7 and EH-3-153-8, 
respectively were lysed with Y-PER and labeled with Monoclonal ANTI-FLAG HRP antibody. 
Two biological replicates were used for each strain indicated as colony 1 and 2 (C1 and C2), 
respectively. The expected sizes are 55.1, 55.9, 16.3 and 17.5 for DacO1, OxyS, DacO4 and OxyR, 
respectively.  
 
I therefore attempted to optimize the functional expression of DacO1 by a number of approaches. 
Namely, fusion to a stable protein, switching to a transcriptional control of an inducible promoter, 
expression in a strain background that has protease deletions, lower temperature culturing and 
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coexpression of pathway proteins. The testing of these expression optimization approaches is 
described in Section 3.4.5. 
Specifically, I attempted N-terminal fusions proteins previously shown to improve expression of 
heterologous proteins in yeast, ubiquitin,(5-8) superoxide dismutase,(9-11) Gal1(8) and γ-
IFN.(12) I also attempted a C- and N-terminal fusion to DacO4, the 5a(11a) reductase enzyme of 
the dactylocycline pathway that I verified to be stably expressed in yeast (Figure 3-1-b).  
Given the homology between OxyS and DacO1, the successful heterologous expression of OxyS 
and the potential importance of the N-terminus of the protein to its in vivo stability,(13) I attempted 
three fusion proteins composed of an N-terminal portion of OxyS and a C-terminal portion of 
DacO1. These fusion proteins include the first 37, 87 and 191 amino acids of OxyS, followed by 
the last 461, 411 and 307 amino acids of DacO1, respectively. In order to determine where to fuse 
the proteins I considered the structure of OxyS as determined previously by X-ray 
crystallography,(1) and made fusions proteins in disordered regions of the structure around 
positions 37, 87 and 191. The homology between DacO1 and OxyS made it simple to determine 
what are the corresponding amino acids at the DacO1 protein, although there is no guarantee the 
disordered regions in OxyS are also disordered in DacO1.  
For inducible promoters I tested pGAL1, induced by galactose, and pADH2, a late stage promoter 
induced in low glucose / high EtOH.(14) The alternative strain background I chose is BJ5464-
NpgA, as the BJ-5464 strain background was previously shown useful for heterologous protein 
production in yeast.(15, 16) For a lower temperature culturing I attempted 25 °C.(17, 18) 
The activity of polyketide biosynthetic enzymes is known to be dependent on an oligomeric 
complexation of biosynthetic enzymes. This is claimed for instance in the case of JadF, JadG and 
JadH of the Jadomycin biosynthetic pathway.(19) Similarly, in the case of an oxytetracycline 
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producing strain, deletion of the gene encoding for OtcC, which is 99% identical to OxyS used in 
this study, led to production of a polyketide with a shorter chain length. Expression of a triply 
mutated, catalytically disfunctional OtcC, restored production of a polyketide with the same chain 
length. Thus, a post-polyketdie synthase (PKS) polyketide biosynthetic enzyme could have a 
structural role in the oligomeric protein complex responsible for polyketide biosynthesis.(20) 
Potential further support for the potential that coexpression of additional proteins from the 
dactylocycline pathway has for improving DacO1 expression could be found in the case of DacO1 
itself. As mentioned above, expression of DacO1 together with the rest of the dactylocyclinone 
pathway in S. lividans led to the production of dactylocyclinone.(2) However, expression of 
DacO1 in the absence of the rest of the dactylocycline pathway in E. coli, Streptomyces,(1) or S. 
cerevisiae (Figure 3-1) yielded no/low levels of soluble protein. In order to provide DacO1 with 
enzymes potentially required to form a functional oligomeric complex I attempted the 
coexpression of DacJ and DacM2. DacJ and DacM2 were chosen since they are the closest 
enzymes to DacO1 in the dactylocycline gene cluster and they are proposed to share with DacO1 
the functional role of aglycone tailoring.(2)  
3.4.2 Searching the bacterial hydroxylase space for 6α-hydroxylation of 
anhydrotetracyclines 
Given the goal to perform 6α-hydroxylation on anhydrotetracyclines it was clear that there is a 
need to go beyond the 6β-hydroxylase OxyS. Expected challenges with the expression of Daco1 
(Section 3.4.1) as well as incongruencies between the DacO1 native substrate 
anhydrodactylocyclinone and anhydrotetracycline affirmed the need to test other hydroxylases as 
well (Scheme 3-1). I therefore looked for homologous enzymes catalyzing hydroxylation in 
polyketides that are structurally related to anhydrotetracycline.  
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Scheme 3-1 Bacterial monooxygenases and their hypothesized substrates and products 
Bacterial flavin-dependent monooxygenases OxyS, DacO1, SsfO1, CtcN and PgaE and their 




SsfO1, the hypothesized flavin-dependent monooxygenases of the 6α-position in SF2575 pathway, 
with 54% homology to OxyS, was an obvious candidate (Scheme 3-1).(2) Flavin-dependent 
monooxygenases of angucyclines, seemed like another promising source for relevant 
monooxygenases, given the structural similarity between angucyclines and tetracyclines. 
Specifically, enzymes that catalyze monooxygenation of position 12 of the angucyclines, 
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analogous to position 6 of the tetracyclines seemed of particular interest.(21) I chose to test PgaE 
(56% homology to OxyS), catalyzing the hydroxylation of UWM6 (Scheme 3-1), in the 
biosynthesis of gaudimycin C since it was previously both analyzed by X-ray crystallography and 
used in chemoenzymatic synthesis.(22, 23) Finally, CtcN, with 69% homology to OxyS was 
chosen since it was shown to be necessary for the 6-hydroxylation step in the chlortetracycline 
pathway.(24) The testing of these bacterial hydroxylases is described in Section 3.4.5. 
3.4.3 Developing a microtiter plate assay for anhydrotetracycline 
hydroxylation 
Given the need to screen for a 6α-hydroxylase of anhydrotetracyclines I developed a high 
throughput screen for hydroxylation of anhydrotetracyclines based on the ready detection of 
anhydrotetracycline hydroxylation by UV/Vis spectroscopy (Figure 2-2). Following colony 
picking onto microtiter plates and overnight culturing to even out the OD across the different wells 
the cells were reinoculated for a 2nd overnight culture, pelleted and resuspended in a Tris reaction 
buffer containing anhydrotetracycline and glucose. The suspension was then diluted in H2O for 
UV/VIS measurements (Figure 3-2).  
 





3.4.4 Evolving a 6α-hydroxylase of anhydrotetracyclines – DacO1 random 
mutagenesis 
Given the low/no hydroxylation activity of DacO1 on anhydrotetracycline, DacO1 optimization 
was attempted by directed evolution. An error-prone mutagenesis library from DacO1 encoding 
plasmid AL-1-31-C7 was made with an average of 3 mutations per 1 kb and transformed into 
FY251. The library was then assayed for anhydrotetracycline hydroxylation by the microtiter plate 
assay for anhydrotetracycline hydroxylation (Figure 3-2) with strains expressing OxyS, DacO1 
(w.t.) and empty plasmid (EH-3-98-6, EH-3-80-2 and EH-3-80-3, respectively) as controls. Over 
500 colonies were screened in the assay using 96-well plates with two potential hits identified. A 
typical plate with no hits, showing only the OxyS expressing strain positive control above 




Figure 3-3 DacO1 error-prone mutagenesis screen excerpt  
DacO1 error-prone mutagenesis screen using the microtiter plate assay for anhydrotetracycline 
hydroxylation. (a) a plate with only the OxyS positive control significantly above background 
fluorescence. (b) a plate with both the OxyS positive control and a DacO1 mutant hit with 
fluorescence significantly above background. Wells 60 and 72 contain the positive control OxyS 
encoding strain EH-3-98-6. λex = 400 nm.  
 
A followup on the two potential DacO1 mutant hits in the screen showed that one of them has a 
slightly increased fluorescence in the Δexcitation spectrum relative to DacO1 (Figure 3-4). The 
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new excitation peak at 375 nm, in 25 nm resolution, is similar to that found for OxyS hydroxylation 
of anhydrotetractycline at 380 nm, in 10 nm resolution, but of a much lower intensity (Figure 2-
2).  Considering that the increase in fluorescence is rather minor I decided to focus in the interim 
on alternatives such as rational design approaches to optimize hydroxylation by DacO1 and 
exploring DacO1 homologs (Sections 3.4.1 and 3.4.2, respectively).  The testing of these 
candidates is described in Section 3.4.5. 
 
Figure 3-4 ΔExcitation spectrum for DacO1 and DacO1 error-prone PCR mutant  
The spectrum shown is a Δ spectrum, that is, the values shown are the emission values for the 
hydroxylase expressing cells minus the emission values of the no hydroxylase control EH-3-80-3. 
λemission = 500 nm. Each value is the average of six biological replicates and the error bars represent 
standard error.  
 
3.4.5 Testing DacO1 expression optimization constructs and other bacterial 
hydroxylases 
I screened the strains generated for the DacO1 optimization attempts as well as their controls, EH-
5-98-1 through EH-5-98-19, EH-3-248-1 through EH-3-248-8, EH-3-80-2, EH-3-80-3, EH-3-98-
6 and EH-5-115-1 through EH-5-115-5 (Sections 3.4.1 and 3.4.2) using the microtiter plate 
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UV/Vis assay (Section 3.4.3). Each of the 35 strains was assayed in four biological replicates, as 
well as in two culturing temperatures, 30 °C and 25 °C, starting from the 2nd inoculation stage 
(Figure 3-2).  The protocol for the microtiter plate UV/Vis assay (Section 3.3.1) was slightly 
modified to accommodate the strains encoding DacO1 controlled by inducible promoters. Thus, 
EH-5-98-7 and EH-5-98-8 encoding pADH2-dacO1 were inoculated in YPD in the 2nd inoculation 
and EH-5-98-4 and EH-5-98-5, encoding pGAL1-dacO1 were inoculated in U- Raffinose and 
supplemented in the next morning with 66.7 μL of 30% galactose in H2O for a total concentration 
of 2%. UV/Vis measurements were taken following one night and after three nights of incubation 
with anhydrotetracycline for the 30 °C plates and after one night only for the 25 °C plates.  
Strains that showed a blue shift in their peak in the Δexcitation spectrum from that of negative 
control strain EH-3-80-2 harboring empty pSP-G1 were indicated as potential hits in the assay and 
are shown in Table 3-1. Specifically, strains listed in the table have shown in the Δexcitation 
spectrum a peak of 405 nm, 380 nm or 355 nm as opposed to the 430 nm peak of negative control 
EH-3-80-3, associated with anhydrotetracycline. Results from three measurements are shown, two 
measurements after overnight incubation of the cells suspensions in the buffer containing 
anhydrotetracycline, one for each of the culturing temperatures (25 °C and 30 °C) and another 
final measurement for the 30 °C culturing condition after 3 nights of suspension in the buffer 
containing anhydrotetracycline. The rank was calculated per plate measured for one of the 
measurements according to the emission at the peak maximum, and should be interpreted only as 
a rough indicator as peak emissions at three different wavelengths are ranked on the same scale. 
The number 1 or 2 after the dot indicates the plate number from which the measurement was taken.  
Reassuringly, the positive control OxyS, whose native substrate is anhydrotetracycline is leading 
the rank in highest emission resulting from a blue-shifted excitation. It is followed by the various 
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DacO1 fusion proteins as well as by hydroxylase alternatives to OxyS and DacO1. Surprisingly, 
empty pSP-G1 and OxyR in the alternative background strain, BJ-5464-NpgA have also displayed 
a blue-shifted peak in the excitation spectrum, although they are the lowest ranking (Table 3-1). 
Also surprisingly, EH-3-80-2 encoding unoptimized DacO1 has not displayed a blue shifted 
excitation peak in the reduction spectrum in contrast to previous experiments (Figure 3-4). Strains 
that exhibited a blue-shifted excitation peak at 25 °C and not in 30 °C are: DacO1-DacO4, 
OxySDacO1-191, no-AB-tags and DacO1-JCAT-BJ. I proceeded to analyze by western blot the 
hydroxylase expression of the strains that displayed a blue-shifted excitation peak in all three 




Table 3-1 Potential hits in the screen of DacO1 expression optimization constructs and other 
bacterial hydroxylases  
Strain 
number 









Rank 30 °C 
measurement I  
EH-3-98-6 OxyS Y Y Y 1.1 
EH-3-98-6 OxyS Y Y Y 1.2 
EH-5-98-9 Ubiquitin-γ-IFN-
DacO1 
Y Y Y 2.1 
EH-3-248-2 OxyS-OxyR-BJ Y Y Y 2.2 
EH-5-98-1 Ubiquitin-DacO1 Y Y Y 3.1 
EH-3-248-1 OxyS BJ Y Y Y 3.2 
EH-5-98-10 γ-IFN-DacO1 Y Y Y 4.1 
EH-5-115-4 OxyS JCAT Y Y Y 4.2 
EH-3-98-2 hSOD-DacO1 Y Y   5.1 
EH-3-248-7 PgaE-JCAT-BJ Y Y Y 5.2 
EH-5-98-3 Gal1-DacO1 Y Y Y 6.1 
EH-3-248-5 CtcN-JCAT-BJ Y Y Y 6.2 
EH-5-98-12 DacO4-DacO1 Y Y Y 7.1 
EH-5-115-5 DacO1-JCAT-BJ Y Y Y 7.2 
EH-5-98-14 OxyS-DacO1-87 Y Y Y 8.1 
EH-3-248-6 SsfO1-JCAT-BJ Y Y Y 8.2 
EH-5-98-13 OxyS-DacO1-37 Y Y Y 9.1 
EH-3-248-4 DacO1-BJ Y Y Y 9.2 
EH-3-248-3 OxyR Y     10.2 
EH-3-248-8 pSP-G1-empty-BJ Y Y Y 11.2 
EH-98-11 DacO1-DacO4   Y     
EH-5-98-15 OxyS-DacO1-191   Y     
EH-5-98-6 DacO1-no-AB-
tags 
  Y     
EH-5-98-16 DacO1-JCAT-BJ   Y     






Figure 3-5 Western blot analysis of DacO1 fusion proteins and other bacterial hydroxylases 
in FY251 
Strain cultures were lysed with Y-PER and labeled with monoclonal ANTI-FLAG HRP antibody. 
Two biological replicates were used for each strain indicated as colony 1 and 2 (C1 and C2), 
respectively. Strain EH-5-98-1, EH-5-98-3, EH-5-98-9, EH-5-98-10 and EH-5-98-13 encode 
DacO1 fusions with ubiquitin, Gal1, Ubiquitin-γ-IFN, γ-IFN, and OxyS (first 37 amino acids) 
respectively. In the latter only the last 461 amino acids of DacO1 are encoded, while in the other 
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DacO1 fusion proteins the complete DacO1 protein is encoded. Strains EH-3-80-2, EH-3-80-3 and 
EH-3-98-6 encode DacO1, no hydroxylase and OxyS, respectively. The size (kDa) indicated below 
the gels is the expected size of the protein based on the amino acid sequence.  
 
 
Figure 3-6 Western blot analysis of bacterial hydroxylases in BJ-5464-NpgA 
Strain cultures were lysed with Y-PER and labeled with monoclonal ANTI-FLAG HRP antibody. 
Two biological replicates were used for each strain indicated as colony 1 and 2 (C1 and C2), 
respectively. The size (kDa) indicated below the gels is the expected size of the protein based on 






Figure 3-7 Western blot analysis of DacO1-DacO4 and DacO4-DacO1 fusion proteins 
Strain cultures were lysed with Y-PER and labeled with monoclonal ANTI-Myc HRP antibody. 
Two biological replicates were used for each strain indicated as colony 1 and 2 (C1 and C2), 
respectively. The size (kDa) indicated below the gels is the expected size of the protein based on 
the amino acid sequence.  
 
 
For the fusion protein constructs in FY251, ubiquitin-DacO1-C1, Gal1-DacO1-C1 and Ubiquitin-
IFN-DacO1-C1 slight bands are observed in the expected sizes that are not observed in the DacO1-
C1 control (55.0, 86.5 and 72.0 kDa, respectively, Figure 3-5). Bands at the expected sizes were 
also observed for OxyS-DacO1-37, SsfO1, OxyS and DacO1-C2, with SsfO1 and OxyS bands 
looking more prominent (55.5, 56.2, 55.9 and 55.1 kDa, respectively, Figure 3-5). OxyS-DacO1-
37 and DacO1-C2 show a 50 < band < 75 kDa that is not observed in the empty pSP-G1 negative 
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control. In all bands, proteins of lower mass are noticeable, potentially corresponding to 
proteolysis products of the hydroxylases retaining the C-terminal FLAG-tag.  
For the protein constructs in BJ-5464-NpgA, clearly less degradation products are observed 
(Figure 3-6). OxyS, SsfO1 and PgaE show very prominent bands at the expected sizes (55.9, 56.2 
and 53.8 kDa) for both colonies; CtcN-C1 shows a slighter band in the expected size (51.9 kDa) 
and DacO1-JCAT-C2 shows an even slighter band of the expected size (55.1 kDa). In addition, 
the codon optimization method (COOL vs JCAT) does not seem to significantly alter expression 
levels in the case of OxyS, or significantly remediate expression levels in the case of DacO1 
(Compare strains EH-3-248-1 and EH-3-248-4 with strains EH-5-115-4 and EH-5-115-5, 
respectively, Figure 3-6). Finally, even though BJ-5464-NpgA expression apparently reduced 
protein degradation for other hydroxylases (e.g. OxyS and SsfO1) it does not seem to have 
promoted significantly expression levels for DacO1 (Figure 3-5 and Figure 3-6).  
The DacO4-DacO1 fusion did not yield a stably expressed protein. While DacO4 under pPGK1 
and labeled with myc-tag is clearly expressed when unfused to DacO1, the DacO4-DacO1 fusion 
is not observed in the gel when under pPGK1 and labeled with myc-tag, in either FY251 or 
BJ5464-NpgA background strain (Figure 3-7). 
Since less protein degradation was observed for OxyS and SsfO1 in BJ5464-NpgA relative to 
FY251 (Compare strain EH-3-248-1 and EH-3-248-6 to strains EH-3-98-6 and EH-5-98-17, 
Figure 3-6 and Figure 3-5, respectively) it was logical to test whether the expression of the DacO1 
N-terminal fusion proteins would be enhanced in BJ5464-NpgA as well. Strains EH-5-163-1 
through EH-5-163-7 were therefore cloned and their DacO1 fusion expression was tested by 




Figure 3-8 Western blot analysis of DacO1 and its fusion proteins in BJ5464-NpgA 
Strain cultures were lysed with Y-PER and labeled with monoclonal ANTI-FLAG HRP antibody. 
Two biological replicates were used for each strain indicated as colony 1 and 2 (C1 and C2), 
respectively. Strains EH-5-163-1, through EH-5-163-7 encode DacO1 fusions with ubiquitin, 
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Gal1, Ubiquitin-γ-IFN, γ-IFN, DacO4, OxyS (first 37 amino acids) and OxyS (first 87 amino 
acids), respectively. In the last two strains only the last 461 and 411 amino acids of DacO1 are 
encoded, respectively, while the other DacO1 fusion proteins the complete DacO1 protein is 
encoded. In contrast to DacO1 and its fusion proteins, PgaE expressing strain in this assay has an 
FY251 background. The size (kDa) indicated below the gels is the expected size of the protein 
based on the amino acid sequence.  
 
In BJ5464-NpgA background, Ubiquitin-DacO1 fusion expression levels seem similar to that of 
unfused DacO1; Gal1-DacO1, Ubiquitin-IFN-DacO1-C2 and IFN-DacO1-C2 fusions gave bands 
at the expected sizes of 86.5 and 72.0, respectively, with IFN-DacO1-C2 showing the most 
prominent band; The OxyS N-terminal fusions to C-terminal DacO1, OxyS-DacO1-37 and OxyS-
DacO1-87 both gave bands at the expected size with OxyS-DacO1-87-C1 showing the more 
prominent band (Figure 3-8). Based on these results, the colonies showing better DacO1 
expression levels were chosen for analysis of anhydrotetracycline hydroxylation by mass 
spectrometry (Scheme 3-2).  
Scheme 3-2 Two-step enzymatic conversion of (6-demethyl-)anhydrotetracycline to (6-
demethyl-)6-epitetracycline 
Cell lysates of strains expressing hydroxylases that showed stronger bands of the expected sizes 
in the Western Blots were incubated in a Tris buffer with anhydrotetracycline and glucose-6-
phosphate. The overnight incubations were then assayed by mass and UV/Vis spectrometry 
(Figure 3-9 and Table 3-2). The strains that show hydroxylation levels potentially above 
background, as indicated by 443.4 ion counts that are more than double those for the no 
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hydroxylase negative control, are those encoding OxyS, PgaE and Ubiquitin-γ-IFN-DacO1 
(labeled as 1, 4 and 9, respectively in Figure 3-9). These three strains, along with three additional 
ones encoding γ-IFN-DacO1, OxySDac37 and OxySDac87, also show a maximal emission and/or 
excitation in the Δspectra that differs from that of the background strain EH-3-248-8 encoding 
empty pSP-G1 (Table 3-2). Therefore, these six strains along with EH-3-248-4 and EH-3-248-8 
as controls were assayed again by mass spectrometry in a wider set of conditions prior to larger 






Figure 3-9 Mass spectrometry analysis of anhydrotetracycline hydroxylation and reduction 
by cell lysates of strains expressing DacO1, its fusion proteins and other bacterial 
hydroxylases 
The analyzed strains shown are EH-3-248-1, EH-3-248-4, EH-3-248-6, EH-3-248-7, EH-3-248-8, 
EH-5-163-1-C1, EH-5-163-2-C1, EH-5-163-2-C2, EH-5-163-3-C2, EH-5-163-4-C2, EH-5-163-
6-C1, EH-5-163-7-C1 encoding hydroxylases OxyS, DacO1, SsfO1, PgaE, pSPG1 (no 
hydroxylase negative control), Ubiquitin-DacO1, Gal1-DacO1, Gal1-DacO1, Ubiquitin-γ-IFN-
DacO1, γ-IFN-DacO1, OxyS-DacO1-37 and OxyS-DacO1-87, respectively. Cell lysates were 
placed overnight in Tris buffer (100 mM, pH 7.45) containing anhydrotetracycline (5.4 mM), 
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glucose (27.8 mM), NADPH (3 mM), glucose-6-phosphate (10 mM) and mercaptoethanol (18.5 
mM). 
 
Table 3-2 UV/Vis spectroscopy results for hydroxylase strains cell lysates incubated with 
anhydrotetracycline and glucose-6-phosphate 
 Strain no. Hydroxylase Max emission  
(λexcitation = 280 nm) 
Max excitation 
(λemission = 500 nm) 
1 EH-3-248-1 OxySb 490 390 
2 EH-3-248-4 DacO1 590 350 
3 EH-3-248-6 SsfO1 580 350 
4 EH-3-248-7 PgaEb 580 370 
5 EH-3-248-8 pSPG1a 580 350 
6 EH-5-163-1-C1 UbiDac 570 350 
7 EH-5-163-2-C1 GalDac 570 350 
8 EH-5-163-2-C2 GalDac 570 350 
9 EH-5-163-3-C2 UbiIFNDacb 690 350 
10 EH-5-163-4-C2 IFNDacb 460 350 
11 EH-5-163-6-C1 OxySDac37b 420 370 
12 EH-5-163-7-C1 OxySDac87b 430 470 
a The maximum emission and maximum absorption spectra of EH-3-248-8 encoding no 
hydroxylase (empty pSP-G1) are shown in italics. For all other strains, the maximum value shown 
are from the Δspectrum of the corresponding strain minus the spectrum of the EH-3-248-8 strain 
encoding no hydroxylase (empty pSP-G1). 
b Maximum emission and excitation values for the Δspectra that are more than 10 nm different 
than the corresponding values obtained for strain EH-3-248-8 encoding no hydroxylase (empty 
pSP-G1) are shown in bold.  
 
In order to select strains and conditions for larger scale reactions, strains encoding hydroxylases 
that performed favorably according to the Western Blot, mass spectrometry and UV/Vis 
spectroscopy results were analyzed in a larger set of conditions using mass spectrometry. 
Following cell lysis, lysates were incubated overnight in four different conditions (Table 3-3) and 
analyzed by mass spectrometry. The rationale behind trying different conditions was that given 
that the conversion rates for all non-OxyS hydroxylases were significantly lower than for OxyS 
(Figure 3-9), the reaction should be optimized to allow enough product to be isolated for NMR 
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analysis. The strains that show hydroxylation levels potentially above background, as indicated by 
443.4 ion counts that are more than double those for the no hydroxylase negative control encoding 
empty pSP-G1, are OxyS and PgaE, with OxyS-DacO1-37 as the closest runner up (Figure 3-10). 
These four strains will be used for a larger scale lysate experiment followed by product isolation 
and analysis by NMR spectroscopy. Condition D, maximizing the m/z peak associated with 
tetracycline ([M + H]+) per amount of cell lysate used will be used to attempt the isolation of 
tetracycline or its 6-epimer and condition B maximizing the m/z peak associated with 5a(11a)-
dehydrotetracycline ([M + H]+) will be used to attempt the isolation of the latter or its 6-epimer.  
Table 3-3 Assay conditions for anhydrotetracycline hydroxylation and reduction in cell 
lysates of strains expressing DacO1, its fusion proteins and other bacterial hydroxylases 
Condition no.a Atc (mM) G6P (10 mM) Cell lysate dilution factor into reaction mix 
A 5.4 +  5X 
B 5.4 -  5X 
C 21.6 +  5X 
D 21.6 +  10X 
aCell lysates were placed overnight in Tris buffer (100 mM, pH 7.45) containing in addition to 
anhydrotetracycline and glucose-6-phosphate at the concentrations mentioned above, glucose 





Figure 3-10 Mass spectrometry analysis of anhydrotetracycline hydroxylation and reduction 
in cell lysates of strains expressing DacO1, its fusion proteins and other bacterial 
hydroxylases 
The analyzed strains shown EH-3-248-1, EH-3-248-4, EH-3-248-7, EH-3-248-8, EH-5-163-3-C2, 
EH-5-163-4-C2, EH-5-163-6-C1, EH-5-163-7-C1 are encoding hydroxylases OxyS, DacO1, 
PgaE, pSPG1 (no hydroxylase negative control), Ubiquitin-γ-IFN-DacO1, γ-IFN-DacO1, OxyS-
DacO1-37 and OxyS-DacO1-87, respectively.  
 
While for both OxyS and PgaE, in the presence of G6P there is an increase in 445 ion counts 
associated with the product of both hydroxylation and reduction reactions (Figure 2-3 and Figure 
3-10), the PgaE samples are consistently associated with higher 445/443 ion count ratios relative 
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to the OxyS samples in the presence of G6P (Figure 3-11). This supports that in the case of PgaE 
hydroxylation a larger fraction of the hydroxylation product ([M-H]+ = 443) gets further reduced 
([M-H]+ = 445). 
  
Figure 3-11 Mass spectrometry analysis of anhydrotetracycline hydroxylation and reduction 
in cell lysates of strains expressing OxyS and PgaE 
The analyzed strains shown are EH-3-248-1 and EH-3-248-7 encoding hydroxylases OxyS and 
PgaE, respectively in condition A (Table 3-3). TIC is total ion count. 443 and 445 refer to ion 
counts of these m/z values. 
 
3.5 Discussion 
3.5.1 Optimizing DacO1 expression in S. cerevisiae – rational design 
DacO1 is hypothesized to be the 6-hydroxylase enzyme in the dactylocycline pathway based on 
its homology to OxyS, the 6-hydroxylase of the oxytetracycline pathway. Based on this 
assignment, DacO1 is performing its 6-hydroxylase function when heterologously expressed 
together with the rest of the dactylocyclinone pathway in S. lividans.(2) Heterologous expression 
of DacO1 exclusively does not yield a stably expressed protein in either E. coli or Stryptomyces,(1) 
and as shown in this study neither does it stably heterolougsly expressed in S. cerevisiae (Figure 
3-1). These results taken together with the importance of coexpression of other pathway proteins 
to the function of other polyketide enzymes,(19, 20) led to the hypothesis that coexpression of 
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pathway proteins might be beneficial for DacO1 stable expression in S. cerevisiae. For the 
particular proteins whose coexpression with DacO1 in S. cerevisiae was attempted, DacJ and 
DacM2, this hypothesis was not confirmed (Table 3-1). However, it could be that other or 
additional proteins from the dactylocycline pathway are needed for stable heterologous expression 
of DacO1. In contrast, the strategy to improve DacO1 expression by N-terminal fusions was 
successful (Sections 3.4.5 and 3.5.5). 
3.5.2 Searching the bacterial hydroxylase space for 6α-hydroxylation of 
anhydrotetracyclines 
The successful identification of PgaE as a hydroxylase of anhydrotetracycline is shown in Section 
3.4.5 and discussed in Section 3.5.5. PgaE heterologous expression in S. cerevisiae thus 
exemplifies the power of natural enzyme diversity harvesting and testing in S. cerevisiae as a 
heterologous host. 
3.5.3 Developing a microtiter plate assay for anhydrotetracycline 
hydroxylation 
The microtiter plate assay for hydroxylation of anhydrotetracyclines is functional, as confirmed 
by differentiation between the OxyS encoding strain and the negative control strain (Figure 3-3) 
and its throughput could be further increased. One approach to increase the assay throughput would 
be to employ an automatic liquid dispenser / colony picker as well as to reduce the volume of each 
well in the assay.(25, 26) In the current assay format only 2 μL of the 300 μL suspension are 
needed for the final UV/Vis analysis. An alternative approach to increase the assay throughput 
would be to grow colonies on agar plates supplemented with anhydrotetracycline and monitor the 
change in fluorescence by a fluorescence agar plate imager and thus circumventing the need for 
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microtiter plate handling. However, given that anhydrotetracycline is toxic to S. cerevisiae at 
elevated concentrations it remains to be determined whether an agar plate UV/Vis assay is 
practical.(27, 28) On the other hand, that very toxicity could prove useful to develop a growth-
based assay, as tetracyclines eukaryotic toxicity is significantly lower than that of 
anhydrotetracyclines. Thus, conversion of anhydrotetracycline to tetracycline could lead to an 
increased growth rate in media containing anhydrotetracycline.(27, 28) 
The stereochemical difference between the expected products of anhydrotetracycline 
hydroxylation by a 6β-hydroxylase such as OxyS and a 6α-hydroxylase such as DacO1, 5a(11a)-
dehydrotetracycline and 5a(11a)-6-epidehydrotetracycline, respectively, might lead to a difference 
in the absorption/emission of the respective products. Thus, an optimized spectrophotometer 
measurement protocol for the microtiter plate assay for anhydrotetracycline hydroxylation might 
be desired. However, in both cases both absorption and emission are expected to be blue-shifted, 
a difference that the current protocol is capable of detecting. DacO1 hydroxylation is supported by 
UV/Vis evidence of the current protocol (Figure 3-4) although it is still to be determined whether 
5a(11a)-6-epidehydrotetracycline is indeed synthesized from the reaction of DacO1 with 
anhydrotetracycline (Section 3.5.5). 
3.5.4 Evolving a 6α-hydroxylase of anhydrotetracyclines – DacO1 random 
mutagenesis 
Importantly, the library-based (Section 3.4.4 and Section 4.4.3) and rational design-based (Section 
3.4.1) approaches for optimizing DacO1 for 6α-hydroxylation of anhydrotetracycline in S. 
cerevisiae are not mutually exclusive. The winner of the DacO1 error-prone mutagenesis screen 
and additional winners of future screens could be sequenced to identify the amino acids at which 
mutations occurred and these sites could be chosen for saturation mutagenesis. The resulting 
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library of size ~100 could be then sequenced by the microtiter plate assay for anhydrotetracycline 
hydroxylation with a followup on screen hits as shown (Figure 3-4). The sequence of the confirmed 
hits can then be fused in DacO1-fusions that were confirmed to be effective in enhancing DacO1 
expression levels such as UbiIFN-DacO1, IFN-DacO1, OxyS-DacO1-37 and OxyS-DacO1-87 
(Figure 3-8). Alternatively the expression optimized DacO1 fusion porteins could be used for EP-
PCR or saturation mutagenesis as per Section 3.4.4 and Section 4.4.3. 
3.5.5 Testing DacO1 expression optimization constructs and other 
hydroxylases 
The attempt to fuse a stable protein or protein fragment at the N-terminus of DacO1, or a DacO1 
fragment in the case of the OxyS fusions, to improve DacO1 expression levels was successful 
(Figure 3-8). However, the more stably expressed DacO1 fusions are still poor hydroxylases of 
anhydrotetracycline at best compared to OxyS (Figure 3-9 and Figure 3-10). A very likely 
hypothesis to explain the poor hydroxylation activity is that the natural substrate of DacO1, 
anhydrodactylocyclinone, is different enough from anhydrotetracycline to impede efficient 
hydroxylation of the latter. In fact, the hydroxylase SsfO1, whose heterologous expression was 
confirmed to be effective in S. cerevisiae (Figure 3-5 and Figure 3-6) did not prove an effective 
hydroxylase of anhydrotetracycline at all (Figure 3-9). The native substrate of DacO1 differs from 
anhydrotetracycline by having 8-methoxy, 7-chloro and 4a-hydroxy instead of protons in 
anhydrotetracycline and it could be that these functional groups serve as recognition elements in 
the substrate (Scheme 3-1). The 8-methoxy and 7-chloro substituents can could further have an 
electronic contribution to the activation energy of the hydroxylation reaction.  
With stably expressed DacO1 fusion proteins at hand such as ubiquitin-γ-IFN-DacO1, γ-IFN-
DacO1, OxyS-DacO1-37 and OxyS-DacO1-87 (Figure 3-8), a few avenues could now be 
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explored: (i) upscale current hydroxylation setup (Table 3-3 and Section 3.4.5) and attempt 
isolation of product and analysis by NMR to verify whether the desired 6α-hydroxylation occurred. 
(ii) mutagenize stably expressed DacO1 fusion proteins by error-prone PCR (Section 3.4.4) or 
saturation mutagenesis (Section 4.4.3) or a combination thereof and then test for 
anhydrotetracycline or 6-demethylanhydrotetracycline(29) hydroxylation by the mutants using the 
microplate UV/Vis assay (Section 3.4.3); (iii) test DacO1 fusion proteins hydroxylation of the 
DacO1 native substrate, anhydrodactylocyclinone (Scheme 3-1) or 6-
demethyanhydrodactylocyclinone; and (iv) test TAN-1612 hydroxylation by coexpressing the 
DacO1 fusion proteins and the TAN-1612 pathway (Chapter 4). Given the high biological 
variation between the different colonies expressing DacO1-fusion proteins (Figure 3-8), testing 
several biological replicates for each strain for these approaches might be crucial. 
Specifically for (iii), Anhydrodactylocyclinone and 6-demethylanhydrodactylocyclinone could be 
obtained either by deleting the dacO1 and dacO4 or the dacO1, dacO4 and dacM2 genes from 
plasmid pDac, respectively, and transforming the resulting plasmid into a K4-114 strain harboring 
pDacT1O3E.(2) Importantly, isolating anhydrodactylocyclinone and/or 6-
demethylanhydrodactylocyclinone using such plasmids would support the functional assignment 
of DacO1, DacO4 and DacM2. Alternatively the DacO1 native substrate could be pursued by 
acidic dehydration of dactylocyclinone,(29) the aglycone of dactylocycline A, which can be 
purified either from its native producer Dactylosporangium sp. SC 14051 (ATCC 53693) or from 
the heterologous producer K4/pDac-T1O3E.(2, 30, 31) A coculture of a (6-demethyl-
)anhydrodactylocyclinone producing strain and the strain encoding the DacO1 fusion protein is 
another potential alternative. Finally, it is also potentially possible to feed the strain encoding the 
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DacO1 fusion protein with crude (6-demethyl-)anhydrodactylocyclinone without prior 
purification. 
PgaE, a bacterial monooxygenase tested as a potential 6α-hydroxylase candidate (Section 3.4.2) 
was found to hydroxylate anhydrotetracycline (Sections 3.4.5 and 3.5.2). Furthermore, in the 
presence of PgaE more reduced product was obtained relative to the hydroxylated product, when 
compared to OxyS (Figure 3-11). Possible reasons for increased reduction proportion of 
hydroxylated anhydrotetracycline in the PgaE sample (Figure 3-11) could be (i) a lower 
hydroxylation rate in the case of PgaE results in less overload on reduction capacities (ii) a different 
hydroxylation product between OxyS and PgaE, such as different stereochemistry that leads to a 
more ready reduction of the PgaE hydroxylation product, (iii) an involvement of OxyS and/or 
PgaE in the reduction process either directly by catalyzing it or indirectly by facilitating the process 
through product binding. These reasons could be tested by isolating the hydroxylation product 
from two different cell lysates expressing OxyS or PgaE and not containing G6P and analyzing 
the hydroxylated product by NMR. Studying and comparing the spectra would support or reject 
reason (ii). The isolated hydroxylated product can then be added to one of three cell lysates in the 
presence of G6P, expressing OxyS or PgaE or no hydroxylase. This will eliminate hydroxylation 
levels influence as per reason (i) and will enable testing whether OxyS and/or PgaE are involved 
in the reduction as per reason (iii), although it is still perhaps possible that involvement of OxyS 
and/or PgaE in the reduction happens only immediately after the hydroxylation before product 
release.  
3.6 Conclusion 
This chapter describes the progress towards 6-demethyl-6-epitetracyclines biosynthesis in S. 
cerevisiae (Scheme 3-2). The biosynthesis of 6-demethyl-6-epitetracyclines as opposed to 6-
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demethyltetracyclines requires a 6α-hydroxylase, such as DacO1, as opposed to a 6β-hydroxylase 
such as OxyS (Scheme 3-1). However, past attempts to stably heterologoulsy express DacO1 
without the rest of its pathway have been unsuccessful.(1)  With the rational design attempt to 
stabilize DacO1 expression by N-terminal fusion proteins proving successful (Figure 3-8), the next 
step is to test the stably expressed DacO1 fusion proteins in larger scale for 6α-hydroxylation of 
anhydrotetracycline and/or anhydrodactylocyclinone and/or 6-demethylanhydrodactylocyclinone 
(Section 3.5.5). This will allow product isolation followed by NMR analysis. In addition, given 
the differences between DacO1’s native substrate and anhydrotetracycline (Scheme 3-1) and given 
that DacO1 fusion proteins are poor hydroxylases of anhydrotetracycline at best (Figure 3-9 and 
Figure 3-10), the stably expressed DacO1 fusion proteins could be subjected to mutagenesis 
(Section 3.4.4 and Section 4.4.3) to identify mutants that readily hydroxylate the desired 
anhydrotetracycline substrate.  
In addition to the use of rational design to improve DacO1 expression, this chapter also describes 
harvesting natural diversity in bacterial hydroxylases towards the search for a 6α-hydroxylase 
(Section 3.4.2). With PgaE, one of these bacterial hydroxylases, proving as a hydroxylase of 
anhydrotetracycline (Figure 3-9 and Figure 3-10) the next step is to analyze its product after large 
scale preparation and isolation and to verify whether it is performing 6α-hydroxylation or 6-
hydroxylation at all on anhydrotetracycline. It also remains to be determined why a larger 
proportion of the hydroxylation product of anhydrotetracycline undergoes reduction when PgaE is 
used as the hydroxylase in comparison to when OxyS is used (Figure 3-11) and whether either of 
these hydroxylases participates in reduction as well. Participation of OxyS or PgaE in the reduction 
reaction could theoretically take place by direct catalysis of the reduction or by facilitating catalysis 
through product binding. These open questions could be better understood by adding the isolated 
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hydroxylation product of OxyS and of PgaE, each to three separate cell lysates of strains encoding 
OxyS, PgaE and no hydroxylases.  
Finally, using a variant of the microtiter plate assay for anhydrotetracycline hydroxylation (Figure 
3-2 and Figure 3-3), the promising 6α-hydroxylation candidates identified in this chapter (Table 
3-2) were screened for hydroxylation of the fungal anhydrotetracycline TAN-1612 in the next 




Table 3-4 Strains used in this study 
 Genotype  Source/Reference 
FY251 MATa leu2Δ1 trpΔ63 ura3-52 his3-200 ATCC 96098 
BJ5464-
NpgA 
MATα ura3-52 his3-Δ200 leu2-Δ1 
trp1 pep4::HIS3 δ:: pADH2-npgA-tADH2 prb1Δ1.6R can1 
GAL 
a / (15) 
EH-3-80-2 FY251 AL-1-31-C7 This Study 
EH-3-80-3 FY251 pSP-G1 Chapter 2 
EH-3-98-6 FY-251 AL-1-101-C10 Chapter 2 
ΕΗ-5-153-7 FY-251 AL-1-173-B-C4 This Study 
ΕΗ-5-153-8 FY-251 AL-1-119-A-C7 Chapter 2 
EH-3-248-1 BJ5464-NpgA AL-1-101-C10 Chapter 2 
EH-3-248-2 BJ5464-NpgA AL-1-119-A-C7 This Study 
EH-3-248-3 BJ5464-NpgA AL-1-26-1-C1 This Study 
EH-3-248-4 BJ5464-NpgA AL-1-31-C7  This Study 
EH-3-248-5 BJ5464-NpgA AL-1-234-B-C2 This Study 
EH-3-248-6 BJ5464-NpgA AL-1-239-B-C3 This Study 
EH-3-248-7 BJ5464-NpgA AL-1-234-C-C1 This Study 
EH-3-248-8 BJ5464-NpgA pSP-G1 Chapter 2 
EH-3-270-9 FY-251 AL-2-8-D This Study 
EH-5-19-2 FY-251 AL-2-8-D This Study 
EH-5-98-1 FY251 EH-5-49-A This Study 
EH-5-98-2 FY251 EH-5-49-B This Study 
EH-5-98-3 FY251 EH-5-49-C This Study 
EH-5-98-4 FY251 EH-5-80-1 This Study 
EH-5-98-5 FY251 EH-5-80-2 This Study 
EH-5-98-6 FY251 EH-5-80-3 This Study 
EH-5-98-7 FY251 EH-5-80-4 This Study 
EH-5-98-8 FY251 EH-5-80-5 This Study 
EH-5-98-9 FY251 EH-5-80-6 This Study 
EH-5-98-10 FY251 EH-5-80-7 This Study 
EH-5-98-11 FY251 EH-5-80-8 This Study 
EH-5-98-12 FY251 EH-5-80-9 This Study 
EH-5-98-13 FY251 EH-5-80-10 This Study 
EH-5-98-14 FY251 EH-5-80-11 This Study 
EH-5-98-15 FY251 EH-5-80-12 This Study 
EH-5-98-16 FY251 AL-1-239-A This Study 
EH-5-98-17 FY251 AL-1-239-B This Study 
EH-5-98-18 FY251 EH-5-90-A This Study 
EH-5-98-19 FY251 EH-5-90-A This Study 
EH-5-115-1 FY251 EH-5-90-A EH-5-105-Α This Study 
EH-5-115-2 FY251 AL-1-31-C7 EH-5-105-A This Study 
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EH-5-115-3 FY251 pSP-G1 EH-5-105-A This Study 
EH-5-115-4 BJ5464-NpgA AL-1-226-A This Study 
EH-5-115-5 BJ5464-NpgA AL-1-239-A This Study 
EH-5-163-1 BJ5464-NpgA EH-5-49-A This Study 
EH-5-163-2 BJ5464-NpgA EH-5-49-C This Study 
EH-5-163-3 BJ5464-NpgA EH-5-80-6 This Study 
EH-5-163-4 BJ5464-NpgA EH-5-80-7 This Study 
EH-5-163-5 BJ5464-NpgA EH-5-80-9 This Study 
EH-5-163-6 BJ5464-NpgA EH-5-80-10 This Study 
EH-5-163-7 BJ5464-NpgA EH-5-80-11 This Study 
EH-5-163-8 FY251 AL-1-234-C-C1 This Study 
a Y. Tang, University of California, Los Angeles, Department of Chemical and Biomolecular 
Engineering & Department of Chemistry and Biochemistry, Department of Bioengineering 
 
Table 3-5 Plasmids used in this study 
 Description  Source/Reference 
pSP-G1 pTEF1-FLAG-tADH1, pPGK1-MYC-tCYC1, 2 μ, Ura Addgene 64736 
pRS413-pGAL1 Shuttle vector (empty), His marker, CEN ATCC 87326 
pRS416- pGAL1 Shuttle vector (empty), Ura marker, CEN ATCC 87332 
pRS426- pGAL1 Shuttle vector (empty), Ura marker, 2 μ ATCC 87361 
AL-1-26-1-C1 pPGK1-oxyR-tCYC1 in pSP-G1 This Studya 
AL-1-31-C7 pTEF1-dacO1-tADH1 in pSP-G1 This Study 
AL-1-101-C10 pTEF1-oxyS-tADH1 in pSP-G1 Chapter 2 
AL-1-119-A-C7 pTEF1-oxyS-tADH1, pPGK1-oxyR-tCYC1 in pSP-G1 Chapter 2 
AL-1-173-B-C4 pTEF1-dacO1-tADH1, pPGK1-dacO4-tCYC1 in pSP-
G1 
This Study 
AL-1-226-A-C2 pTEF1-oxyS-tADH1 in pSP-G1 JCAT codon opt. This Study 
AL-1-234-B-C2 pTEF1-ctcN-tADH1 in pSP-G1 JCAT codon opt. This Study 
AL-1-234-C-C1 pTEF1-pgaE-tADH1 in pSP-G1 JCAT codon opt. This Study 
AL-1-239-A-C2 pTEF1-dacO1-tADH1 in pSP-G1 JCAT codon opt. This Study 
AL-1-239-B-C3 pTEF1-ssfO1-tADH1 in pSP-G1 JCAT codon opt. This Study 
AL-2-8-D Error-prone mutagenesis library of AL-1-31-C7  This Study 
EH-5-49-A pTEF1-UBI4-dacO1-tADH1 in pSP-G1 This Study 
EH-5-49-B pTEF1-SOD1-dacO1-tADH1 in pSP-G1 This Study 
EH-5-49-C pTEF1-GAL1-dacO1-tADH1 in pSP-G1 This Study 
EH-5-80-1 pGAL1-dacO1-tCYC1 in pRS416 This Study 
EH-5-80-2 pGAL1-dacO1-tCYC1 in pRS426 This Study 
EH-5-80-3 pTEF1-dacO1-tADH1 in pSP-G1 (no antibody tag) This Study 
EH-5-80-4 pADH2-dacO1-tCYC1 in pRS416 This Study 
EH-5-80-5 pADH2-dacO1-tCYC1 in pRS426 This Study 
EH-5-80-6 pTEF1-UBI4-IFNG-dacO1-tADH1 in pSP-G1b This Study 
EH-5-80-7 pTEF1-IFNG-dacO1-tADH1 in pSP-G1b This Study 
EH-5-80-8 pPGK1-dacO4-dacO1-tCYC1 in pSP-G1 This Study 
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EH-5-80-9 pPGK1-dacO1-dacO4-tCYC1 in pSP-G1 This Study 
EH-5-80-10 pTEF1-oxyS-dacO1-37-tADH1 in pSP-G1 This Study 
EH-5-80-11 pTEF1-oxyS-dacO1-87-tADH1 in pSP-G1 This Study 
EH-5-80-12 pTEF1-oxyS-dacO1-191-tADH1 in pSP-G1 This Study 
EH-5-90-A pTEF1-dacO1-tADH1, pPGK1-dacJ-tCYC1 in pSP-G1 This Study 
EH-5-105-Α pGPD-dacM2-tCYC1 in pRS413 This Study 
a See Chapter 2 for sequence.  
b the sequence of UBI4 and of IFNG used in the gene contrasts here is partial. See Table 3-6 
 
Table 3-6 Sequences used in this study 
Sequences for the hydroxylases DacO1 (GenBank: AFU65892.1), PgaE (PDB: 2QA1_A), SsfO1 
(GenBank: GQ409537.1), CtcN (GenBank: D38214.1) and the DacO1 fusion proteins with UBI4 
(GenBank: AF134781.1), SOD1 (GenBank: KJ892183.1), GAL1 (NM_001178368.1), IFNG 
(GenBank: X62468.1) and OxyS (AAZ78342.1) are shown capitalized within the context of the 
pSP-G1 backbone containing pTEF1, the FLAG tag and tADH1 (partial, decapitalized).  
Sequences for DacO4 (GenBank: JX262387.1), the DacO1-DacO4 and DacO4-DacO1 fusions and 
DacJ (GenBank: JX262387.1) are shown capitalized within the context of the pSP-G1 backbone 
containing pPGK1, the myc tag and tCYC1 (partial, decapitalized). 
The sequence for DacM2 (GenBank: JX262387.1) is shown along with the pGPD (pTDH3) 
promoter capitalized within the context of the pRS413 backbone containing the tCYC1 terminator 
(partial, decapitalized).  
The sequences for DacO1 in pRS backbone under the control of pGAL1 or pADH2 is shown 
capitalized along with the promoter (decapitalized in the case of pGAL1 and capitalized in the case 



































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































1. Wang P, Bashiri G, Gao X, Sawaya MR, Tang Y. Uncovering the Enzymes that Catalyze 
the Final Steps in Oxytetracycline Biosynthesis. J Am Chem Soc. 2013;135(19):7138-7141. doi: 
10.1021/ja403516u. 
2. Wang P, Kim W, Pickens LB, Gao X, Tang Y. Heterologous Expression and Manipulation 
of Three Tetracycline Biosynthetic Pathways. Angewandte Chemie-International Edition. 
2012;51(44):11136-11140. doi: 10.1002/anie.201205426. 
3. SDS gel-loading buffer (2X). Cold Spring Harbor Protocols. 2006;2006(1). doi: 
10.1101/pdb.rec407. 
4. Gallagher SR. One-Dimensional SDS Gel Electrophoresis of Proteins. Curr Protoc Mol 
Biol. 2006;75(1):10.12.11-10.12A.37. doi: 10.1002/0471142727.mb1002as75. 
5. Ecker DJ, Stadel JM, Butt TR, Marsh JA, Monia BP, Powers DA, Gorman JA, Clark PE, 
Warren F, Shatzman A, et al. Increasing gene expression in yeast by fusion to ubiquitin. J Biol 
Chem. 1989;264(13):7715-7719. 
6. Ecker DJ, Khan MI, Marsh J, Butt TR, Crooke ST. Chemical synthesis and expression of 
a cassette adapted ubiquitin gene. J Biol Chem. 1987;262(8):3524-3527. 
7. Schuster M, Einhauer A, Wasserbauer E, Süßenbacher F, Ortner C, Paumann M, Werner 
G, Jungbauer A. Protein expression in yeast; comparison of two expression strategies regarding 
protein maturation. J Biotechnol. 2000;84(3):237-248. doi: 10.1016/s0168-1656(00)00355-2. 
8. Stȩpień PP, Brousseau R, Wu R, Narang S, Thomas DY. Synthesis of a human insulin gene 
VI. expression of the synthetic proinsulin gene in yeast. Gene. 1983;24(2-3):289-297. doi: 
10.1016/0378-1119(83)90089-6. 
9. Cousens LS, Shuster JR, Gallegos C, Ku L, Stempien MM, Urdea MS, Sanchez-Pescador 
R, Taylor A, Tekamp-Olson P. High level expression of proinsulin in the yeast, Saccharomyces 
cerevisiae. Gene. 1987;61(3):265-275. doi: 10.1016/0378-1119(87)90190-9. 
10. Steimer KS, Higgins KW, Powers MA, Stephans JC, Gyenes A, George-Nascimento C, 
Luciw PA, Barr PJ, Hallewell RA, Sanchez-Pescador R. Recombinant polypeptide from the 
128 
 
endonuclease region of the acquired immune deficiency syndrome retrovirus polymerase (pol) 
gene detects serum antibodies in most infected individuals. J Virol. 1986;58(1):9-16. 
11. Barr P, Steimer K, Sabin E, Parkes D, Georgenascimento C, Stephens J, Powers M, Gyenes 
A, Vannest G, Miller E. Antigenicity and immunogenicity of domains of the human 
immunodeficiency virus (HIV) envelope polypeptide expressed in the yeast Saccharomyces 
cerevisiae. Vaccine. 1987;5(2):90-101. doi: 10.1016/0264-410x(87)90053-3. 
12. Barr PJ, Inselburg J, Green KM, Kansopon J, Hahm BK, Gibson HL, Lee-Ng CT, Bzik DJ, 
Li W-b, Bathurst IC. Immunogenicity of recombinant Plasmodium falciparum SERA proteins in 
rodents. Mol Biochem Parasitol. 1991;45(1):159-170. doi: 10.1016/0166-6851(91)90038-8. 
13. Bachmair A, Finley D, Varshavsky A. In vivo half-life of a protein is a function of its 
amino-terminal residue. Science. 1986;234(4773):179-186. doi: 10.1126/science.3018930. 
14. Peng B, Williams TC, Henry M, Nielsen LK, Vickers CE. Controlling heterologous gene 
expression in yeast cell factories on different carbon substrates and across the diauxic shift: a 
comparison of yeast promoter activities. Microbial Cell Factories. 2015;14(1). doi: 
10.1186/s12934-015-0278-5. 
15. Ma SM, Li JWH, Choi JW, Zhou H, Lee KKM, Moorthie VA, Xie X, Kealey JT, Da Silva 
NA, Vederas JC, Tang Y. Complete Reconstitution of a Highly Reducing Iterative Polyketide 
Synthase. Science. 2009;326(5952):589-592. doi: 10.1126/science.1175602. 
16. Jones EW. Tackling the protease problem in Saccharomyces cerevisiae. Methods Enzymol. 
1991;194:428-453. doi: 10.1016/0076-6879(91)94034-A. 
17. Romanos MA, Scorer CA, Clare JJ. Foreign gene expression in yeast: a review. Yeast. 
1992;8(6):423-488. doi: 10.1002/yea.320080602. 
18. Tøttrup HV, Carlsen S. A process for the production of human proinsulin inSaccharomyces 
cerevisiae. Biotechnol Bioeng. 1990;35(4):339-348. doi: 10.1002/bit.260350403. 
19. Rix U, Wang C, Chen Y, Lipata FM, Remsing Rix LL, Greenwell LM, Vining LC, Yang 
K, Rohr J. The Oxidative Ring Cleavage in Jadomycin Biosynthesis: A Multistep Oxygenation 




20. Perić-Concha N, Borovička B, Long PF, Hranueli D, Waterman PG, Hunter IS. Ablation 
of theotcC Gene Encoding a Post-polyketide Hydroxylase from the Oxytetracyline Biosynthetic 
Pathway inStreptomyces rimosusResults in Novel Polyketides with Altered Chain Length. J Biol 
Chem. 2005;280(45):37455-37460. doi: 10.1074/jbc.M503191200. 
21. Kharel MK, Pahari P, Shepherd MD, Tibrewal N, Nybo SE, Shaaban KA, Rohr J. 
Angucyclines: Biosynthesis, mode-of-action, new natural products, and synthesis. Nat Prod Rep. 
2012;29(2):264-325. doi: 10.1039/c1np00068c. 
22. Koskiniemi H, Metsä-Ketelä M, Dobritzsch D, Kallio P, Korhonen H, Mäntsälä P, 
Schneider G, Niemi J. Crystal Structures of Two Aromatic Hydroxylases Involved in the Early 
Tailoring Steps of Angucycline Biosynthesis. J Mol Biol. 2007;372(3):633-648. doi: 
10.1016/j.jmb.2007.06.087. 
23. Kallio P, Liu Z, Mäntsälä P, Niemi J, Metsä-Ketelä M. Sequential Action of Two 
Flavoenzymes, PgaE and PgaM, in Angucycline Biosynthesis: Chemoenzymatic Synthesis of 
Gaudimycin C. Chem Biol. 2008;15(2):157-166. doi: 10.1016/j.chembiol.2007.12.011. 
24. Dairi T, Nakano T, Aisaka K, Katsumata R, Hasegawa M. Cloning and Nucleotide 
Sequence of the Gene Responsible for Chlorination of Tetracycline. Biosci, Biotechnol, Biochem. 
2014;59(6):1099-1106. doi: 10.1271/bbb.59.1099. 
25. Kong F, Yuan L, Zheng YF, Chen W. Automatic Liquid Handling for Life Science. Journal 
of Laboratory Automation. 2012;17(3):169-185. doi: 10.1177/2211068211435302. 
26. Dörr M, Fibinger MPC, Last D, Schmidt S, Santos-Aberturas J, Böttcher D, Hummel A, 
Vickers C, Voss M, Bornscheuer UT. Fully automatized high-throughput enzyme library screening 
using a robotic platform. Biotechnol Bioeng. 2016;113(7):1421-1432. doi: 10.1002/bit.25925. 
27. Oliva B, Gordon G, McNicholas P, Ellestad G, Chopra I. Evidence that tetracycline analogs 
whose primary target is not the bacterial ribosome cause lysis of Escherichia coli. Antimicrob 
Agents Chemother. 1992;36(5):913-919. doi: 10.1128/aac.36.5.913. 
28. Gossen M, Bujard H. Anhydrotetracycline, a novel effector for tetracycline controlled gene 
expression systems in eukaryotic cells. Nucleic Acids Res. 1993;21(18):4411-4412. doi: 
10.1093/nar/21.18.4411. 
29. Asai M. Studies on Pillaromycin A. II. The Structure of Pillaromycinone. Chem Pharm 
Bull (Tokyo). 1970;18(9):1706-1712. doi: 10.1248/cpb.18.1706. 
130 
 
30. Wells JS, O'Sullivan J, Aklonis C, Ax HA, Tymiak AA, Kirsch DR, Trejo WH, Principe 
P. Dactylocyclines, novel tetracycline derivatives produced by a Dactylosporangium sp. I. 
Taxonomy, production, isolation and biological activity. J Antibiot. 1992;45(12):1892-1898. doi: 
10.7164/antibiotics.45.1892. 
31. Tymiak AA, Aklonis C, Bolgar MS, Kahle AD, Kirsch DR, O'Sullivan J, Porubcan MA, 
Principe P, Trejo WH. Dactylocyclines: novel tetracycline glycosides active against tetracycline-











4 Towards the biosynthesis of 6-demethyl-6-









*The contents of this chapter will be published in: 
E. Herbst, V. W. Cornish, et al “Biosynthesis of 6-demethyl-6-epitetracycline analogs of TAN-
1612 in Saccharomyces cerevisiae”, in preparation.  
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4.1 Chapter outline 
This chapter describes the work towards 6-demethyl-6-epitracycline derivatives of the fungal 
anhydrotetracycline TAN-1612 in Saccharomyces cerevisiae. Building on the previous chapters 
describing anhydrotetracycline hydroxylations, this chapter begins by exploring the product 
formed by coexpressing the TAN-1612 pathway and the bacterial hydroxylase PgaE (Section 
4.4.1). The testing of fungal hydroxylase homologs to DacO1, the 6α-hydroxylase of 
anhydrodactylocyclinone is then described (Section 4.4.2) followed by the description of a method 
for bacterial monooxygenase saturation mutagenesis near the anhydrotetracycline binding site, 
with OxyS as an example (Section 4.4.3). Finally, the screening process of this natural diversity 
and generated diversity by mutagenesis is described (Section 4.4.4) with future directions for 
followup discussed. A key result described in this chapter is the isolation and characterization of 
a new major product in a strain coexpressing PgaE and the TAN-1612 pathway that differs from 
the TAN-1612 major product in the strain expressing the TAN-1612 pathway without PgaE 
(Figure 4-2, Figure 4-3 and Figure 4-5). The followup plan on this result and on the screen for 
TAN-1612 hydroxylases is outlined in the Discussion.  
4.2 Introduction 
TAN-1612, a fungal anhydrotetracycline derivative originally produced by Aspergillus niger, has 
been introduced to S. cerevisiae by the Tang laboratory and our laboratory has further improved 
its titers in synthetic media, thus allowing the heterologous production of TAN-1612 
derivatives.(1) TAN-1612 differs from anhydrotetracycline in five functional groups, an A-ring 
methyl ketone instead of the A-ring amide, a 4α-proton instead of the 4α-dimethylamino, a 4a-
hydroxy instead of the 4a-proton, a 6-proton instead of the 6-methyl and an 8-methoxy instead of 
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the 8-proton (Scheme 4-2). The stereochemistry of TAN-1612 at the 4a,12a positions has not yet 
been verified, although the stereochemistry of the product of the homologous fungal polyketide 
pathway, viridicatumtoxin, has been determined to be the same as anhydrotetracycline in these 
positions.(2, 3) As outlined in the introduction chapter, the synthesis of 6-demethyl-6-
epiglycotetracyclines is highly desirable (Section 1.6). TAN-1612 presents a unique scaffold for 
the biosynthesizing these derivatives in S. cerevisiae due to its ready biosynthesis in this 
heterologous host and its unique functional groups among anhydrotetracycline (Section 1.6.4). 
Much of the knowledge generated in the process of anhydrotetracycline hydroxylation by OxyS 
and PgaE, as well as DacO1 expression optimization, described in the previous chapters, is directly 
relevant to the hydroxylation of TAN-1612 in S. cerevisiae as outlined in this chapter.  
4.3 Materials and methods 
See Chapter 5 for general methods. See Chapter 3 for general protocol for high throughput assay 
of hydroxylation/reduction assay in whole cells in microtiter plates and a general protocol for 
western blots.  
4.3.1 General protocol for high throughput assay of TAN-1612 hydroxylation 
in whole cells in microtiter plates 
Fresh colonies of strains harboring a plasmid encoding the TAN-1612 pathway and a hydroxylase 
and control strains (EH-5-212-2 encoding PgaE and the TAN-1612 pathway as positive control 
and EH-5-212-4 encoding the TAN-1612 pathway and no hydroxylase as a negative control) were 
inoculated in 200 μL selective media (UT -) in 96-well plates (Corning 353072) and placed in 
shaker overnight. Overnight cultures were used to inoculate 300 μL selective media (UT-) cultures 
in deep well plates (Corning P-2ML-SQ-C-S) with an average starting OD of 0.01. The plate was 
covered with two layers of SealMate film (Excel Scientific, SM-KIT-BS) and placed in shaker at 
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800 rpm for three nights. 200 μL H2O were then added and after resuspension 20 μL were diluted 
into 180 μL of H2O in Corning 3603 plates before UV/VIS spectroscopic measurements. UV/VIS 
spectroscopic measurements taken were as follows: (i) absorption spectrum 350 nm – 600 nm, (ii) 
emission spectrum 450 nm – 650 nm (λexcitation = 400 nm), (iii) excitation spectrum 300 nm – 450 
nm (λemission = 500 nm), (iii) excitation spectrum 300 nm – 450 (λemission = 560 nm). Spectral steps 
in the spectra were 50 nm. 
4.3.2 Protocol for selecting amino acids for mutagenesis in hypothesized 
binding pockets of monooxygenases 
The structure of aklavinone-11 hydroxylase with FAD and aklavinone (PDB ID 3IHG) was loaded 
on PyMOL. Residues that are within 5 Å from the substrate aklavinone were selected as follows:  
PyMOL>hide everything, all 
PyMOL>select contacts, (resn VAK and chain A) around 5 
 Selector: selection "contacts" defined with 88 atoms. 
PyMOL>select contacts_res, byres contacts 
 Selector: selection "contacts_res" defined with 268 atoms. 
PyMOL>show sticks, contacts_res 
Setting: seq_view set to on. 




4.4.1 Testing PgaE and other bacterial hydroxylases for TAN-1612 
hydroxylation  
Considering the mass spectrometry support for hydroxylation of anhydrotetracycline by OxyS and 
PgaE (Chapter 3, Section 3.4.5) it was logical to test them for TAN-1612 hydroxyaltion (Scheme 
4-1). SsfO1 was tested as well because of its efficient expression in S. cerevisiae and 6α-
hydroxylation of its native substrate (Section 3.4.5 and Scheme 4-2).  





Scheme 4-2 Bacterial monooxygenases and their hypothesized substrates and products 
Bacterial flavin-dependent monooxygenases OxyS, DacO1, SsfO1, CtcN and PgaE and their 
native substrates. Marked in blue are differences between the native substrate and TAN-1612. 
 
 
The strain expressing the TAN-1612 pathway without an additional hydroxylase has an excitation 
peak at 420 nm for 560 nm emission and an emission peak of 530 nm for 400 nm excitation (Figure 
4-1). This strain was confirmed to produce TAN-1612 as the major compound of 400 nm 
absorption (Figure 4-5-a and Figure 4-2). The strains expressing OxyS and SsfO1 have similar 
excitation and emission peaks, although both are increased for the sample encoding OxyS. 
Notably, the strain encoding PgaE has a significantly reduced emission in 560 nm when excited at 
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420 +/- 30 nm (Figure 4-1), indicating that TAN-1612 is either not produced or produced in much 
lower quantities than in the other strains.  
 
Figure 4-1 UV/Vis analysis of hydroxylation attempt of TAN-1612 by bacterial hydroxylases 
(a) Excitation spectrum (λemission = 560 nm) (b) emission spectrum (λexcitation = 400 nm) of strains 
EH-5-212-1, EH-5-212-2, EH-5-212-3 and EH-5-212-4 harboring a plasmid encoding the TAN-
1612 pathway as well as a plasmid encoding OxyS, PgaE, SsfO1 and no hydroxylase, respectively. 
Emission and excitation spectra were taken after diluting cultures that were incubated for 3 nights 
in UT- media (4 mL) in 15 mL culture tubes (Corning 352059). Each data point and error bar 




In order to test which compound or compounds are being produced instead of TAN-1612 in the 
strain expressing the TAN-1612 pathway and PgaE, both that strain and the control strain 
expressing no hydroxylase were cultured in 500 mL scale to allow purification and further analysis 
by mass spectrometry and NMR. Following three nights of culturing each culture was extracted 
twice with EtOAc and the combined organic extract was washed with H2O and dried with Na2SO4 
with the organic solvent removed under reduced pressure. The extract was then purified by 
semiprepative HPLC prior to NMR and mass spectrometry analysis.  
As the absorption chromatogram of the semipreparative HPLC separation shows, the main product 
with regards to both 400 nm absorption and 254 nm absorption is modified in the +PgaE sample 
relative to the -PgaE control. While the main product in the -PgaE control elutes after 37 minutes, 
the main product in the +PgaE sample elutes after 34 minutes (Figure 4-2). Interestingly the -PgaE 
sample has a minor product eluting after 34 minutes, which could be the same product as the main 




Figure 4-2 UV/Vis chromatogram of the HPLC separation of extracts from +/- PgaE strains 
encoding the TAN-1612 pathway.  
Strains EH-5-212-2 and EH-5-212-4 harboring a plasmid encoding the TAN-1612 pathway as well 
as a plasmid encoding PgaE and no hydroxylase, respectively are indicated as +PgaE and -PgaE, 
respectively. Both strains were cultured in 500 mL scale for three nights. Prior to HPLC separation 
the culture was extracted twice with EtOAc and the combined organic extract was washed with 
H2O and dried with Na2SO4, with the organic solvent removed under reduced pressure. Absorption 
chromatograms are shown for 254 and 400 nm for an HPLC separation method of 10:90 to 90:10 




The main product of each HPLC separation was isolated and analyzed by NMR and mass 
spectrometry. The mass spectrometry analysis of the -PgaE compound clearly supports that TAN-
1612 was isolated (MS (ES+): m/z calc’d for C21H19O9
+, 415.1029; found 415.1026 [M + H]+ 
(Figure 4-3-a) and the NMR spectrum matches the published TAN-1612 spectrum (Figure 4-5-
a).(1) For the +PgaE sample, the mass spectrum shows four major peaks for an elution peak with 
absorbance at both 254 nm and 400 nm: 593.1218, 298.0743, 279.0966 and 278.0483 (Figure 4-3-
b). The NMR spectrum of the sample does not show the methoxy and methyl ketone protons of 
shifts 3.89 and 2.58 ppm as well as the two aromatic protons of chemical shifts 7.05 and 6.45 ppm 
and does show additional 7 aromatic protons in their stead (Figure 4-5-b). The possible identity of 








Figure 4-3 Mass spectrometry analysis of isolate from +/-PgaE strain encoding the TAN-
1612 pathway. 
Liquid chromatography mass spectrometry analyses for isolates from strains EH-5-212-2 and EH-
5-212-4 harboring a plasmid encoding the TAN-1612 pathway as well as a plasmid encoding PgaE 
and no hydroxylase, respectively are shown in (b) and (a), respectively. Both strains were cultured 
in 500 mL scale for three nights. Prior to HPLC separation the culture was extracted twice with 
EtOAc and the combined organic extract was washed with H2O and dried with Na2SO4, with the 
organic solvent removed under reduced pressure. The LCMS separation method is 5:95 to 95:5 
MeCN in 99.9% H2O/0.1% formic acid over 2 min.   
 
 
Figure 4-4 MSMS analysis of isolate from +PgaE strain encoding the TAN-1612 pathway. 
Liquid chromatography MSMS analyses for isolate from strain EH-5-212-2 harboring a plasmid 
encoding the TAN-1612 pathway as well as a plasmid encoding PgaE with ion selection at mass 
593. The LCMSMS separation method is 5:95 to 95:5 MeCN in 99.9% H2O/0.1% formic acid over 









1H-NMR spectra of isolates from strains EH-5-212-2 and EH-5-212-4 harboring a plasmid 
encoding the TAN-1612 pathway as well as a plasmid encoding PgaE and no hydroxylase, are 
shown in (b) and (a), respectively. Both strains were cultured in 500 mL scale for three nights. 
Prior to HPLC separation the culture was extracted twice with EtOAc and the combined organic 
extract was washed with H2O and dried with Na2SO4, with the organic solvent removed under 
reduced pressure. NMR spectra shown are in MeOD-d4 for the major product of each strain 
according to HPLC chromatogram (Figure 4-2). 1H NMR (for (b), δ>4 ppm, 500 MHz, MeOD-
d4): δ 7.61 (dd, J = 8.0, 1.0 ,1H), 7.47 (d, J = 8.6, 2H), 7.22 (dd, J = 8.0, 1.1, 1H), 6.88 (dd, J = 
8.6, 2H), 6.85 (dd, J = 8.0, 1H), 6.72 (s, 1H). 
   
 
Figure 4-6 COSY NMR spectrum of isolate from +PgaE strain encoding the TAN-1612 
pathway. 
Strain EH-5-212-2 harboring a plasmid encoding the TAN-1612 pathway as well as a plasmid 
encoding PgaE. Both strains were cultured in 500 mL scale for three nights. Prior to HPLC 
separation the culture was extracted twice with EtOAc and the combined organic extract was 
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washed with H2O and dried with Na2SO4, with the organic solvent was removed under reduced 
pressure. NMR spectra shown is in MeOD-d4 for the major product according to the HPLC 
chromatogram (Figure 4-2).  
 
 
4.4.2 Searching the fungal hydroxylase space for 6α-hydroxylation of TAN-
1612 
Given the expression challenges with the bacterial monooxygenase DacO1 (Section 3.4.1) it was 
logical to test fungal monooxygenases as well. Fungal monooxygenases were chosen based on 
homology to DacO1 and/or based on the presence of anhydrotetracycline monooxygenase in their 
CDS product name. Table 4-1 shows the first twelve such enzymes attempted. Western blot 
analysis revealed that expression challenges could be prevalent with fungal hydroxylases as well, 
with only 25% of the fungal hydroxylases assayed displaying a band at the expected size (Figure 
4-7). The strains that did not indicate any protein expression at the expected size encoded fungal 
monooxygenases of entries 1, 2, 4, 5, 6, and 11 from Table 4-1. The two strains that did exhibit 
protein expression at the expected size encoded fungal hydroxylases entries 8 and 12 from Table 
4-1 (Figure 4-7). For the small sample tested, the two codon optimized fungal monooxygenases 
did not present a band of the expected size in S. cerevisiae. Two of the six non-codon optimized 
did presented such a band. The two strains that exhibited a protein of the expected size had a higher 
identity %, positives % and query cover with both DacO1 and OxyS than the six strains that did 
not exhibit a band of the expected size but not necessarily to a statistically significant degree 





Table 4-1 Fungal monooxygenases biomined for TAN-1612 6α-hydroxylation in S. cerevisiae 
Entry Gene product 
label 


































strain CBS 132785 
MNBE01
000128.1 











N 30/41/510 34/45/537 


































































































N 32/45/521 34/47/529 
aDacO1 [Dactylosporangium sp. SC14051] GenBank: AFU65892.1 





Figure 4-7 Western blot analysis of fungal hydroxylase expression in BJ5464-NpgA 
Strain cultures were lysed with Y-PER and labeled with Monoclonal ANTI-FLAG HRP antibody. 
The size (kDa) indicated below the gels is the expected size of the protein based on the amino acid 
sequence. Strains EH-5-227-1 through EH-5-227-9 encode Fungal monooxygenase entry 6, 5, 1, 
4, 2, 2, 8, 11, 12, from Table 4-1, respectively. 
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4.4.3 Evolving monooxygenases for 6α-hydroxylation of anhydrotetracyclines 
– OxyS example 
Considering the effective hydroxylation of anhydrotetracycline in yeast by OxyS (Chapter 2), its 
apparent lack of hydroxylation activity on TAN-1612 (Section 4.4.1) and an effective UV/Vis 
assay for anhydrotetracyclines hydroxylation (Sections 3.4.3-3.4.5), directed evolution of OxyS to 
accept TAN-1612 as a substrate seemed logical. In addition, OxyS structure was previously probed 
by X-ray crystallography, as well as the structure of a homologous protein, Aklavinone-11-
Hydroxylase, along with its native substrate, aklavinone (42% homology, PDB ID 4K2X and 
3IHG, respectively).(4, 5) Thus, the substrate binding pocket of OxyS could be identified with 
some confidence and mutated accordingly.  
In order to perform saturation mutagenesis on residues that are in proximity to the hypothesized 
substrate binding pocket of OxyS, residues of Aklavinone-11-Hydroxylase that are within 5 Å of 
aklavinone were listed (Section 4.3.2). Then the homologous residues in OxyS were noted as well 
(Table 4-2). Some of these homologous residues in OxyS indeed sit in proximity to a cavity that 
is a continuation of the cavity in which FAD is situated in the OxyS crystal structure (Figure 4-8). 













1 R45 PYPRAAG K42 FSKALGV 4-5 
2 A47 PRAGQN A43 SKALGVH <4 
3 G48 AAGQNPR G45 KALGVHAR 4-5 
4 I72 ADDIRG - - <4 
5 F79 QGDFVIR - - <4 
6 I81 QGDFVIR - - 4-5 
7 M101 DDMVAA - - 4-5 
8 W113 PAGWAM L95 PYALFV 4-5 
9 M115 PAGWAMLSQD F96 PYAL-FVPQV <4 
10 M201 LTHMVGV M176 --HMFAV <4 
11 W221 GTTGWYYL W211 DLRAWFAAFP <4 
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12 Y223 TGWYYLH F212 DLRAWFAAFPL <4 
13 T232 PEFKGTFGPTDRP T225X ATVA <4 
14 P235 TFGPTDRP F228 TVAFFDRP 4-5 
15 F245 RHTLFVEYDPDEG V240X RRAPVTEED <4 
16 W287 VDIQGWEMAARIA - - <4 
17 M289 WEMAARIA - - 4-5 
18 P314 VTPPTGGMSG P295X IHLPAGGQGL <4 
19 T315 VTPPTGGMSG A296X IHLPAGGQGL <4 
20 G316 VTPPTGGMSG G297X IHLPAGGQGL <4 
21 G317 VTPPTGGMSG G298X IHLPAGGQGL <4 
22 R373 AIYAQRMAP P357 LIDPDPRYE 4-5 
23 M374 AIYAQRMAP R358 LIDPDPRYE 4-5 





Figure 4-8 PyMOL illustrations of amino acids in proximity to the anhydrotetracycline 
substrate in aklavinone-11-Hydroxylase and in OxyS 
PyMOL illustration of (a) alkavinone and FAD (stick representation, carbons colored white) 
surrounded by amino acids of aklavinone-11-Hydroxylase within 5 Å of alkavinone (stick 
representation, carbons colored green, PDB ID 3IHG) and (b) FAD (carbons colored white) 
surrounded by OxyS (surface representation, carbons colored green, PDB ID 4K2X) and its amino 
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acids that are homologous to those of aklavinone-11-Hydroxylase amino acids that are within 5 Å 
of alkavinone in the structure shown in (a).  
 
4.4.4 Library screening for TAN-1612 hydroxylation in S. cerevisiae 
Following the assembly of the libraries of fungal monooxygenases (Section 4.4.2) and OxyS 
saturation mutagenesis (Section 4.4.3) the libraries were screened for TAN-1612 hydroxylation 
using a variant of the microtiter plate assay for anhydotetracycline hydroxylation (Section 3.4.3 
and 4.3.1). As negative control a strain encoding the TAN-1612 pathway without an additional 
hydroxylase was used. As positive control a strain encoding the TAN-1612 pathway and PgaE was 
used, as that strain was already shown to produce an alternative major product instead of TAN-
1612 (Figure 4-2). 
Given that the positive control strain expressing PgaE showed a significantly reduced emission at 
560 nm upon 400 and 450 nm excitation, colonies were plotted according to their absorbance at 
these wavelengths and normalized to OD6oo: (400 + 450 nm) / 600 nm. When colonies of each 96-
well plate was ranked according to this absorption criteria the PgaE positive control was ranked 
on average 83.6 (out of 96) with a standard deviation of 10.0 (Table 4-3 and Figure 4-9). A low 
rank of PgaE is expected in the likely scenario that most strains screened do not encode an efficient 
TAN-1612 hydroxylase. Wells 84 and 96 containing no cells consistently ranked the lowest in the 
measurement of (400 + 450)/600 nm (Figure 4-9). 
Table 4-3 Rank of PgaE positive control in screen for TAN-1612 hydroxylase 
Plate Strain  Absorbance C1 
(400 + 450)/600 
Absorbance C2 
(400 + 450)/600 
 
a EH-5-217-2 89 59  
b EH-5-217-2 91 92  
c EH-5-217-2 94 68  
d EH-5-217-4 88 79  
e EH-5-217-4 78 85  
f EH-5-217-4 93 87  
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g EH-5-217-1 and 
EH-217-3 
81 87  
Average (all)    83.6 
Standard 
deviation (all) 
   10.0 
 
 
Figure 4-9 Library screening for TAN-1612 hydroxylation in S. cerevisiae 
Y axes shows the sum of absorption at 400 and 450 nm divided by absorption at 600 nm while the 
X axes show the colony number. Plates a, b and c are screens of strain library EH-5-217-2. Plates 
d, e and f are screens of strain library EH-5-217-4. Both strain libraries EH-5-217-2 and EH-5-
217-4 encode the same OxyS saturation mutagenesis library and differ in the background TAN-
1612 producing strain. Plate g contains strain libraries EH-5-217-1 and EH-5-217-3 encoding 
bacterial and fungal hydroxylases, including selected DacO1 fusion proteins. Strains EH-5-212-1, 
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EH-5-212-2 and EH-5-212-4 encoding the TAN-1612 pathway along with OxyS, PgaE and no 
hydroxylase, are labeled in blue, red and white, respectively. 
 
4.5 Discussion 
4.5.1 Testing PgaE and other bacterial hydroxylases for TAN-1612 
hydroxylation  
Despite the structural dissimilarities between UWM6, the native susbstrate of PgaE and TAN-
1612 (Scheme 4-2) it is PgaE and not OxyS or SsfO1 whose coexpression with the TAN-1612 
pathway has led to the production of a different major product of 400 and 254 nm absorption 
instead of TAN-1612. Both the chromatograms for the HPLC separation of the +PgaE and -PgaE 
samples, as well as the excitation and emission spectra support that PgaE is converting TAN-1612 
or an intermediate in its biosynthesis (Figure 4-2, Figure 4-1). It would therefore be of interest to 
test other enzymes involved in the 12-position hydroxylation of UWM6, such as CabE, LanE, 
UrdE and GilOI.(6, 7) 
The protons of chemical shifts 7.47 and 6.88 ppm with coupling constant of 8.6 Hz are likely two 
pairs of equivalent aromatic protons at ortho to each other and they are shown to interact in the 
COSY spectrum as well (Figure 4-5 and Figure 4-6); the protons of chemical shifts 7.61, 7.22 and 
6.85 ppm are likely three adjacent protons in one aromatic ring that has three other substituents, 
with the protons of chemical shifts 7.22 and 7.61 ppm likely meta to each other. Interactions 
between the protons of chemical shifts 7.61 and 6.85 as well as 7.22 and 6.85 ppm are also readily 
observed in the COSY spectrum and the coupling constants, characteristic of ortho interactions, 
are 8.0 Hz each (Figure 4-5 and Figure 4-6). The singlet at 6.72 ppm is likely a single proton in an 
aromatic ring, possibly the only remaining proton in the D-ring of the substituted TAN-1612 or its 
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intermediate (Figure 4-5). The absence of the methoxy shift in the new major product at 3.89 ppm 
(Figure 4-5) can indicate that PgaE derivatization occurs prior to AdaD methylation, which is 
assumed to be the last step in TAN-1612 biosynthesis.(1) It could be that following hydroxylation 
by PgaE and a potential further derivatization by a yeast endogenous molecule, substrate affinity 
of AdaD to the modified product is too low to allow methylation. Examples for the moieties that 
might be part of the newly formed major compound are shown in Figure 4-10. Importantly, not all 
moieties are necessarily part of the same molecule, as can be verified by larger scale fermentation 
followed by further purification and NMR analysis. The aromatic moiety of Figure 4-10-c could 
theoretically represent a doubly hydroxylated TAN-1612 or any of the TAN-1612 intermediates 
of Figure 4-11. However such an assignment is questionable, given the lack of the protons of 
chemical shift 3.89 and 2.58 ppm corresponding to the methoxy and methyl ketone at the NMR 
spectrum of the newly formed major compound (compare Figure 4-5-a and Figure 4-5-b).  
 
Figure 4-10 Possible moieties in the product isolated from +PgaE strain coexpressing the 
TAN-1612 bioysnthetic pathway 
Either of the two aromatic moieties of (a) could be responsible for generating the protons of 
chemical shifts 7.61, 7.22 and 6.85 ppm, the aromatic moiety of (b) could be responsible for 
generating protons of chemical shifts 7.47 and 6.88 ppm and either of the aromatic moieties of (c) 
could be responsible for generating a proton of chemical shifts 6.72 ppm in the 1H-NMR spectrum 
of the product isolated from +PgaE strain coexpressing the TAN-1612 bioysnthetic pathway 





Figure 4-11 Possible intermediates in the biosynthesis of TAN-1612  
TAN-1612 (1) and its intermediates 2-10 that can occur in the case of exclusion or disfunction of 
AdaB, AdaC or AdaD, the three post PKS biosynthetic enzymes of the TAN-1612 biosynthetic 




The mass spectrum of the isolated compound from the +PgaE culture has major peaks with m/z 
values of 593.1218, 298.0743, 279.0966 and 278.0483 (Figure 4-3). The 593.1218 ion has an 
elution peak after 1.60 and after 1.47 min, but an absorption peak at 254 nm and 400 +/- 60 nm is 
noted only slightly before the 1.60 min (Figure 4-3) and not slightly before the 1.47 peak (the ions 
are first detected at the diode array before mass spectrometry scanning). Assuming that the two 
593.1218 ions could be related stereoisomers of the same exact mass, it is perhaps doubtful 
whether any of them corresponds to a derivative of the TAN-1612 intermediates shown in Figure 
4-11. This is because at any stereoisomeric form such compounds would be expected to have 
absorption at 400 and/or 254.  
The 298.0743 and 278.0483 ions are four protons and one oxygen different in their m/z values. 
Possibly a molecule of H2O + oxidation / reduction apart. In the MSMS spectrum for the ions of 
m/z 593 both the ions 278.0452 and 296.0551 appear (Figure 4-4), the former being the mass of 
H2O less than the latter and the latter being H2 away from 298.0743 in its mass. Also of note is 
that the 593.1218 ion could be a result of a dimer of the 296.0551 ion plus the mass of a proton. 





+ as they differ in 0.0022, 0.0028, 0.0008 
and 0.0030 u, respectively, from the expected masses of these ions. These could be ions of some 
xanthurenic acid derivatives that PgaE might or might not have a contribution to their biosynthesis 
(Figure 4-12). While the derivatives of xanthurenic acid shown in Figure 4-12 are not known in 
yeast, xanthurenic acid is a known yeast metabolite.(8) This proposal of structure or any other 
structure that involves only yeast metabolites and their derivatives could be explaining the mass 
and NMR spectra of the isolated major compound in the +PgaE sample (Figure 4-3, Figure 4-4, 
Figure 4-5 and Figure 4-6). However, a major compound that does not involve a derivative of 
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TAN-1612 or its intermediate still does not directly explain how the expression of PgaE leads to 
the reduction in the TAN-1612 absorbance and fluorescence (Figure 4-1 and Figure 4-2). 
 
Figure 4-12 xanthurenic acid and its derivatives that could correspond to experimental mass 
and NMR spectra 
The xanthurenic acid derivatives presented in this figure have [M + H]+ values of 593.1196, 
298.0715 and 296.0559 that are 0.0022, 0.0028 and 0.0008 amu from the experimental values 
detected 593.1218, 298.0743 and 296.0551 (Figure 4-3 and Figure 4-4). In addition, the protons 
of a molecule such as the one shown with chemical formula C16H11NO5 can correspond to the 6 
proton types identified in the NMR spectrum (Figure 4-5 and Figure 4-6) and identified to 
potentially belong to the moieties described in Figure 4-10. 
 
In order to determine the structure of the newly formed major compound with regards to 254 nm 
and 400 nm absorption in the +PgaE sample coexpressing the TAN-1612 pathway, the reaction 
would be repeated in larger scale to isolate enough of the newly formed compound for HSBC and 
HMBC proton coupled carbon NMR spectra. Furthermore, the minor compound eluting at 34 min 
for the -PgaE sample will be isolated and analyzed as well to identify whether it is identical or at 
all related to the product isolated from the +PgaE sample that elutes at 34 min (Figure 4-2). This 
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characterization can assist in understanding the role PgaE has on the biosynthesis of the newly 
formed major compound with respect to 400 nm and 254 nm absorption in the +PgaE sample 
(Figure 4-2). Another source of information would be the culturing and isolation of another control 
strain encoding PgaE but not encoding the TAN-1612 pathway and examining whether such strain 
displays a similar major peak in the HPLC chromatogram of 254 and 400 nm absorption as the 
strain that encodes the TAN-1612 pathway. 
4.5.2 Searching the fungal hydroxylase space for 6α-hydroxylation of TAN-
1612 
Importantly, the library generation approaches used to generate 6α-hydroxylases of 
anhydrotetracycline (Subsections 3.4.2 and 3.4.4) could be used for generating TAN-1612 
hydroxylases (Subsections 4.4.2 and 4.4.3) and vice versa. The expression analysis of fungal 
monooxygenases showed that while branching towards fungal monooxygenases might be a useful 
strategy to find 6α-hydroxylases and specifically 6α-hydroxylases of TAN-1612, the fungal 
monooxygenases do not necessarily present an advantage over their bacterial counterparts as far 
as expression challenges in S. cerevisiae are concerned (Figure 4-7 and Chapter 3).  
4.5.3 Evolving monooxygenases for 6α-hydroxylation of anhydrotetracyclines 
Amino acids in OxyS were chosen for mutagenesis based on homology to amino acids in the 
proximity of the substrate in the crystal structure of RdmE and this approach could be implemented 
in other monooxygenases, such as PgaE or expression optimized DacO1 (Chapter 3). Importantly, 
implementing this approach does not require an existing crystal structure of the monooxygenase 
of interest. Also, as seen in the case of OxyS, at least some of the amino acids chosen for 
mutagenesis according to this strategy actually sit in proximity to the anhydrotetracycline cavity 
of OxyS (Figure 4-8). However, in the case of OxyS, an approach that uses the published crystal 
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structure of OxyS to choose additional amino acids for mutagenesis or to avoid mutating some of 
the amino acids that are not in proximity to the cavity might have been preferred. Further 
mutagenesis is being performed to explore the effect of additional mutations of OxyS in positions 
that are homologous to amino acids in RdmE structure that are up to 8 Å from aklavinone in 3IHG. 
Finally, similar followup mutagenesis studies on stably expressed DacO1 fussion proteins, as well 
as PgaE will be directly relevant for testing 6α-hydroxylation of TAN-1612. Specifically for PgaE, 
much structural information is available to guide the amino acid choice for saturation mutagenesis 
from its crystal structure and from biochemical analyses.(6, 9-11) 
4.5.4 Library screening for TAN-1612 hydroxylation in S. cerevisiae 
In the screen for TAN-1612 hydroxylation, a variant of the microtiter plate assay for 
anhydrotetracycline hydroxylation described in Chapter 3 was used. Chapter 3 also discusses non-
microtiter plate avenues for the anhydrotetracycline hydroxylation (Section 3.5.3) and these would 
be especially interesting to examine in the context of TAN-1612 hydroxylation, as TAN-1612 does 
not need to be exogenously supplied to the cells.  
Similarly to the followup on the +PgaE +TAN-1612 encoding strain (Sections 4.4.1 and 4.5.1), 
strains with a lower (400 + 450)/600 nm absorption than the PgaE positive control (Figure 4-9) 
will be assayed for TAN-1612 hydroxylation by UV/Vis and mass spectrometry. If data supports 
production of an alternative major product to TAN-1612 these strains will be cultured in larger 
scale to allow purification and analysis of the product by NMR. If data does not support TAN-
1612 hydroxylation in any of the assayed strains, strain selection for further assay will be attempted 
based on other criteria such as 550 + 600 – 450 nm emission upon 400 nm excitation or 400 + 450 
– 350 nm excitation for 560 nm emission. These criteria are based on the reduced emission and 




This chapter describes the progress towards TAN-1612 hydroxylation in S. cerevisiae, the first 
step in the synthesis of 6-demethyl-6-epitetracycline from TAN-1612 in S. cerevisiae. This chapter 
shows that a strain expressing both PgaE and the TAN-1612 pathway produces a major compound 
with regards to 400 nm and 254 nm absorption that differs from TAN-1612 (Sections 4.4.1 and 
4.5.1, Figure 4-1, Figure 4-2, Figure 4-3 and Figure 4-5). Future work towards TAN-1612 
hydroxylation in S. cerevisiae should include a larger scale culturing of the +PgaE +TAN-1612 
pathway strain to enable followup NMR experiments. In addition, the minor compound eluting at 
34 min for the -PgaE sample (Figure 4-2) will be isolated and analyzed to verify whether it is 
identical or at all related to the product isolated from the +PgaE sample that elutes at 34 min. 
Another control strain encoding PgaE but not encoding the TAN-1612 pathway will be cultured 
and examined to discover whether it displays a similar major peak in the HPLC chromatogram to 
that of the +PgaE +TAN-1612 pathway strain. 
This chapter also describes a hydroxylase harvesting and mutagenesis strategy as well as a UV/Vis 
assay as a platform for identifying TAN-1612 hydroxylation. This platform was applied to the 
screening for TAN-1612 hydroxylation (Section 4.4.4) by OxyS mutants (Section 4.4.3), DacO1 
fusion proteins (Sections 3.4.1 and 3.4.5),  and other hydroxylases from bacterial (Sections 3.4.2 
and 3.4.5) and fungal sources (Section 4.4.2).  Followup culturing and spectroscopic analysis will 
be done on strains coexpressing the TAN-1612 pathway and one of the above mentioned 
hydroyxlases, identified as potentially hydroxylating TAN-1612 in the UV/Vis assay (Figure 4-9). 
In addition to the followup on PgaE and on the other hydroxylases described in this chapter, other 
enzymes involved in the 12-position hydroxylation of UWM6, such as CabE, LanE, UrdE and 
GilOI should also be tested for TAN-1612 hydroxylation.(6, 7) With a mutagenesis strategy that 
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does not require a crystal structure that could be used for DacO1 (Figure 4-8) and with the 
additional benefit of the PgaE crystal structure,(9) followup mutagenesis studies such as shown on 
OxyS (Section 4.4.3) and on DacO1 (Section 3.4.4) on stably expressed DacO1 fusion proteins 
(Section 3.4.5), as well as on PgaE could prove beneficial for 6α-hydroxylation of TAN-1612. 
Identification and overexpression of a reductase responsible for 5a(11a)-dehydrotetracycline 
reduction in S. cerevisiae (Section 2.4.2 and 2.5.2) will be potentially useful for the reduction of 
the hydroxylation product of TAN-1612 as would be other efforts in the reduction of 5a(11a)-
dehydrotetracycline in S. cerevisiae (Section 3.4.5 and 3.5.5). Finally, the anhydrotetracycline 
hydroxylations described in this chapter and in Chapters 2 and 3 relies heavily on the UV/Vis assay 
developed for the hydroxylation of anhydrotetracyclines (Section 3.4.3, 3.4.5, and 4.4.4). More 
broadly, high-throughput assays are of very high importance to small molecule production in 
microorganisms because of the inability to predict in advanced the successful strain modifications 
needed in the complex environment of the cell.(12) TAN-1612 and anhydrotetracycline 
hydroxylation belong to a special group of biochemical transformations that are easy to assay in 
high throughput because of the inherent change in the chromophore of the CD ring (Scheme 4-2). 
However, the next steps for 6-demtehyl-6-epiglycotetracyclines from TAN-1612 will require a 
general, readily implemented, high-throughput assay for tetracycline biosynthesis in yeast. The 




Table 4-4 Strains used in this study 
Strain Genotype  Source/Reference 
BJ5464-
NpgA 
MATα ura3-52 his3-Δ200 leu2-Δ1 
trp1 pep4::HIS3 δ:: pADH2-npgA-tADH2 prb1Δ1.6R 
can1 GAL 
a / (13) 








PBA-1333 PBA482 pPBA-L2BWG9 P. A. Baldera-
Aguayob 
PBA-1337 PBA1277 pPBA-L6BWG9 P. A. Baldera-
Aguayob 
EH-5-212-1 PBA-1337 AL-1-101-C10 This Study 
EH-5-212-2 PBA-1337 AL-234-C-C1 This Study 
EH-5-212-3 PBA-1337 AL-239-B This Study 
EH-5-212-4 PBA-1337 pSP-G1 (Addgene 64736) This Study 
EH-5-217-1 PBA-1337 Plasmid Libraries A + C This Studyc 
EH-5-217-2 PBA-1337 Plasmid Library D This Studyc 
EH-5-217-3 PBA-1333 Plasmid Libraries B + C This Studyc 
EH-5-217-4 PBA-1333 Plasmid Library D This Studyc 
EH-5-227-11 BJ5464-NpgA AL-2-72-B-C6 This Study 
EH-5-227-12 BJ5464-NpgA AL-2-72-D-C5 This Study 
EH-5-227-13 BJ5464-NpgA AL-2-72-F-C4 This Study 
EH-5-227-14 BJ5464-NpgA AL-2-79-J-C4 This Study 
EH-5-227-15 BJ5464-NpgA AL-2-79-K-C5 This Study 
EH-5-227-16 BJ5464-NpgA AL-2-79-L-C6 This Study 
EH-5-227-17 BJ5464-NpgA AL-2-86-D-C5 This Study 
EH-5-227-18 BJ5464-NpgA AL-2-86-I-C5 This Study 
EH-5-227-19 BJ5464-NpgA AL-2-86-A-C1 This Study 
a Y. Tang, University of California, Los Angeles, Department of Chemical and Biomolecular 
Engineering & Department of Chemistry and Biochemistry, Department of Bioengineering 
b Integrated Program in Cellular, Molecular and Biomedical Studies, Cornish Laboratory, 
Columbia University, New York, NY 10032, USA 





Table 4-5 Plasmids used in this study 
 Description  Source/Reference 
pSP-G1 pTEF1-FLAG-tADH1, pPGK1-MYC-tCYC1, 2 μ, Ura Addgene 64736 
AL-1-101-C10 pTEF1-oxyS-tADH1 in pSP-G1 Chapter 2 
AL-1-234-C-C1 pTEF1-pgaE-tADH1 in pSP-G1 JCAT codon opt. Chapter 3 
AL-1-239-B-C3 pTEF1-ssfO1-tADH1 in pSP-G1 JCAT codon opt. Chapter 3 
AL-2-72-B-C6 pTEF1-Fungal-monooxygenase-6-tADH1 in pSP-G1c This Study 
AL-2-72-D-C5 pTEF1-Fungal-monooxygenase-5-tADH1 in pSP-G1c This Study 
AL-2-72-F-C4 pTEF1-Fungal-monooxygenase-1-tADH1 in pSP-G1c This Study 
AL-2-79-J-C4 pTEF1-Fungal-monooxygenase-4-tADH1 in pSP-G1c This Study 
AL-2-79-K-C5 pTEF1-Fungal-monooxygenase-2-tADH1 in pSP-G1c This Study 
AL-2-79-L-C6 pTEF1-Fungal-monooxygenase-2-tADH1 in pSP-G1c This Study 
AL-2-86-D-C5 pTEF1-Fungal-monooxygenase-8-tADH1 in pSP-G1c This Study 
AL-2-86-I-C5 pTEF1-Fungal-monooxygenase-11-tADH1 in pSP-G1c This Study 
AL-2-86-A-C1 pTEF1-Fungal-monooxygenase-12-tADH1 in pSP-G1c This Study 
EH-5-49-C pTEF1-GAL1-dacO1-tADH1 in pSP-G1 Chapter 3 
EH-5-80-6 pTEF1-UBI4-IFNG-dacO1-tADH1 in pSP-G1 Chapter 3 
EH-5-80-7 pTEF1-IFNG-dacO1-tADH1 in pSP-G1 Chapter 3 
EH-5-80-10 pTEF1-oxyS-dacO1-37-tADH1 in pSP-G1 Chapter 3 
EH-5-80-11 pTEF1-oxyS-dacO1-87-tADH1 in pSP-G1 Chapter 3 
pAV124 Trp1, 2 μ acceptor vector for yeast golden gate Addgene 
63190/(14) 
















a Integrated Program in Cellular, Molecular and Biomedical Studies, Cornish Laboratory, 
Columbia University, New York, NY 10032, USA 
b Fungal-monooxygenase-X refers to the fungal monooxygenase from Table 4-1 entry X. Thus, 





Plasmid libraries used for making strains EH-5-217-1 through EH-5-217-4 
Table 4-6 Plasmid Library A – Strain EH-5-217-1 
Library component 
no.  
Plasmid  Plasmid common 
name 
Colony # 
1 EH-5-49-C Gal1-DacO1 1 
2 EH-5-80-6 9 - ubiIFN H 
3 EH-5-80-7 9 - IFN H 
4 EH-5-80-10 11-OxyS-DacO1-37 G 
5 EH-5-80-11 11-OxyS-DacO1-87 H 
 
Table 4-7 Plasmid Library B – Strain EH-5-217-3 
Library component 
no.  
Plasmid  Plasmid common 
name 
Colony # 
1 EH-5-49-C Gal1-DacO1 1 
2 EH-5-80-6 9 - ubiIFN H 
3 EH-5-80-7 9 - IFN H 
4 EH-5-80-10 11-OxyS-DacO1-37 G 
5 EH-5-80-11 11-OxyS-DacO1-87 H 
6 AL-234-C PgaE in pSPG1 1 
7 AL-1-101 OxyS 10 
8 AL-239-B SsfO1 3 
 
Table 4-8 Plasmid Library C – Strain EH-5-217-1 and EH-5-217-3 
* AL-2-79-K and AL-2-86-L are the same plasmid but one of them does and the other does not 
encode a mutation in the sequence. 
 
  
no.  Plasmid  Plasmid common name Colony # 
1 AL-2-72-B Atc Moase Valsa Mali Var Pyr  C6 
2 AL-2-72-D Atc Moase G Cichoaracearumi C5 
3 AL-2-72-F Atc Moase Valsa Mali CM C4 
4 AL-2-79-J Related to tetra hydroxylase P subalpina C4 
5 AL-2-79-K Atc Moase P subrubescens C5 
6 AL-2-79-L* Atc Moase P subrubescens C6 
7 AL-2-86-D Pentachlorophenol-4-Moase Hypoxylon C5 
8 AL-2-86-I Pentachlorophenol-4-Moase Colletotrichum orbiculare C5 





Table 4-9 Plasmid Library D – Strains EH-5-217-2 and EH-217-4 
no.  Plasmid  Plasmid common name 
1 AL-2-57-A F96X OxyS Library 
2 AL-2-57-B M176X OxyS Library 
3 AL-2-57-C W211X OxyS Library 
4 AL-2-57-D F212X OxyS Library 
5 AL-2-57-E T225X OxyS Library 
6 AL-2-57-F V240X OxyS Library 
7 AL-2-57-G P295X OxyS Library 
8 AL-2-57-H A296X OxyS Library 
9 AL-2-83-A A43X OxyS Library 
10 AL-2-83-B G297X OxyS Library 
11 AL-2-83-C G298X OxyS Library 
 
Table 4-10 Sequences used in this study 
Sequences for the hydroxylases fungal hydroxylases of Table 4-1 are shown capitalized within the 


















































































































































































































































































































































































































































































































































































Table 4-11 Primers used for OxyS saturation mutagenesis in this study  
To create a saturation mutagenesis of the positions outlined in Table 4-2 the even numbered 
primers were used for PCR amplification with EH414 and the odd numbered primers were used 
for PCR amplification with EH745. The resulting amplicons were gel purified and used for Gibson 
Assembly with pSP-G1 (empty) digested with SpeI and NotI.  
EH414 GCTCATTAGAAAGAAAGCATAGC  




EH724 CTAGGAGTCCACGCTCGC A43X 



















EH734 GTCGCCTTTTTCGATAGACCG T225X 





























EH815 GTCCACGCTCGCACTGTTG G45X 











EH821 CGCTACGAGGGTTTAAGGGA P357X 
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5 A yeast three hybrid assay for metabolic engineering 









*The contents of this chapter were published in: 
E. Herbst, P. A. Baldera-Aguayo, H. Lee and V. W. Cornish “A Yeast Three Hybrid Assay for 




5.1 Chapter outline 
Metabolic engineering stands to transform the discovery and production of a wide range of 
chemicals, but metabolic engineering currently demands considerable resource investments that 
restrict commercial application. To facilitate the applicability of metabolic engineering, general 
high-throughput and readily-implemented technologies are needed to assay vast libraries of strains 
producing desirable chemicals. Towards this end we describe here the development of a yeast three 
hybrid (Y3H) assay as a general, high-throughput, versatile and readily-implemented approach for 
the detection of target molecule biosynthesis. Our system detects target molecule biosynthesis 
through a change in reporter gene transcription that results from the binding of the target molecule 
to a modular protein receptor. We demonstrate the use of the Y3H assay for detecting the 
biosynthesis of tetracyclines, a major class of antibiotics, based on the interaction between 
tetracyclines and the tetracycline repressor protein (TetR). Various tetracycline derivatives can be 
detected using our assay, whose versatility enables its use both as a screen and a selection to match 
the needs and instrumentation of a wide range of end-users. We demonstrate the applicability of 
the Y3H assay to metabolic engineering by differentiating between producer and non-producer 
strains of the natural product anhydrotetracycline TAN-1612. The Y3H assay is superior to state-
of-the-art HPLC-MS methods in throughput and limit of detection of tetracycline derivatives. 
Finally, our establishment of the Y3H assay for detecting the biosynthesis of a tetracycline 





Metabolic engineering is a potentially greener and more economical approach than traditional 
organic synthesis for the production of a wide range of organic chemicals. As opposed to organic 
synthesis, metabolic engineering is capable of producing valuable chemicals from readily available 
and renewable carbon sources and significantly reducing the use of organic solvents and 
reagents.(1, 2) Traditional methods in DNA mutagenesis and increasingly, advances in DNA 
synthesis, DNA assembly and genome engineering are enabling high throughput strain 
construction in metabolic engineering.(3-8) High-throughput strain construction is necessary 
because not only the multi-gene biosynthetic pathway for the natural product, but also the 
underlying metabolism of the host must be optimized.(9) Assuming a biosynthetic pathway of 5 
genes and 10 interacting host genes, to test just 5 variants for each of these genes results already 
in a library size exceeding 1010. However, the throughput of the most highly employed assaying 
methods such as LC-MS is only ~102-103 samples per day and is thus heavily limiting in assaying 
strains for successful metabolic engineering.(5, 9) 
The currently employed methods for assaying metabolite production in metabolic engineering are 
either low-throughput and general or high-throughput but not general. LC-MS methods are general 
but low-throughput, enabling the screening of only about 102-103 samples per day.(9) Colorimetric, 
fluorometric and growth assays for molecules that are colored, fluorescent, essential for producer 
strain growth or could be easily converted to one of these, are high-throughput but not general.(10) 
Attempts have been made to develop assays that are both high-throughput and general, but it is yet 
to be determined whether or not these assays could be widely implemented.(10, 11) Versatile, 
general, readily implemented high-throughput assays are required to transform metabolic 
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engineering from a field with a high potential to a field with an extensive real-world impact on the 
way chemicals are made. 
We set out to adapt the Y3H assay, previously employed for various basic science applications by 
our laboratory and others,(12-18) to a general, readily implemented, high-throughput versatile 
assay for metabolic engineering. We wished to develop an assay that can be readily adapted to 
new target molecules, used as either a screen or a selection, and minimizes handling, to match 
varying needs and instrumentation of end-users.  
Here, we demonstrate the application of the Y3H assay to detect the biosynthesis of tetracyclines, 
one of the major classes of antibiotics. We describe the engineering of the Y3H system to detect 
tetracyclines by synthesizing a minocycline-methotrexate chemical inducer of dimerization (CID) 
and cloning a LexA-TetR (tetracycline repressor) fusion protein.(14) Reporter gene expression 
responds to tetracycline in our system by competitive binding of tetracycline and the CID to the 
LexA-TetR protein fusion (Figure 5-1). Our assay can report the presence of tetracyclines using 
various reporter gene outputs, enabling the use of the assay both as a screen and a selection to 
match the needs and instrumentation of a variety of end-users. We show the applicability of our 
assay to metabolic engineering through the differentiation between producer and non-producer 
strains of the natural product anhydrotetracycline, TAN-1612.  
 
Figure 5-1 Detection of a target molecule biosynthesis by the yeast three hybrid system. 
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Low/no production of a target molecule is detected by high reporter gene expression (left). High 
production titers of the target molecule outcompete the chemical inducer of dimerization (CID) 
from the fusion protein receptor and are detected by lower gene expression (right). DBD = DNA 
binding domain; AD = activation domain; PR = protein receptor (e.g., TetR); DHFR = 
dihydrofolate reductase. 
 
5.3 Materials and methods 
General methods. Absorption and fluorescence spectra were recorded on Infinite-M200 
fluorescent spectrometer. DNA sequences were purchased from IDT. Polymerases, restriction 
enzymes and Gibson Assembly mix were purchased from New England Biolabs. Sanger 
sequencing was performed by Genewiz. Yeast strains were grown at 30 °C and shaker settings 
were 200 rpm, unless otherwise indicated. Yeast transformations were done using the lithium 
acetate method.(19) Plasmids were cloned and amplified using Gibson Assembly and cloning 
strain C3040 (New England Biolabs).(20) Unless otherwise indicated, yeast strains were grown on 
synthetic minimal media lacking histidine and/or uracil and/or tryptophan and/or leucine, as 
indicated by the abbreviation HUTL-.(21) Yeast strain patches were obtained from glycerol stocks 
by streaking on an agar plate of synthetic medium lacking the appropriate amino acid markers, 
incubating at 30 °C for 3 days, patching single colonies onto a fresh agar plate and incubating at 
30 °C overnight. Unless otherwise indicated, when 96 well plates were placed in the yeast shaker, 
95% of the interface between the plate and its cover was wrapped with laboratory film (Parafilm, 
Bemis PM999). All Y3H assays were performed with sterile components and three biological 
replicates. Protein homology was calculated by BLAST (https://blast.ncbi.nlm.nih.gov) using the 
standard sequence alignment parameters. DataExpress was used to analyze mass spectrometry 
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peaks. Protein visualization was performed using The PyMOL Molecular Graphics System, 
Version 2.3 Schrödinger, LLC. 
Codon optimization by COOL (http://cool.syncti.org/index.php) was used for all hydroxylases and 
reductases unless noted explicitly that JCAT or no optimization was used (http://www.jcat.de/). 
Optimization parameters chosen were individual codon use, codon context GC content of 39.3% 
and S. cerevisiae organism. The following restriction sites were generally excluded: GAGACC, 
GGTCTC, GGATCC, GAGCTC, CTCGAG, GAAGAC, GTCTTC, CGTCTC, GAGACG, 
GAATTC, TTAATTAA, TCTAGA, ACTAGT, CCCGGG, CTGCAG, AAGCTT, GTCGAC, 
ACGCGT, GGTACC, GCGGCCGC, AGATCT, GGCCGGCC, CCGCGG, GCTAGC, 
CCATGG. 
All chemical reactions were carried out under Argon atmosphere with anhydrous solvents unless 
otherwise indicated. Analytical high-pressure liquid chromatography (HPLC) was performed with 
a C-18 column, 2.6 μ, 250x4.6 mm, eluent given in parentheses. Unless stated otherwise, reactions 
were monitored using analytical HPLC with a separation gradient of 10% to 90% MeCN in 0.1% 
(v/v) TFA aqueous solution over 20 minutes. Preparative HPLC was carried out with a C-18 5 μ 
column, 250x10 mm, eluent given in parentheses. NMR spectra were obtained using Bruker 400 
MHz or 500 MHz instruments, as indicated. Unless stated otherwise, mass spectroscopy 
measurements were performed on Advion CMS mass spectrometer equipped with atmospheric 
pressure chemical ionization (APCI) and electrospray ionization (ESI) sources. TAN-1612 
quantification was performed using a phenyl-hexyl 1.7 μ 100x3 mm column, on a Waters SQD2 
quadrupole mass spectrometer equipped with a UPC2 SFC inlet, a photodiode array (PDA) UV-
Vis detector, and a dual ESI/APCI probe. HRMS spectra were taken on a Waters ACQUITY UPLC 
BEH C18 column (2.1 x 50 mm) at 30 °C with a flow rate of 0.8 mL/min.  Unless stated otherwise, 
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all reagents, salts and solvents were purchased from commercial sources and used without further 
purification.  
Synthesis of the Min-Mtx CID (1, Scheme 5-1). Step a. To 9-NH2-minocycline (100 mg, 0.2 
mmol), Boc-11-aminoundecanoic acid (89 mg, 0.3 mmol), EDC (75 mg, 0.4 mmol) and HOBt (60 
mg, 0.4) were added DMF (1 mL) and Et3N (139 μL, 1.0 mmol) and the reaction was mixed at r.t 
for 6 h. The reaction progress was monitored by RP-HPLC. Aqueous NaHCO3 (0.05 M)(22) was 
then added and the aqueous phase was extracted three times with CHCl3. The combined organic 
fraction was extracted with brine, the combined brine extracts were extracted twice with CHCl3, 
the combined organic fraction was dried with Na2SO4 and the solvent was removed under reduced 
pressure. The crude product was purified in two batches by preparative RP-HPLC (30-35% MeCN 
in 99.9%:0.1% H2O:TFA, 45 min) to afford compound 3 (53.4 mg, 36%) as a yellow solid.  
1H-
NMR (400 MHz, MeOD d4) δ 8.60 (s, 1H), 4.11 (s, 1H), 3.24 (dd, J = 15.4, 4.2, 1H), 3.14 (s, 6H), 
3.08 (m, 3H), 3.02 (s, 6H), 2.50 (t, J = 7.4, 2H), 2.44 (t, J = 14.3, 1H), 2.24 (m, 1H), 1.72 (m, 1H), 
1.62 (m, 1H), 1.43 (s, 9H), 1.42 (m, 4H) 1.38 (m, 2H), 1.32 (m, 10H). MS (APCI+): m/z calc. for 
C39H58N5O10
+: 756.42; found: 756.4 [M + H]+; MS (APCI-): m/z calc. for C39H56N5O10
-: 754.40; 
found: 754.3 [M – H]-.   
Steps b-d. To compound 3 (27.3 mg, 0.036 mmol) were added DCM (0.5 mL) and TFA (0.5 mL) 
and the reaction was mixed at r.t. for 12 min. The solvent was removed under reduced pressure. 
PhMe was added and the solvent was again removed under reduced pressure. PhMe addition and 
solvent removal was repeated once more. Methotrexate-α-OtBu (27.5 mg, 0.054 mmol)(23, 24) 
and PyBOP (37.5 mg, 0.072 mmol) were added, followed by DIPEA (11.5 mg, 0.09 mmol) in 
DMF (1 mL) and the reaction was mixed at r.t.. After 22 h EtOAc and aqueous NaHCO3 were 
added and the aqueous phase was extracted twice with EtOAc. The combined organic fraction was 
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extracted with brine and the brine extract was filtered. The solid residue was redissolved in MeOH 
and the solvent was removed under reduced pressure. The crude product was purified in two 
batches by preparative RP-HPLC (20-30% MeCN in 99.9%:0.1% H2O:TFA, 50 min). Following 
solvent removal under reduced pressure, TFA (2 mL) was added and the reaction was stirred at r.t. 
for 90 min. The reaction progress was monitored by RP-HPLC. The solvent was removed under 
reduced pressure to afford compound 1 (4.1 mg, 10%) as a yellow solid. 1H-NMR (500 MHz, 
MeOD d4) δ 8.64 (s, 1H), 8.25 (s, 1H), 7.76 (d, J = 8.8, 2H), 6.86 (d, J = 8.8, 2H), 4.92 (s, 2H), 
4.54 (dd, J = 8.8, 4.5, 1H), 4.08 (s, 1H), 3.27 (s, 3H), 3.11 (m, 2H), 3.00 (s, 6H), 2.83 (s, 3H), 2.80, 
(s, 3H), 2.47 (m, 2H), 2.41-2.05 (m, 6H), 1.70-1.59 (m, 4H), 1.48-1.28 (m, 16H)  MS (ESI+): m/z 
calc. for C54H71N13O12
2+: 1093.54; found: 546.9 [M + 2H]2+.  
Y3H strain construction  
LexA-TetR plasmids. Plasmids PBA-Gib5 and HL-249-1 through HL-249-6 encoding LexA-
TetR protein fusions for the various TetR classes were cloned by Gibson Assembly of the 
appropriate TetR sequence with pMW103 digested with restriction enzymes BamHI-HF and 
EcoRI-HF (Table S3). All TetR sequences with the exception of TetR(B) were obtained as IDT 
gBlocks. TetR(B) sequence was amplified from pET21d-TetR, courtesy of A. Davidson.(25, 26)  
LacZ assay strain construction. V506 was grown overnight in UT- media.(27) The culture was 
then diluted 104-105X with UT- and plated on UT- plates. Single colonies were streaked on HTU- 
and UT- plates and a streak growing on UT- but not on HTU-, indicating the loss of the 
pMW3(GSG)2rGR2 plasmid, was glycerol stocked as PBA5. This strain was further used for the 




Growth assay strain construction. Yeast strain LW2635(28) was transformed with plasmid 
PBA-Gib5 to generate strain PBA6. PBA6 was transformed with pMW2eDHFR(27) to generate 
the Y3H growth assay strain PBA14.  
mCherry reporter plasmid. Reporter plasmid HL-174-2 encoding mCherry under the 
transcriptional control of LexA operators was cloned by Gibson Assembly of an mCherry sequence 
amplified from yEpGAP-Cherry(29) and an 8LexA-min-pGal1 sequence amplified from 
pMW112(14) into pRS416 digested with SacI and XhoI. 
Fluorescent protein assay strain construction. V506 was grown overnight in T- media. The 
culture was then diluted 104-105X with T- and plated on T- plates. Single colonies were streaked 
on TU-, HT- and T- plates and a streak growing on T- but not on UT- or on HT-, indicating the loss 
of the pMW106 and pMW3(GSG)2rGR2 plasmids, was glycerol stocked as PBA3. This strain was 
transformed with plasmid HL-174-2 to generate yeast strain HL-294-7. The latter was transformed 
with PBA-Gib5 to generate the Y3H fluorescent reporter assay strain HL-2-4-1. 
TAN-1612 producer/non-producer strain construction. TAN-1612 producer and non-producer 
strains EH-3-54-4 and EH-3-54-2 were obtained by transforming plasmids pYR342 and pYR291 
or pYR342 and pRS426, respectively, into yeast strain BJ5464-NpgA (Table 5-1 and Table 
5-2).(30) 
Protocol for fluorescent protein Y3H assay 
Fresh patches of Y3H strain HL-2-4-1 were inoculated into HTU- media (1 mL) in 24-well plates 
(flat, clear bottom, Corning #3526) and placed in shaker. After 24 hours the cells were pelleted by 
centrifugation at 3,250 rpm and resuspended in H2O (1 mL). Pelleting and resuspension were 
repeated once more. OD600 was measured by diluting 10X into H2O and the cells were diluted 
accordingly into H2O for OD600 = 1 to be used as a 10X solution. 20 μL cells of OD600 = 1 were 
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added to the assay plate as the last component in the assay plate (flat, clear bottom, black 96-well 
plate, Corning #3603). Each well of the assay plate contained 200 μL total liquid volume, 20 μL 
cells, 100 μL of 2X HTU- media of 4% raffinose and no glucose, 20 μL of 10X 20% galactose 
aqueous solution, 20 μL of 10X CID solution of 100 μM in 10% DMSO aqueous solution, 20 μL 
supernatant and 20 μL purified TAN-1612 in a 10% DMSO aqueous solution,(30) or a 10% DMSO 
aqueous solution. Starting conditions in the assay plate were OD600 = 0.1, 2% galactose, 2% 
raffinose, 0% glucose, 1X HTU-, 10 μM CID, 2% DMSO. The assay plate was placed in the 30 °C 
shaker overnight before measuring OD600 and 620 nm fluorescence (λex = 588 nm).(31) 
TAN-1612 supernatants from flask cultures were obtained by inoculating TAN-1612 producing 
and non-producing strains, EH-3-54-4 and EH-3-54-2 respectively, in UT- media (5 mL) in 15 mL 
culture tubes (Corning 352059) and placing in shaker overnight; Overnight cultures were used to 
inoculate 100 mL YPD in 500 mL conical flasks with a starting OD600 of 0.08. After 68 h, 1 mL 
of culture was pelleted in 1.5 mL Eppendorf tubes at 14,000 rpm, sterile filtered and diluted 20X 
into H2O to be used as a 10X stock solution.  
TAN-1612 supernatants from 96-well plate cultures were obtained by inoculating 12 and 84 
colonies of TAN-1612 producing and non-producing strains, EH-3-54-4 and EH-3-54-2 
respectively, in UT- media (0.5 mL) in a 96-well plate (Corning P-2ML-SQ-C-S). The plate was 
covered with two layers of SealMate film (Excel Scientific, SM-KIT-BS) and placed in a shaker 
overnight. Overnight cultures were used to inoculate 300 μL YPD in an identical setup with a 
starting OD600 of 0.1 and placed in 800 rpm shaker overnight. After 54 h, 150 μL of H2O were 
added to the cultures to prevent drying of cultures due to evaporation and two new layers of 
Sealmate film were replaced. After 78 h, the cultures were pelleted at 3,250 rpm and the 
supernatant was diluted 20X into H2O to be used as a 10X stock solution.  
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Protocol for Y3H growth assay 
Fresh patches of Y3H strain PBA14 were inoculated in HT- media (1 mL) and placed in shaker 
overnight. Cultures were then centrifuged at 3,000 rpm for 3 min and the pellets were resuspended 
with H2O (1 mL). Pelleting and resuspension was repeated twice more. OD600 was measured and 
the cells were diluted accordingly into H2O to OD600 = 1 to be used as a 10X stock solution. 20 μL 
cells of OD600 = 1 were added as the last component to the assay plate (flat, clear bottom, black 
96-well plate, Corning #3603). Each well of the assay plate contained 200 μL total liquid volume, 
20 μL cells, 100 μL of 2X HT- media with 4% raffinose, 4% galactose, 0% glucose, 0.4% 5-FOA, 
20 μL of 0/250 μM 10X CID in 10% DMSO aqueous solution, 20 μL of doxycycline (0/50 μM in 
10% EtOH aqueous solution) and 40 μL H2O. Starting conditions in the assay plate were OD600 = 
0.1, 2% galactose, 2% raffinose, 0% glucose, 0.2% 5-FOA, 1X HT-, 25 μM CID, 1% DMSO, 1% 
EtOH. The assay plate was placed in the 30 °C shaker for 5 days with daily measurements of 
OD600. 
Protocol for Y3H LacZ assay 
Fresh patches of Y3H strains PBA-8 and HL-260-1 through HL-260-7 were inoculated into HTU- 
media (1 mL) in 24-well plates (flat, clear bottom, Corning #3526) and place at 30 °C shaker. After 
24 hours the cells were pelleted by centrifugation at 3000 rpm for 5 min and resuspended in H2O 
(1 mL). Pelleting and resuspension were repeated once more. OD600 was measured and the cells 
were diluted accordingly into H2O to OD600 = 1 to be used as a 10X solution. 20 μL cells of OD600 
= 1 were added to the assay plate as the last component in the assay plate (clear v-bottom, clear 
96-well plate, Corning #3894). Each well of the assay plate contained 200 μL total liquid volume, 
20 μL cells, 100 μL of 2X HTU- media of 4% raffinose and no glucose, 20 μL of 10X 20% 
galactose aqueous solution, 20 μL of 10X CID solution in 10% DMSO aqueous solution or a 10% 
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DMSO aqueous solution, 20 μL of the tetracycline ligand in 10% EtOH aqueous solution and 20 
μL water. Starting conditions in the assay plate are OD600 = 0.1, 2% galactose, 2% raffinose, 0% 
glucose, 1X HTU-, varying concentration CID, varying concentration of tetracycline ligand, 1% 
DMSO and 1% EtOH. The assay plate was placed in the shaker overnight. OD measurements were 
then taken after 24 h and the cells were pelleted and resuspended in 100 μL Z-buffer (60 mM 
Na2HPO4, 40 mM NaH2PO4, 10 mM KCl, 2 mM MgSO4, pH adjusted to 7, 2.7 mL/L β-
mercaptoethanol added fresh the day of the assay). The cells were pelleted again, resuspended in 
100 μL Y-PER buffer (Fisher Scientific, #78990) and lysed for 30 min at r.t. before the addition 
of o-Nitrophenyl β-D-galactopyranoside (ONPG) in Z-buffer (8.5 μL, 10 mg/mL). After 90 min a 
Na2CO3 solution (1 M, 110 μL) was added to quench the reaction. After pelleting at 3,000 rpm, 
175 μL of the supernatant was transferred into flat clear-bottom 96-well plates (Corning #353072) 
and OD420 was measured. The limit of detection was calculated as the concentration of molecule 
at which the signal-to-noise ratio of the assay was > 3:1.(32, 33) 
5.4 Results 
5.4.1 Y3H system design and CID design and synthesis 
For a Y3H system detecting tetracyclines, we cloned a Y3H strain encoding LexA-TetR and 
DHFR-B42 fusion proteins and synthesized a minocycline-methotrexate (Min-Mtx) CID (Figure 
5-1). We chose to base our Y3H system on well-studied components. Namely, the LexA DNA 
binding domain (DBD) and B42 activation domain (AD),(34) respectively, introduced by Brent 
and coworkers,(14, 27, 35, 36) as well as the DHFR- methotrexate and TetR-tetracycline 
interactions. The latter two are highly characterized receptor-ligand interactions of picomolar 
affinity,(37) and the methotrexate-DFHR interaction has been used numerous times by our 
laboratory.(27, 35) We used LexA-TetR fusion proteins of TetR variants that were highly studied, 
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such as the variants from classes B and D,(37-39) as well TetR variants from the much less studied 
TetR classes A,(40, 41) C,(42, 43) E,(44, 45) G,(46) and H.(47-50) TetR and LexA form stable 
homodimers, with each of the TetR monomers binding tetracyclines and LexA binding DNA as a 
dimer.(38, 51) Thus it is possible that the monomer ratio of TetR / LexA in the LexA-TetR fusion 
protein is unequal to 1, affecting accordingly the local concentrations of the Min-Mtx CID and 
DHFR-B42 as well. In any case, increased levels of tetracyclines are expected to outcompete the 
CID from the LexA-TetR protein fusion and lower reporter protein expression (Figure 5-1). 
Our design and synthesis of the Min-Mtx CID is based on the wealth of structure activity 
relationship (SAR) data for the interaction of tetracyclines with TetR, as well as our laboratory’s 
previously reported CIDs.(27, 35) It is known from inspection of the high-resolution structure of 
TetR bound to tetracycline derivatives as well as biochemical characterization that tetracyclines 
can be derivatized at the D ring without disrupting binding to TetR (Scheme 5-1).(37, 38, 52) 
Moreover, the FDA-approved analog tigecycline and the clinical candidates eravacycline and TP-
271 are all 9-amidotetracyclines;(53, 54) thus, synthesis of a 9-amidotetracycline CID was logical. 
Specifically, 9-aminominocycline was chosen as the starting material because of its high acid 
stability relative to tetracycline as well as its commercial availability.(55) The design and synthesis 
of the Mtx component of the Min-Mtx CID was based on our laboratory’s previously reported 
methotrexate CIDs (Scheme 5-1).(27, 35) 




aReagents and conditions: (a) Boc-11-aminoundecanoic acid (1.5 equiv), EDC (2 equiv), HOBt (2 
equiv), Et3N (5 equiv), DMF, 22 
oC, 6 h, 36%; (b) TFA:DCM (1:1), 22 oC, 12 min; (c) 
Methotrexate-α-OtBu (1.5 equiv),(23, 24) PYBOP (2 equiv), DIPEA (2.5 equiv), DMF, 22 oC, 22 
h; (d) TFA, 22 oC, 1.5 h, 10% over three steps. EDC = N-(3-Dimethylaminopropyl)-N′-
ethylcarbodiimide hydrochloride, HOBt = 1-hydroxybenzotriazole, TFA = trifluoroacetic acid, 
PyBOP = (Benzotriazol-1-yloxy)tripyrrolidinophosphonium hexafluorophosphate, DIPEA = N-
Ethyldiisopropylamine. 
 
5.4.2 Initial characterization of the Y3H assay for tetracycline derivatives 
With the Y3H strains and Min-Mtx CID at hand we verified the functionality of our Y3H system 
and determined the optimal CID concentration and TetR variant to further use in the assay. First, 
we confirmed that reporter gene output in our system is dependent upon the presence of the CID 
and determined the desired range of CID concentration to use in the assay (Figure 5-2a). We then 
tested candidates from each of the TetR classes as protein receptors and observed that the Y3H 
system is responsive to the CID with all known TetR classes except for the TetR(C) variant we 
used (Figure 5-2b). Given that TetR(B) and TetR(G) showed the best response to the CID and to 
maintain consistency with the highly studied TetR(B),(37-39) we focused our further experiments 
on TetR(B).  
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We show that our assay can differentiate sub-μM concentrations of various tetracyclines (Figure 
5-2c), key for its applicability to differentiate between high and low producer strains. Our Y3H 
system differentiates doxycycline, tetracycline and 9-NH2-minocycline concentrations in the range 
of 2 – 200 nM, 0.02 – 2 μM and 0.2 – 20 μM, respectively. The limit of detection in our Y3H assay 
is ≤ 0.2 μM for doxycycline and ≤ 2 μM for tetracycline and 9-NH2-minocycline.(32)  
 
Figure 5-2 Characterization of the dynamic range of the Y3H assay for tetracyclines 
Characterization of the dynamic range of the Y3H assay for tetracyclines in (a) varying 
concentrations of the Min-Mtx CID, (b) varying TetR classes and (c) varying target molecule 
structure and concentrations. LacZ was used as a reporter gene. Miller units were calculated as 
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(1000*OD420)/(well-volume(mL)*reaction-time(min)*OD600).(56) “+TetR” and “-TetR” are 
strains HL-260-5 and HL-260-7 encoding LexA-TetR(G) and LexA, respectively; Error bars 
represent the standard error of the mean (s.e.m) from three biological replicates.  
After confirming the functionality of the Y3H system for tetracyclines we proceeded to show that 
it can report the presence of tetracyclines with a modular output, key for enabling versatile use by 
various end-users. Using a URA3 reporter gene and growing the yeast in the presence of 5-
fluorouracil (5-FOA) we show that yeast growth is doxycycline-dependent in the presence, but not 
in the absence of the Min-Mtx CID (Figure 5-3a). We additionally show that the Y3H assay for 
tetracyclines can be used as a colorimetric as well as a fluorometric assay, by employing a LacZ 
or and mCherry reporter gene, respectively (Figure 5-3b, Figure 5-3c). As expected, while reporter 
gene activity is dependent on CID and doxycycline in the Y3H strain, such dependence is not 




Figure 5-3 The modularity of the yeast three hybrid assay enables both screening and 
selecting for biosynthesis of target tetracyclines 
The modularity of the yeast three hybrid assay enables both screening and selecting for 
biosynthesis of target tetracyclines by enabling (a) a growth assay, (b) a colorimetric assay and a 
(c) fluorometric assay. (a) Yeast growth, (b) LacZ transcription and (c) mCherry transcription are 
dependent on doxycycline (Dox) in the presence, but not in the absence of the CID. CID, Dox 
concentrations = (a) 25 μM, 5 μM (b) 25 μM, 0.2 μM (c) 10 μM, 1 μM. Error bars represent the 
standard error of the mean (s.e.m) from three biological replicates. Miller units were calculated as 
(1000*OD420)/(well-volume(mL)*reaction-time(min)*OD600).(56) mCherry (620 nm)/OD600 
was calculated by dividing mCherry fluorescence (620 nm, λex = 588 nm) by OD600.  
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5.4.3 Applying the Y3H assay to the detection of target molecule biosynthesis  
We demonstrate the applicability of the Y3H assay to metabolic engineering by differentiating 
between producer and non-producer strains of TAN-1612 (Figure 5-4a).(30) For the TAN-1612 
producer strain we used S. cerevisiae strain EH-3-54-4, encoding all four genes of the TAN-1612 
biosynthetic pathway as previously reported by Tang and coworkers and producing ~60 μM TAN-
1612 (Supplementary methods).(30) The non-producer control we used, S. cerevisiae strain EH-
3-54-2, does not encode the polyketide synthase AdaA and has no measurable production of TAN-
1612 (data not shown). 
The Y3H assay for tetracyclines can differentiate between supernatants of producer and non-
producer strains of TAN-1612 (Figure 5-4b). When purified TAN-1612 is spiked into non-
producer supernatants, the resulting Y3H signal resembles the signal obtained with producer 
supernatant (Figure 5-4b). These results agree with our hypothesis that TAN-1612, present in the 
producer strain supernatant but not in the non-producer strain supernatant, outcompetes the CID 
from the LexA-TetR fusion protein.  
The Y3H assay for tetracyclines also differentiates TAN-1612 producer colonies from a non-
producing population cultured in a 96-well plate (Figure 5-4c). The 12 producer colonies gave an 
average mCherry fluorescence / OD600 signal of 132 with a standard deviation of 17 and the 84 
non-producer colonies gave an average mCherry fluorescence / OD600 signal of 210 with a standard 
deviation of 16. Thus, assuming normal distribution there is less than 2.5% overlap in the Y3H 




Figure 5-4 Differentiation of a producer and a non-producer strain of a target molecule by 
the Y3H assay for tetracyclines, demonstrating the applicability of the Y3H assay to 
metabolic engineering. 
(a) Workflow for screening colonies for production of a target molecule using the Y3H assay. (b) 
The Y3H assay for tetracyclines differentiates between the supernatants of TAN-1612 producer 
and TAN-1612 non-producer cultured in shake flasks. (c) The Y3H assay for tetracyclines 
differentiates the supernatants of TAN-1612 producer colonies from a non-producing population 
cultured in a 96-well plate. The non-producer strain does not encode AdaA, the polyketide 
synthase of the TAN-1612 biosynthetic pathway, while the producer strain encodes the complete 
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pathway (Table 5-1 and Table 5-2). The concentration of TAN-1612 in the Y3H assay well from 
the supernatant and from the purified sample is ~0.3 μM and 0.5 μM, respectively (Supplementary 
methods). mCherry (620 nm)/OD600 was calculated by dividing mCherry fluorescence (620 nm, 
λex = 588 nm) by OD600. Error bars represent the standard error of the mean (s.e.m) from three 




The Y3H assay for tetracyclines is advantageous compared to the state-of-the-art methods for 
tetracycline detection in terms of throughput, cost, instrumentation requirements and limit of 
detection. Being readily performed in 96-well microtiter plates, the Y3H assay throughput is >1000 
samples / hour when measured by a standard laboratory plate reader (Infinite-M200). By 
comparison, the throughput of the previous state-of-the-art HPLC-based methods for tetracycline 
detection is <10 samples/hour.(33, 57) The use of a plate reader to measure the Y3H assay output 
is also advantageous in terms of cost to state-of-the-art chromatography-based methods such as 
HPLC and even more so, LCMS. The price difference is both in the initial investment in 
instrumentation, as spectrophotometers are cheaper than LC instruments, and in the reagent costs 
of 96 well plates vs LC-grade solvents. In terms of limit of detection the Y3H assay has a limit of 
detection of ≤ 200 nM for doxycycline (Figure 5-2c), which is better than the state-of-the-art HPLC 
limit of detection of ≥ 4.5 μM for doxycycline.(33, 57) The low limit of detection our assay exhibits 
enables it to differentiate producer from non-producer strains even in low titers of initial strain 
development (Figure 5-4 and Section 5.7.1 5.7.2, ~60 μM). Differentiating between production 
levels in higher titer ballparks in later stages of producer strain optimization would simply require 
a higher dilution factor of supernatants into the Y3H strain media. Future generations of this Y3H 
201 
 
assay might include TetR mutants that are more specific and have a lower detection limit to 
tetracycline derivatives of interest.  
The Y3H assay for metabolic engineering also compares well with our laboratory’s recently 
published FP assay,(58) because of two key differences in setup requirements and output. First, 
since the Y3H assay does not require the purification of the protein receptor, it is used much more 
readily to screen for the ultimate protein receptor for the assay. Thus, we show here the first 
comparison of all TetR classes for binding of a small molecule in an attempt to identify the best 
TetR variant for differentiating between + and – CID (Figure 5-2b). Further optimization of a 
protein receptor for the assay of a specific target molecule is readily enabled in the Y3H assay 
simply by cloning the protein variants into the same plasmid backbone and transforming into yeast. 
The versatility in choice of output in the Y3H assay is a key enabling factor for the advantages the 
Y3H assay has over the FP assay since it makes the assay accessible to a wider range of users. The 
fluorescent output in the Y3H assay enables measurements with a standard laboratory plate reader, 
eliminating the requirement for anisotropy capacities (Figure 5-3c). The LacZ output could also 
be measured by a standard plate reader as well as by the naked eye (Figure 5-3b).  
If the Y3H system and the metabolic pathway for the small molecule of interest are cloned into 
the same strain, colonies can be assayed for production even more directly, increasing throughput 
and minimizing handling. The Y3H assay can then enable screening colonies for production of the 
target molecule directly on an agar plate without the need for further handling of the colonies in 
microtiter plates. The agar plate screen could be performed with the naked eye or a simple camera 
by using X-Gal plates and the LacZ reporter or fluorescent camera/microscope by using the 
mCherry reporter. Finally, the Y3H assay throughput could be vastly increased by selecting for 
high producing strains en masse in flask or fermenter culturing using the growth assay or 
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fluorescence assisted cell sorting (FACS). Such en masse screening methods not only greatly 
enhance the throughput but also minimize the labor, instrumentation, cost and time, required to 
obtain results. The Y3H assay for tetracyclines can report the presence of a target molecule with 
any of the above mentioned outputs (Figure 5-3), enabling metabolic engineering applications for 
a range of end users with varying needs and instrumentation availabilities.  
While a TetR-tetO-based assay could conceivably be developed for the metabolic engineering of 
tetracycline derivatives,(59) our TetR-based Y3H assay is advantageous for two main reasons. For 
one, the Y3H assay can potentially be applied to a greater variety of tetracycline derivatives as 
TetR-binding to the tetracycline suffices and there is no demand for a TetR conformational change. 
By comparison, signal transduction in the TetR-tetO system is dependent on coupling between 
tetracycline binding and a conformational change in TetR.(26, 38) It has been hypothesized that 
high-affinity binding may be a necessary but not sufficient property for TetR induction in the TetR-
TetO system.(60) In practice, while it was possible to detect binding to a tetracycline analog, 4-
de(dimethylamino)-anhydrotetracycline, no induction was detected using a TetR-TetO-based 
assay.(37) Thus, the use of TetR in a Y3H system can facilitate the evolvement of TetR mutants 
with specific binding to tetracycline derivatives of interest in future generations of the assay. 
Furthermore, the Y3H system for metabolic engineering can be readily modified to apply for many 
metabolites of interest beyond tetracyclines, as detailed below. In contrast, the TetR-TetO system 
is much more limited in the scope of molecules it could be applied to, namely transcriptional 
regulators.(61) 
A Y3H system as described here for the metabolic engineering of tetracycline derivatives can be 
designed for any target molecule with a receptor. Given T, a desirable target, PR, a protein receptor 
for T, and T’, a readily derivatizable analog of T, two new components need to be generated for a 
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Y3H assay to detect biosynthesis of T. The first is a Mtx-T’ CID and the second is a LexA-PR 
fusion protein (Figure 5-1). This approach is especially amenable for the development of assays 
for molecules of pharmacological interest. The reason is that such molecules often have a known 
protein target as well as an established derivatization chemistry and SAR that greatly support the 
design and synthesis of a CID. More broadly, building from the Cornish Laboratory’s early reports 
of chemical complementation,(17, 62, 63) this work advances the enabling technology of the Y3H 
system for the emerging field of synthetic biology for handling the diversity of engineering multi-
gene pathways and assaying for chemistry not natural to the cell. 
5.6 Conclusion 
This chapter describes the development of a yeast three hybrid (Y3H) assay as a general, high-
throughput, versatile and readily-implemented approach for the detection of target molecule 
biosynthesis. We demonstrate the use of the Y3H assay for detecting the biosynthesis of 
tetracyclines, a major class of antibiotics, based on the interaction between tetracyclines and the 
tetracycline repressor protein (TetR). We demonstrate the applicability of the Y3H assay to 
metabolic engineering by differentiating between producer and non-producer strains of the natural 
product anhydrotetracycline TAN-1612. The Y3H assay is superior to state-of-the-art HPLC-MS 
methods in throughput and limit of detection of tetracycline derivatives. Finally, our establishment 
of the Y3H assay for detecting the biosynthesis of an anhydrotetracycline supports the generality 
of the Y3H assay for detecting the biosynthesis of many other target molecules. Specifically, future 
versions of this assay to screen or select for further modifications of TAN-1612 that could not be 
assayed by the UV/Vis assay for hydroxylation of anhydrotetracycline used in the previous 





5.7.1 Supplementary figures 
 
 
Figure 5-5 LacZ readout of strain harboring plasmid encoding for LexA-TetR (PBA-8) and 
strain without the plasmid (PBA-5). 
Only the strain with the LexA-TetR fusion protein responds to the CID. Addition of Dox lowers 
reporter gene expression only in the strain with LexA-TetR in the presence of the CID. 
Concentrations of CID and Dox are 25 μM and 200 nM, respectively. Miller units were calculated 
as (1000*OD420)/(well-volume(mL)*reaction-time(min)*OD600).(56) Error bars represent the 




































Figure 5-6 standard curve for TAN-1612 quantification in cultures. 
A Purified TAN-1612 was analyzed at different concentrations on a separation gradient of 5% to 
95% MeCN in supercritical CO2 over 5.5 minutes. Absorption between 390 nm to 410 nm was 
integrated at retention times of 0.87 – 1.50 min, which corresponds to TAN-1612 (MS (AI-): m/z 
calc. for C21H17O9
-: 413.09; found: 413.4 [M - H]-; MS (EI-): m/z calc. for C21H17O9
-: 413.09; 
found: 413.4 [M - H]-).  
 
5.7.2 Supplementary methods 
Quantification of TAN-1612 concentration in cultures.  
TAN-1612 cultures for quantification were obtained by inoculating two biological replicates of 
each of TAN-1612 producing and non-producing strains, EH-3-54-4 and EH-3-54-2 respectively, 
in UT- media (5 mL) in 15 mL culture tubes (Corning 352059) and placing in shaker overnight. 
Overnight cultures were used to inoculate 100 mL YPD in 500 mL conical flasks with a starting 
OD600 of 0.08. After 68 h, the 100 mL from the two biological replicates were combined and 
extracted with 200 mL of EtOAc in 8 x 50 mL falcon tubes (Corning 352098) by mixing at 
maximal speed in Orbital Shaker (Bellco Glass) at r.t. for 1.5 h and centrifuging at 3,300 rpm at 
r.t. for 15 min. The solvent of the combined organic phase was removed under reduced pressure 

































and the sample was redissolved in MeOH (1.5 mL) and filtered (Acrodisc® Syringe Filters, 13mm, 
0.2 μm, Pall Laboratory, PTFE Membrane, 4422). The filtered sample was diluted 50X in MeOH 
and analyzed by Supercritical Fluid Chromatography / Mass spectrometry (SFC/MS) equipped 
with a photodiode array (PDA) UV-vis detector. Absorption between 390 nm to 410 nm was 
integrated at retention times of 0.87 – 1.50 min, which corresponds to TAN-1612 (MS (AI-): m/z 
calc. for C21H17O9
-: 413.09; found: 413.4 [M - H]-. The TAN-1612 concentration in the extract 
was calculated to be 161 μM according to the following linear function: 
concentration=[ln(absorption 390-410 nm)-8.1328]/0.016 (Figure 5-6). The concentration of 
TAN-1612 in the culture is therefore estimated to be ~60 μM, assuming a quantitive yield for the 
extraction process.  
5.7.3 Supplementary tables  
Table 5-1 Strains used in this study 
Strain Genotype  Source/Reference 
FY250 MATα ura3-52 trp1 63 his3 200 leu2 1 gal L.P. Guarentea 





MATα ura3-52 his3-Δ200 leu2-Δ1 
trp1 pep4::HIS3 δ:: pADH2-npgA-tADH2 prb1Δ1.6R can1 
GAL  
Y. Tangb/(64) 
V506 FY250 pMW106, pMW3(GSG)2rGR2, pMW2eDHFR /(27) 
PBA-5 FY250 pMW106, pMW2eDHFR This study 
HL-260-1 FY250 pMW106, pMW103TetR(A), pMW2eDHFR This study 
PBA-8 FY250 pMW106, pMW103TetR(B), pMW2eDHFR This study 
HL-260-2 FY250 pMW106, pMW103TetR(C), pMW2eDHFR This study 
HL-260-3 FY250 pMW106, pMW103TetR(D), pMW2eDHFR This study 
HL-260-4 FY250 pMW106, pMW103TetR(E), pMW2eDHFR This study 
HL-260-5 FY250 pMW106, pMW103TetR(G), pMW2eDHFR This study 
HL-260-6 FY250 pMW106, pMW103TetR(H), pMW2eDHFR This study 
HL-260-7 FY250 pMW106, pMW103(empty), pMW2eDHFR This study 
PBA-6 LW2635 PBA-Gib5 This study 
PBA-14 LW2635 PBA-Gib5, pMW2eDHFR This study 
PBA-3 FY250 pMW2eDHFR This study 
HL-294-7 FY250 pMW2eDHFR HL-174-2 This study 
HL-2-4-1 FY250 pMW2eDHFR pMW103TetR(B), HL-174-2 This study 
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EH-3-54-4 BJ5464-NpgA pYR291, pYR342 This study 
EH-3-54-2 BJ5464-NpgA pRS426, pYR342 This study 
a L. P. Guarente, Massachusetts Institution of Technology, Biology Department 
b Y. Tang, University of California, Los Angeles, Department of Chemical and Biomolecular 
Engineering & Department of Chemistry and Biochemistry, Department of Bioengineering 
 
Table 5-2 Plasmids used in this study 
Plasmid Description Source/Reference 
pMW2eDHFR pGal1-eDHFR-B42, trp marker, 2 μ /(27) 
pMW106 LacZ under control of 8 tandem LexA operators, Ura 
marker 
/(27, 65) 
pMW103 pADH1-LexA (empty), His marker, 2 μ R. Brenta/(65) 
pMW112 LacZ under control of 8 tandem LexA operators, Ura 
marker 
R. Brent/(14, 65) 
HL-249-1 pADH1-LexA-TetR(A)-tADH1 on pMW103 This study 
PBA-Gib5 pADH1-LexA-TetR(B)-tADH1 on pMW103 This study 
HL-249-2 pADH1-LexA-TetR(C)-tADH1 on pMW103 This study 
HL-249-3 pADH1-LexA-TetR(D)-tADH1 on pMW103 This study 
HL-249-4 pADH1-LexA-TetR(E)-tADH1 on pMW103 This study 
HL-249-5 pADH1-LexA-TetR(G)-tADH1 on pMW103 This study 
HL-249-6 pADH1-LexA-TetR(H)-tADH1 on pMW103 This study 
pRS416 Shuttle vector (empty), uracil marker, CEN ATCC87521 
HL-174-2 8LexAOp-minpGal1-mCherry-tCyc1, Ura marker, CEN This study 
pYR291 AdaA expression in S. cerevisiae, uracil marker, 2 μ Y. Tangb/(30) 
pYR342 AdaB-D expression in S. cerevisiae, Tryp marker, 2 μ Y. Tang/(30) 
pRS426 Shuttle vector (empty), uracil marker, 2 μ ATCC77107 




mCherry, uracil marker, 2 μ Neta Deand/(29) 
a R. Brent, Fred Hutchinson Cancer Research Center, Division of Basic Sciences 
b Y. Tang, University of California, Los Angeles, Department of Chemical and Biomolecular 
Engineering & Department of Chemistry and Biochemistry, Department of Bioengineering 
c A. Davidson, Dept. of Molecular Genetics, Dept. of Biochemistry, Faculty of Medicine, 
University of Toronto 
d Neta Dean, Department of Biochemistry and Cell Biology, Stony Brook University 
 
Table 5-3 Sequences of the various TetR classes in the within the pMW103 backbone. 
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Sequences for the TetR classes are shown decapitalized within the context of LexA-DBD (partial, 
capitalized) in the 5’ end and the tADH1 terminator at the 3’ end (partial, capitalized).  
The NCBI and GenBank Reference Sequences used to order/clone DNA for the different TetR 
classes A, B, C, D, E, G and H are NC_006143.1, CP012140.1, NC_002056.1, CP000650.1, 
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